nevirapine has been researched along with Pregnancy in 667 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
Excerpt | Relevance | Reference |
---|---|---|
"To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine resistance in pregnant, HIV-infected women." | 9.17 | Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013) |
"Pharmacokinetic data for lopinavir in late pregnancy and in breastfeeding are limited, and no data for abacavir in breast milk are available." | 9.17 | Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ( Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL, 2013) |
"Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)." | 9.17 | Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013) |
"Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy." | 9.16 | A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012) |
"Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission." | 9.14 | Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009) |
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer." | 9.12 | Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007) |
" We aimed to establish whether pregnancy rates differ between HIV-positive women who use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens." | 8.91 | Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. ( Blat, C; Bukusi, EA; Cohen, CR; Gandhi, M; Hagey, J; Newmann, SJ; Onono, M; Patel, RC; Shade, SB; Vittinghoff, E, 2015) |
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 8.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed." | 7.88 | Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018) |
" Patients were allocated to 2groups according to exposure to nevirapine during pregnancy." | 7.83 | [Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy]. ( Figueras-Nadal, C; Fortuny-Guasch, C; Iveli, P; Martín-Nalda, A; Noguera-Julian, A; Rovira-Girabal, N; Soler-Palacín, P, 2016) |
"Previous studies on nevirapine pharmacokinetics during pregnancy reported contradictory findings." | 7.83 | Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study. ( Back, D; Bolaji, O; Khoo, S; Neary, M; Olagunju, A; Owen, A, 2016) |
"The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission." | 7.81 | Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015) |
"An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a study of HIV-1 transmission rates among NVP-experienced compared with NVP-naïve women in "The Nevirapine Repeat Pregnancy (NVP-RP) Study" at the Makerere University-Johns Hopkins University Research Collaboration, Kampala-Uganda, between June 2004 and June 2006." | 7.81 | A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". ( Bakaki, PM; Fowler, MG; Kiweewa, FM; Kusasira, F; McConnell, MS; Mubiru, MC; Musisi, M; Musoke, P; Nakayiwa, F; Nakintu, D; Namirembe, C, 2015) |
"Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 7.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
" We compared the pregnancy outcomes of women exposed to EFV and to nevirapine (NVP) during the first trimester." | 7.77 | Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. ( Amani-Bosse, C; Anglaret, X; Coffie, PA; Dabis, F; Danel, C; Eholié, SP; Ekouevi, DK; Messou, E; Moh, R; Ouattara, E; Sissoko, M, 2011) |
"Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis." | 7.75 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009) |
"Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers." | 7.74 | Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008) |
"Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings." | 7.74 | Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007) |
"To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population." | 7.74 | Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. ( Aweeka, F; Best, B; Burchett, SK; Capparelli, EV; Foca, M; Hitti, J; Hu, C; Jimenez, E; Mirochnick, M; Nachman, S; Read, JS; Shearer, WT; Smith, E; Spector, SA; Stek, A; Thorpe, EM; Watts, H, 2008) |
"Nelfinavir- or nevirapine-containing HAART regimens during pregnancy are well tolerated." | 7.73 | Nelfinavir and nevirapine side effects during pregnancy. ( Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005) |
"The incidence of adverse events with nevirapine may be lower than previously reported (13% versus 29%) and may be primarily noted with initiating the drug late in pregnancy." | 7.73 | Third-trimester maternal toxicity with nevirapine use in pregnancy. ( Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005) |
"To describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity." | 7.73 | Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. ( Bergin, C; Geoghegan, J; Hopkins, S; Kelleher, B; Lyons, F; McCormick, PA; McGeary, A; Mulcahy, FM; Sheehan, G, 2006) |
" We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation." | 7.72 | Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003) |
" The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL." | 6.71 | Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004) |
"The risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women." | 6.49 | Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. ( Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Shubber, Z, 2013) |
"To investigate if pregnancy is a risk factor for SJS among HIV-infected women taking NVP-containing regimens and registered within the Medunsa National Pharmacovigilance Centre database." | 5.39 | Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012. ( Adewusi, E; Dube, N; Summers, R, 2013) |
"Pregnancy has a moderate but significant lowering effect on NVP plasma concentrations." | 5.35 | Steady-state nevirapine plasma concentrations are influenced by pregnancy. ( Boer, K; Burger, DM; Damming, M; de Wolf, F; Godfried, MH; Nellen, JF; Prins, JM; van der Ende, ME; Wit, FW, 2008) |
" The influence of gender, age, body weight and comedication on minimum and maximum concentrations (C(min), C(max)), area under the concentration-time curve (AUC), total clearance (CL(tot)), half-life (t(1/2)) and volume of distribution (V(d)) was analysed by multivariate techniques." | 5.33 | A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. ( Carlebach, A; Gute, P; Haberl, A; Harder, S; Klauke, S; Knecht, G; Kurowski, M; Rohrbacher, M; Staszewski, S; Stocker, H; von Hentig, N, 2006) |
"To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine resistance in pregnant, HIV-infected women." | 5.17 | Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013) |
"ART use did not affect risk of ovulation or pregnancy in women taking COCs, suggesting that nevirapine-containing ART does not interfere with COC contraceptive effectiveness." | 5.17 | Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness. ( Delany-Moretlwe, S; Dubé, K; Edward, VA; Kwok, C; Lendvay, A; Mirembe, FM; Molife, L; Mpairwe, B; Nakubulwa, S; Nanda, K, 2013) |
"Although substantiated by little evidence, concerns about zidovudine-related anaemia in pregnancy have influenced antiretroviral (ARV) regimen choice for preventing mother-to-child transmission of HIV-1, especially in settings where anaemia is common." | 5.17 | Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries. ( Chersich, MF; Farley, TM; Luchters, S; Meda, N; Mwaura, M; Newell, ML; Sartorius, BK; Temmerman, M, 2013) |
"Pharmacokinetic data for lopinavir in late pregnancy and in breastfeeding are limited, and no data for abacavir in breast milk are available." | 5.17 | Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ( Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL, 2013) |
"Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)." | 5.17 | Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013) |
"Extended nevirapine and cotrimoxazole prophylaxis through 6 months of age among HIV-exposed uninfected infants did not appear to increase the immediate or long-term risk of neutropenia, anemia or skin-rash." | 5.16 | Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated. ( Aizire, J; Bolton, SG; Brown, ER; Coovadia, H; Fowler, MG; Kamateeka, M; Musoke, PM; Shetty, AK; Stranix-Chibanda, L; Wang, J, 2012) |
"Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy." | 5.16 | A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012) |
"Women randomized to valacyclovir suppressive therapy during pregnancy and postpartum had greater increases in CD4 counts and smaller increases in plasma HIV-1 RNA levels than women in the placebo arm." | 5.16 | Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. ( Drake, AL; Emery, S; Farquhar, C; John-Stewart, GC; Kiarie, JN; Matemo, DN; Ongecha-Owuor, F; Overbaugh, J; Richardson, B; Roxby, AC; Wald, A, 2012) |
"In neonates whose mothers did not receive ART during pregnancy, prophylaxis with a two- or three-drug ART regimen is superior to zidovudine alone for the prevention of intrapartum HIV transmission; the two-drug regimen has less toxicity than the three-drug regimen." | 5.16 | Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. ( Bastos, FI; Bethel, J; Bryson, YJ; Camarca, M; Ceriotto, M; Dickover, R; Fonseca, R; Gray, G; Grinsztejn, B; Joao, EC; Kreitchmann, R; Machado, D; Mirochnick, M; Mofenson, LM; Moreira, RI; Morgado, MG; Moye, J; Mussi-Pinhata, MM; Nielsen-Saines, K; Pilotto, JH; Pinto, J; Santos, B; Siberry, G; Theron, G; Veloso, VG; Watts, DH; Xu, J, 2012) |
"Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission." | 5.14 | Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009) |
"For almost a decade, single-dose nevirapine (sdNVP) has been proven to be a safe and effective drug for the prevention of mother-to-child transmission (PMTCT) of HIV." | 5.14 | Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia. ( Bweupe, M; Dirks, R; Kabaso, M; Kasonde, P; Mandala, J; Sangiwa, G; Torpey, K, 2010) |
"Pregnant HIV-1 seropositive women (CD4+ T-cell count >250 and <500 cells/mm3) electing to breastfeed in Nairobi, Kenya were randomized to highly active antiretroviral therapy (HAART; zidovudine [ZDV], lamivudine and nevirapine [NVP]) during pregnancy and 6 months post-partum or to short-course ZDV plus single-dose NVP (ZDV/NVP)." | 5.13 | Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial. ( Chung, MH; John-Stewart, GC; Kiarie, JN; Kinuthia, J; Lehman, DA; Njiri, F; Overbaugh, J; Richardson, BA, 2008) |
"In a setting of high perinatal nevirapine use, acute chorioamnionitis was not associated with vertical HIV-1 transmission." | 5.12 | Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission. ( Chi, BH; Goldenberg, RL; Levy, J; Mudenda, V; Sinkala, M; Stringer, JS, 2006) |
"Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer." | 5.12 | Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007) |
"Large numbers of women receive single-dose nevirapine (sdNVP) to prevent mother-to-child transmission (MTCT) of HIV; over time, an increasing proportion will return to prevention of MTCT programs for a second pregnancy." | 5.12 | Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. ( Becquet, R; Dabis, F; Dhlamini, P; Ekouevi, DK; Gray, GE; Leroy, V; Lupodwana, P; Martinson, NA; McIntyre, JA; Morris, L; Steyn, JG; Tonwe-Gold, B; Viho, I, 2007) |
"We conducted a randomized, double-blind trial of three treatment regimens in Thai women who were receiving zidovudine therapy during the third trimester of pregnancy." | 5.11 | Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. ( Jourdain, G; Kanshana, S; Koetsawang, S; Lallemant, M; Le Coeur, S; Mary, JY; McIntosh, K; Ngo-Giang-Huong, N; Thaineua, V, 2004) |
"We randomly assigned 1844 women in Thailand who received zidovudine during the third trimester of pregnancy to receive intrapartum nevirapine or placebo." | 5.11 | Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. ( Ariyadej, S; Bowonwatanuwong, C; Hammer, S; Jourdain, G; Kantipong, P; Lallemant, M; Le Coeur, S; Leechanachai, P; Leenasirimakul, P; Ngo-Giang-Huong, N, 2004) |
" However, zidovudine administered with lamivudine and indinavir was associated with increased risk of preterm births, zidovudine administered with nevirapine was associated with increased risk of stillbirths, and lamivudine administered with stavudine and efavirenz was associated with increased risk of low birth weight." | 4.98 | Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. ( Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA, 2018) |
" Second, we discuss the existing clinical data on this topic, including the observational study from Kenya showing women using implants plus efavirenz-based ART had three-fold higher rates of pregnancy than women using implants plus nevirapine-based ART." | 4.95 | Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. ( Cohen, CR; Kiarie, J; Morroni, C; Patel, RC; Scarsi, KK; Sripipatana, T, 2017) |
" We aimed to establish whether pregnancy rates differ between HIV-positive women who use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens." | 4.91 | Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. ( Blat, C; Bukusi, EA; Cohen, CR; Gandhi, M; Hagey, J; Newmann, SJ; Onono, M; Patel, RC; Shade, SB; Vittinghoff, E, 2015) |
" Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 4.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
" Women appear to be at an especially high risk for lactic acidosis, nevirapine-associated rashes and hepatotoxicity, and fat redistribution after highly active antiretroviral therapy exposure." | 4.82 | Sex differences in antiretroviral therapy-associated intolerance and adverse events. ( Clark, R, 2005) |
"Maternal HIV drug resistance and maternal viral load were independent risk factors for vertical transmission during breastfeeding, suggesting that nevirapine alone may be insufficient infant prophylaxis against drug-resistant variants in maternal breast milk." | 4.12 | Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants. ( Beck, IA; Boyce, CL; DeMarrais, P; Flynn, PM; Fowler, MG; Frenkel, LM; Ko, D; Owor, M; Sils, T; Stranix-Chibanda, L; Styrchak, SM; Taha, TE; Tierney, C; Wong-On-Wing, A, 2022) |
"Despite improved policies to prevent mother-to-child HIV transmission (MTCT), adherence to maternal antiretroviral therapy (ART) and infant Nevirapine prophylaxis (NVP) is low in South Africa." | 3.91 | Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa. ( Ayalew, K; Cheyip, M; Chirinda, W; Dinh, TH; Goga, A; Jackson, D; Kindra, G; Larsen, A; Lombard, C; Magasana, V; Ngandu, N, 2019) |
" This study utilized Bayesian logistic regression to examine maternal-level predictors of adherence to infant nevirapine prophylaxis, including intimate partner violence, maternal adherence, HIV serostatus disclosure reaction, recency of HIV diagnosis, and depression." | 3.88 | A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa. ( Cook, RR; Jones, DL; Peltzer, K; Rodriguez, VJ; Weiss, SM, 2018) |
"Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed." | 3.88 | Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018) |
"Syphilis is associated with increased human immunodeficiency virus acquisition and sexual transmission; we examined impact on human immunodeficiency virus mother-to-child transmission among mother-infant pairs enrolled in the India Six-Week Extended-Dose Nevirapine study." | 3.85 | Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission. ( Bharadwaj, R; Bhat, J; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kinikar, A; Kulkarni, V; Mave, V; McIntire, KN; Patil, S; Suryavanshi, N, 2017) |
" Patients were allocated to 2groups according to exposure to nevirapine during pregnancy." | 3.83 | [Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy]. ( Figueras-Nadal, C; Fortuny-Guasch, C; Iveli, P; Martín-Nalda, A; Noguera-Julian, A; Rovira-Girabal, N; Soler-Palacín, P, 2016) |
" Antiretroviral treatment-naive women started a nevirapine-based triple combination regimen from the third trimester of pregnancy until at least 6 months of exclusive breastfeeding." | 3.83 | Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. ( Amici, R; Andreotti, M; Baroncelli, S; Galluzzo, CM; Giuliano, M; Jere, H; Mancinelli, S; Marazzi, MC; Palombi, L; Vella, S, 2016) |
" In the study, women with baseline CD4(+) <350/mm(3) received a combination of stavudine, lamivudine, and nevirapine during pregnancy (from week 25 of gestation) and continued it indefinitely after delivery." | 3.83 | Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Pirillo, MF; Sagno, JB; Scarcella, P; Vella, S, 2016) |
" We found that nevirapine use and pregnancy are independently associated with severe skin reaction." | 3.83 | Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. ( Boulle, A; Cohen, K; de Waal, R; Lehloenya, R; Maartens, G; Stewart, A, 2016) |
"The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission." | 3.81 | Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015) |
"An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a study of HIV-1 transmission rates among NVP-experienced compared with NVP-naïve women in "The Nevirapine Repeat Pregnancy (NVP-RP) Study" at the Makerere University-Johns Hopkins University Research Collaboration, Kampala-Uganda, between June 2004 and June 2006." | 3.81 | A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". ( Bakaki, PM; Fowler, MG; Kiweewa, FM; Kusasira, F; McConnell, MS; Mubiru, MC; Musisi, M; Musoke, P; Nakayiwa, F; Nakintu, D; Namirembe, C, 2015) |
", maternal zidovudine and infant ARV prophylaxis) of the World Health Organization's 2010 guidelines, no studies have assessed adherence to ARVs during pregnancy up to the postpartum period." | 3.81 | Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia. ( Chirwa, M; Ishikawa, N; Jimba, M; Kapyata, H; Komada, K; Miyano, S; Msiska, CY; Okawa, S; Syakantu, G; Yasuoka, J, 2015) |
"Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 3.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
"Data from cost studies and other published sources were used to determine the cost, per woman and per cohort (1000 breastfeeding and 1000 non-breastfeeding women), of switching from Option B (maternal triple antiretroviral [ARV] regimen during pregnancy and breastfeeding plus daily nevirapine for the infant for 6 weeks) to Option B+ (maternal triple ARV regimen initiated during pregnancy and continued for life)." | 3.80 | The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV. ( Abimbola, TO; O'Brien, L; Sangrujee, N; Shaffer, N, 2014) |
" We compared the pregnancy outcomes of women exposed to EFV and to nevirapine (NVP) during the first trimester." | 3.77 | Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. ( Amani-Bosse, C; Anglaret, X; Coffie, PA; Dabis, F; Danel, C; Eholié, SP; Ekouevi, DK; Messou, E; Moh, R; Ouattara, E; Sissoko, M, 2011) |
"From the ATHENA cohort study, three scenarios were selected for which the guideline recommended TDM: 1) start of a combination of lopinavir/ritonavir + efavirenz or nevirapine (drug-drug interaction); 2) start of efavirenz (routine TDM); and 3) use of nelfinavir during pregnancy." | 3.77 | Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands. ( Burger, DM; de Wolf, F; Franssen, EJ; Kroon, F; Richter, C; Rigter, IM; Smit, C; van Luin, M; Wit, FW, 2011) |
" We compared five PMTCT regimens at a fixed level of PMTCT medication uptake: 1) no antenatal ARVs (comparator); 2) sdNVP; 3) WHO 2010 guidelines using "Option A" (zidovudine during pregnancy/infant NVP during breastfeeding for women without advanced HIV disease; lifelong 3-drug antiretroviral therapy (ART) for women with advanced disease); 4) WHO "Option B" (ART during pregnancy/breastfeeding without advanced disease; lifelong ART with advanced disease); and 5) "Option B+:" lifelong ART for all pregnant/breastfeeding, HIV-infected women." | 3.77 | WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. ( Chu, J; Ciaranello, AL; Dabis, F; Engelsmann, B; Freedberg, KA; Keatinge, J; Maruva, M; Mugwagwa, R; Mushavi, A; Perez, F; Walensky, RP, 2011) |
" Patients were offered nevirapine-based triple ART initiated in pregnancy until 6 months postpartum." | 3.77 | Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. ( Buonomo, E; Ceffa, S; Haswell, J; Liotta, G; Magid, NA; Marazzi, MC; Narciso, P; Nielsen-Saines, K; Palombi, L; Paturzo, G; Scarcella, P; Zimba, I, 2011) |
" Unbooked HIV positive pregnant women, who had not received antiretroviral drugs during the antenatal period but received nevirapine in labour, referred to as untreated-maternal HIV infection, were compared with women who received HAART early in pregnancy." | 3.77 | Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection. ( Biodun, O; Joseph, O; Michael, E, 2011) |
"Compare the risk of HIV drug resistance in women stopping suppressive nelfinavir (NFV)-based or Nevirapine (NVP)-based antiretroviral therapy (ART) after pregnancy." | 3.77 | Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. ( Ellis, GM; Frenkel, LM; Hitti, J; Huang, S, 2011) |
" Baseline median CD4 T-cell count: 417 cell/ųl; 98% received antiretroviral drugs during pregnancy [2 nucleoside analogs plus either nevirapine (55%) or a protease inhibitor (32%)]." | 3.77 | HIV and pregnancy: maternal and neonatal evolution. ( Cecchini, D; Mecikovsky, D; Trinidad, P; Urueña, A; Vesperoni, F, 2011) |
" All women received zidovudine and lamivudine during pregnancy; 76% also received nelfinavir and 8." | 3.76 | Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. ( Cheng, I; Kuritzkes, DR; Paredes, R; Tuomala, RE, 2010) |
"Conflicting data exist regarding the effect of pregnancy on steady-state nevirapine pharmacokinetics (PK), although steady-state nevirapine concentrations during pregnancy have never been characterized in sub-Saharan Africa." | 3.76 | Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. ( Back, DJ; Boffito, M; Byakika-Kibwika, P; Flaherty, JP; Khoo, S; Lamorde, M; Merry, C; Nakabiito, C; Namakula, R; Okaba-Kayom, V; Ryan, M; Scarsi, KK, 2010) |
"Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis." | 3.75 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009) |
"To estimate whether the association between nevirapine (NVP) and hepatotoxicity differs according to pregnancy status in HIV-infected women." | 3.75 | Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. ( Brogly, SB; French, AL; Hershow, RC; Leighty, RM; Lu, M; Ouyang, DW; Shapiro, DE; Thompson, B; Tuomala, RE, 2009) |
"Limited information is currently available on the metabolic profile of nevirapine in pregnancy." | 3.75 | Plasma lipid profile in pregnant women with HIV receiving nevirapine. ( Anzidei, G; Dalzero, S; Floridia, M; Guaraldi, G; Guerra, B; Meloni, AM; Molinari, A; Pinnetti, C; Ravizza, M; Tamburrini, E; Tibaldi, C; Vimercati, A, 2009) |
"Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers." | 3.74 | Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008) |
"a retrospective study was performed between January 2003 and December 2006 analysing all women prescribed nevirapine in pregnancy." | 3.74 | [Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital]. ( Astori, Ade A; Fernandes, Rde B; Gomes, Sel-K; Kondo, W; Sasaki, Md; Sbalqueiro, RL, 2008) |
"Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings." | 3.74 | Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007) |
"To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population." | 3.74 | Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. ( Aweeka, F; Best, B; Burchett, SK; Capparelli, EV; Foca, M; Hitti, J; Hu, C; Jimenez, E; Mirochnick, M; Nachman, S; Read, JS; Shearer, WT; Smith, E; Spector, SA; Stek, A; Thorpe, EM; Watts, H, 2008) |
"In the Western Cape province of South Africa, an intensified regimen for the prevention-of-mother-to-child-transmission-of-HIV consisting of zidovudine (AZT) from 34 weeks of pregnancy plus single dose (sd) nevirapine (NVP) during labor was instituted in 2004." | 3.74 | Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. ( Claassen, M; Cotton, MF; Engelbrecht, S; Laten, JD; Preiser, W; Theron, GB; van Zyl, GU, 2008) |
"This study used Markov modeling to define the circumstances under which the following interventions would be cost-effective: BF for 6 months with daily infant nevirapine (NVP) prophylaxis; maternal combination antiretroviral therapy (ART) during pregnancy and for 6 months of BF; and maternal combination ART only for women who meet CD4 criteria." | 3.73 | Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding. ( Maclean, CC; Stringer, JS, 2005) |
"Nelfinavir- or nevirapine-containing HAART regimens during pregnancy are well tolerated." | 3.73 | Nelfinavir and nevirapine side effects during pregnancy. ( Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005) |
"The incidence of adverse events with nevirapine may be lower than previously reported (13% versus 29%) and may be primarily noted with initiating the drug late in pregnancy." | 3.73 | Third-trimester maternal toxicity with nevirapine use in pregnancy. ( Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005) |
"To describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity." | 3.73 | Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. ( Bergin, C; Geoghegan, J; Hopkins, S; Kelleher, B; Lyons, F; McCormick, PA; McGeary, A; Mulcahy, FM; Sheehan, G, 2006) |
" We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation." | 3.72 | Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003) |
" The majority of the HIV positive mothers received nevirapine in labour while 35% had combination ARV drugs in pregnancy." | 3.72 | Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria. ( Audu, BM; Chama, CM; Kyari, O, 2004) |
"The following were determined using data from eight African countries: national program costs and impact on infant infections; reductions in adult HIV prevalence and unintended pregnancies among HIV-infected women that would have equivalent impact on infant HIV infections averted as the nevirapine intervention; and the cost threshold for drugs with greater efficacy than nevirapine yielding an equivalent cost per DALY saved." | 3.72 | Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. ( de Zoysa, I; Denison, J; O'Reilly, KR; Schmid, GP; Sweat, MD, 2004) |
"To describe the experience of four London HIV centres prescribing nevirapine (NVP) to HIV-1 infected pregnant women with respect to immunological and virological response, tolerability and pregnancy outcome." | 3.71 | Experience of nevirapine use in a London cohort of HIV-infected pregnant women. ( de Ruiter, A; Easterbrook, P; Edwards, SG; Hay, P; Larbalestier, N; Taylor, GP; Welch, J, 2001) |
"Results of ACTG 076, a clinical trial funded by the National Institute of Allergy and Infectious Disease (NIAID), indicate that perinatal HIV transmission rates could be significantly reduced by treating HIV-positive pregnant women with an intensive zidovudine (AZT) regimen during the second half of pregnancy and during labor and delivery, and by treating the infants for the first six weeks of life." | 3.69 | Preventing HIV infection in infants in developing countries: NIAID's role. National Institute of Allergy and Infectious Diseases. ( , 1997) |
"Nevirapine exposure was assessed in all patients with available blood samples and safety was assessed in all participants." | 3.01 | Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. ( Bryson, Y; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Coletti, A; Cotton, MF; Hazra, R; Jean-Philippe, P; LeBlanc, R; Mirochnick, M; Naidoo, KL; Nelson, BS; Persaud, D; Reding, C; Ruel, TD; Spector, SA; Tierney, C; Zimmer, B, 2021) |
"Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates." | 2.84 | Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. ( Aarons, L; Borkird, T; Capparelli, EV; Cressey, TR; Jittayanun, K; Jourdain, G; Lallemant, M; Le Coeur, S; Luvira, A; Phanomcheong, S; Puangsombat, A; Punyawudho, B; Saenjum, C; Sukrakanchana, PO; Urien, S, 2017) |
"Levonorgestrel implants were inserted at baseline in all women." | 2.82 | Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. ( Back, DJ; Buzibye, A; Byakika-Kibwika, P; Cohn, SE; Darin, KM; Dilly Penchala, S; Else, LJ; Lamorde, M; Merry, C; Nakalema, S; Scarsi, KK, 2016) |
" In a pharmacokinetic investigation, breast milk and plasma samples of mothers and newborns were collected." | 2.78 | Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns. ( Frank, M; Harms, G; Kloft, C; Kunz, A, 2013) |
"We evaluated disease progression among HIV-infected women not on ART with CD4⁺ lymphocyte counts above 200 cells per microliter at delivery." | 2.78 | HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial. ( Brown, ER; Chipato, T; Coovadia, H; Fawzi, W; Fowler, M; George, K; Herron, C; Maldonado, Y; Manji, K; Moodley, D; Nakabiito, C; Reddy, L; Richardson, P; Watts, DH; Zwerski, S, 2013) |
" The primary efficacy endpoint was HIV-1 infection in infants at 6 months and safety endpoints were adverse reactions in both groups." | 2.77 | Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. ( Andrew, P; Brown, ER; Chetty, V; Chipato, T; Coovadia, HM; Eshleman, SH; Fawzi, W; Fowler, MG; George, K; Guay, L; Kisenge, R; Lynn, DJ; Maldonado, Y; Manji, K; Mofenson, LM; Moodley, D; Msweli, L; Musoke, P; Mwatha, A; Nakabiito, C; Richardson, P; Stranix-Chibanda, L; Zwerski, S, 2012) |
"Lamivudine resistance was detected by ASP in only 1 of 51 women who received CBV." | 2.77 | Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. ( Boltz, VF; Chow, JY; Coffin, JM; Gray, GE; Hall, DB; Hopley, MJ; Maldarelli, F; Martinson, NA; Mayers, D; McIntyre, JA; Mellors, JW; Palmer, S; Robinson, P, 2012) |
"46%), underweight (27% vs." | 2.77 | Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India. ( Bollinger, RC; Gupta, A; Gupte, N; Khandave, M; Kinikar, AA; Nayak, U; Ram, M; Sastry, J; Shankar, AV, 2012) |
" A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0." | 2.76 | Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ( Arrivé, E; Avit, D; Benaboud, S; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; McIntyre, J; Nerrienet, E; Rey, E; Sim, KL; Tréluyer, JM; Urien, S, 2011) |
"Birth defects were evaluated among infants on the Pediatric AIDS Clinical Trials Group 316 trial that studied addition of peripartum nevirapine to established ARV regimen for prevention of mother-to-child transmission." | 2.76 | Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. ( Culnane, M; Cunningham, CK; Delfraissy, JF; Huang, S; Kaiser, KA; Mandelbrot, L; Mofenson, L; Newell, ML; Scheuerle, A; Stanley, K; Watts, DH, 2011) |
" Similarly, the proportion of serious adverse events in the HIVIGLOB/sdNVP and sdNVP arms, respectively, for mothers (18." | 2.76 | Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). ( Antelman, G; Falksveden, L; Fowler, MG; Guay, L; Jackson, JB; Mmiro, F; Moulton, LH; Mubiru, M; Musoke, P; Nakabiito, C; Omer, SB; Onyango-Makumbi, C; Wahren, B; Wigzell, H; Zwerski, S, 2011) |
"However, neutropenia was no longer associated with antenatal exposure to HAART after 1 month of age." | 2.73 | Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. ( Bae, WH; Essex, M; Lockman, S; Onyait, K; Shapiro, RL; Smeaton, LM; Thior, I; Wester, C, 2008) |
" Mothers in the usZDV/sdNVP group received a loading dose of zidovudine (600 mg administered orally) and continued to receive 300-mg doses of zidovudine orally every 3 h while in labor, and their infants received zidovudine at a dosage of 2 mg per kg of body weight 4 times per day orally for 72 h." | 2.73 | A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. ( Arbess, G; Boyle, E; Chipato, T; Chitsike, I; Glazier, RH; Gottesman, M; Pilon, R; Silverman, M; Simor, A; Spitzer, RF; Thistle, P, 2007) |
"Nevirapine was detected in the cord blood of 244 of 259 (94%) infants whose mothers reported they took nevirapine in labor more than 1 h before delivery and in 12 of 13 (92%) infants whose mothers reported they took nevirapine less than 1 h before delivery." | 2.72 | Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. ( Donnell, D; Fleming, T; Fowler, MG; Guay, L; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Musoke, P; Nakabiito, C; Parsons, T, 2006) |
" Lower predose nevirapine concentrations were associated with lower cord blood concentrations and a shorter interval between maternal dosing and delivery." | 2.71 | Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. ( Blanchard, S; Culnane, M; Cunningham, CK; Dorenbaum, A; Gelber, RD; Mirochnick, M; Mofenson, L; Sullivan, JL, 2003) |
"Nevirapine was associated with a 41% (95% CI 16-59) reduction in relative risk of transmission through to age 18 months." | 2.71 | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. ( Allen, M; Bagenda, D; Bakaki, P; Bray, D; Deseyve, M; Ducar, C; Duefield, C; Emel, L; Fleming, T; Fowler, MG; Gigliotti, M; Guay, LA; Jackson, JB; Miotti, P; Mirochnick, M; Mmiro, F; Mofenson, L; Musoke, P; Mwatha, A; Nakabiito, C; Owor, M; Sherman, J, 2003) |
" Our data indicate that NVP prophylaxis for 6 months was safe and well tolerated in infants." | 2.71 | Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. ( Abdool Karim, SS; Bassett, MT; Coovadia, HM; Emel, L; Eshleman, SH; Fleming, T; George, K; Jones, SA; Katzenstein, DA; Maldonado, Y; Maponga, CC; Mirochnick, MM; Mofenson, LM; Mwatha, A; Shetty, AK; Wells, J, 2003) |
" The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL." | 2.71 | Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004) |
"The median NVP level fell to 68 ng/mL (range: <50-228, n = 43) 8 to 14 days after dosing and to 51 ng/mL (range: <50-166, n = 25) between 15 and 21 days." | 2.71 | Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. ( Capparelli, E; Cressey, TR; Jackson, JB; Jourdain, G; Kunkeaw, S; Lallemant, MJ; Mirochnick, M; Musoke, P, 2005) |
"Nevirapine resistance was more frequent in infants with subtype C than with subtypes A and D (87 versus 50%, P = 0." | 2.71 | Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. ( Chen, S; Eshleman, SH; Fiscus, SA; Guay, LA; Hoover, DR; Hudelson, SE; Jackson, JB; Kumwenda, N; Mmiro, F; Musoke, P; Mwatha, A; Taha, T, 2005) |
"Pediatric AIDS Clinical Trials Group protocol 316 was an international, multicenter, placebo-controlled trial comparing single-dose oral nevirapine (200 mg to mother and 2 mg/kg to infant) with placebo in human immunodeficiency virus (HIV)-infected pregnant women receiving standard antiretroviral therapy." | 2.70 | Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3 ( Bazin, B; Britto, P; Chaix, ML; Cunningham, CK; Delfraissy, JF; Dorenbaum, A; Gelber, RD; Mofenson, L; Rekacewicz, C; Rouzioux, C; Sullivan, JL, 2002) |
" Initial dose pharmacokinetic profiles in the pregnant women were similar to those seen in nonpregnant adults." | 2.70 | Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. ( Fenton, T; Lugo, M; Mirochnick, M; Siminski, S; Sullivan, JL, 2001) |
"As part of an on-going clinical trial in Malawi, infants born to women who received (early presenters) or did not receive (late presenters) standard intrapartum nevirapine (NVP) dosing were randomized to receive orally either single dose NVP alone or NVP plus zidovudine (twice daily for 1 week)." | 2.70 | Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. ( Broadhead, R; Fiscus, S; Gibbons, A; Hoover, D; Kumwenda, N; Lema, V; Liomba, G; Mukiibi, J; Taha, TE, 2002) |
"Nevirapine elimination was prolonged in both mothers and infants, with median half-lives ranging from 36." | 2.69 | Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. ( Beckerman, K; Fenton, T; Gagnier, P; Gwynne, M; Jimenez, E; Mirochnick, M; Pav, J; Siminski, S; Spector, SA; Sperling, RS; Sullivan, JL; Yogev, R, 1998) |
"Nevirapine, 200 mg, was given as a single dose during labor to 21 HIV-1-infected pregnant Ugandan women." | 2.69 | A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). ( Allen, M; Bagenda, D; Dransfield, K; Elliott, T; Fleming, T; Fowler, MG; Guay, LA; Hom, D; Horton, S; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Murarka, A; Musoke, P; Nakabiito, C; Pav, JW, 1999) |
"Drugs most likely to interact with combined oral contraceptives, transdermal and implant contraceptives include protease inhibitors, the NNRTIs efavirenz and nevirapine, and cobicistat-boosted elvitegravir." | 2.49 | Drug interactions between antiretrovirals and hormonal contraceptives. ( Hills-Nieminen, C; Tseng, A, 2013) |
"The risk of adverse drug events associated with nevirapine (NVP) is suggested to be greater in pregnant women." | 2.49 | Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis. ( Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Shubber, Z, 2013) |
"We reviewed studies comparing serious adverse NVP-related events among ART-naive pregnant women who commenced therapy at higher v." | 2.48 | Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis. ( Bera, E; Mia, R, 2012) |
" The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial." | 2.47 | Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. ( Brocklehurst, P; Siegfried, N; Sint, TT; van der Merwe, L, 2011) |
" More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy." | 2.47 | Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ( Back, DJ; Else, LJ; Khoo, SH; Taylor, S, 2011) |
" Sources included adverse event reports from pharmaceutical manufacturers and the US FDA, reports from peer-reviewed journals/scientific meetings and the Research on Adverse Drug events And Reports (RADAR) project." | 2.45 | Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. ( Bennett, CL; Chandler, KL; Differding, V; Johnson, S; McKoy, JM; Obadina, E; Palella, F; Parada, JP; Raisch, DW; Scarsi, KK; Scheetz, MH; Sutton, S; Yarnold, PR, 2009) |
" The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial." | 2.44 | Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. ( Brocklehurst, P; Siegfried, NL; van der Merwe, L; Volmink, J, 2007) |
"Nevirapine resistance has been detected in a considerable proportion of women after single-dose nevirapine (SD-NVP) for the prevention of mother-to-child human immunodeficiency virus-1 transmission." | 2.44 | Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? ( Eshleman, SH; Kourtis, AP; McConnell, MS; Stringer, JS; Weidle, PJ, 2007) |
" Based on current knowledge, the immense benefits of antiretroviral prophylaxis in reducing the risk of MTCT, far outweigh the potential for adverse effects." | 2.43 | The safety of antiretroviral drugs in pregnancy. ( Newell, ML; Thorne, C, 2005) |
" To minimize toxicity, clinicians must adhere to dosing guidelines, avoid prescribing the drug in patients with known increased risk of toxicity, and promptly recognize toxicities, which are mainly cutaneous and hepatic." | 2.43 | Nevirapine toxicity. ( Taiwo, BO, 2006) |
"Nevirapine is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase." | 2.41 | Nevirapine: pharmacokinetic considerations in children and pregnant women. ( Clarke, DF; Dorenbaum, A; Mirochnick, M, 2000) |
" Although possessing a common mechanism of action, these agents can be differentiated by both molecular and pharmacokinetic characteristics." | 2.41 | Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. ( DiCenzo, R; Morse, GD; Smith, PF, 2001) |
"Lopinavir was mostly requested in patients when adherence measures did not correlate with the clinical picture, suspected non-adherence, lopinavir-rifampicin interactions and for neonatal safety monitoring." | 1.56 | Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital. ( Decloedt, EH; Engelbrecht, AE; Norman, J; Rabie, H; Wiesner, L, 2020) |
"A physiologically-based pharmacokinetic (PBPK) model for nevirapine, which is metabolized by the cytochrome P450 (CYP) 3A4, 2B6 and 2D6 pathways, was developed to predict maternal and fetal pharmacokinetics (PK)." | 1.46 | A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways. ( Benaboud, S; Blanche, S; Bouazza, N; De Sousa Mendes, M; Foissac, F; Hirt, D; Lui, G; Pressiat, C; Treluyer, JM; Urien, S; Valade, E; Zheng, Y, 2017) |
"Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes." | 1.43 | Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. ( Maharaj, N; Moodley, D; Moodley, T; Sartorius, B; Sebitloane, M, 2016) |
" We investigated the frequency and severity of adverse events (AE) in infants receiving multiple drug prophylaxis compared to ZDV alone." | 1.42 | Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review. ( Barr, E; Davies, J; Forster, JE; Kinzie, K; Levin, MJ; McFarland, EJ; Pappas, J; Paul, S; Smith, C; Weinberg, A, 2015) |
"Nevirapine was the offending drug in 21/22 (95%) cases." | 1.42 | Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women. ( Knight, L; Lehloenya, RJ; Matjila, M; Muloiwa, R; Todd, G, 2015) |
"Only zidovudine has adequate dosing recommendations for treating term and preterm infants and has an intravenous formulation, essential if feeding intolerance occurs." | 1.42 | The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. ( Cotton, MF; Holgate, S; Mirochnick, M; Nelson, A; Rabie, H; Wedderburn, C, 2015) |
"To investigate if pregnancy is a risk factor for SJS among HIV-infected women taking NVP-containing regimens and registered within the Medunsa National Pharmacovigilance Centre database." | 1.39 | Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012. ( Adewusi, E; Dube, N; Summers, R, 2013) |
" Mice were dosed twice daily until PND 28." | 1.39 | Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u ( , 2013) |
"Demographic, treatment and pregnancy related data were collected." | 1.38 | Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. ( Boer, K; de Wolf, F; Godfried, MH; Nellen, JF; Smit, C; Snijdewind, IJ; van der Ende, ME, 2012) |
"We compared adverse events among breast-feeding neonates born to Kenyan mothers receiving triple-antiretroviral therapy, including either nevirapine or nelfinavir." | 1.38 | Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. ( Akoth, B; Angira, F; Masaba, R; Mills, LA; Minniear, TD; Ndivo, R; Oyaro, B; Peters, PJ; Polle, N; Thomas, TK; Zeh, C, 2012) |
"Nevirapine was given at delivery to 93/135 (69%) women, and to 128/135 (95%) children." | 1.38 | HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective observational study. ( Anh, NM; Bao, NH; Cam, PD; Caridha, R; Ehrnst, A; Gaseitsiwe, S; Ha, TT; Hien, NT; Tuan, PL, 2012) |
" Our study suggests that NVP dosing of preterm infants as soon as possible after birth without maternal intrapartum dosing may be as effective as combined maternal and infant dosing." | 1.37 | Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1. ( Cotton, MF; Els, I; Hall, D; Madsen, R; Mirochnick, M; Mugabo, P; Rabie, H; Smith, J; Smith, P; Steyn, W, 2011) |
" Pharmacokinetic parameter estimates and model-predicted HIV-1 transmission rates were very consistent with other studies." | 1.37 | Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. ( Frank, M; Harms, G; Kloft, C; Kunz, A; Schütte, C; von Kleist, M, 2011) |
"Nevirapine is widely used to treat HIV-1 infection to prevent mother-to-child transmission; unfortunately adverse drug reactions have been reported." | 1.36 | Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. ( Altan, AM; Borgiani, P; Bramanti, P; Ceffa, S; Ciccacci, C; Marazzi, MC; Novelli, G; Palombi, L; Paturzo, G; Sirianni, E, 2010) |
"To investigate uptake and provision of antenatal care (ANC) services in the Uzazi Bora project: a demonstration-intervention project for Safe Motherhood and prevention of mother-to-child transmission of HIV in Kenya." | 1.36 | A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT. ( Chersich, MF; Delva, W; Luchters, S; Muigai, E; Oyier, V; Temmerman, M; Yard, E, 2010) |
"Predictors of adverse events (AE) associated with nevirapine use are needed to better understand reports of severe rash or liver enzyme elevation (LEE) in HIV+ women." | 1.36 | Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. ( Aaron, E; Bachmann, LH; Criniti, S; Gracely, E; Kempf, MC; Kumar, R; Tedaldi, E; Warriner, A, 2010) |
"Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively." | 1.35 | Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ( Capparelli, E; Fowler, MG; Holland, D; Masaba, R; Mirochnick, M; Odhiambo, P; Thigpen, MC; Thomas, T; Weidle, PJ; Zeh, C, 2009) |
"Non-nevirapine regimens were initiated following biochemical and symptomatic improvement; symptoms did not recur." | 1.35 | Incidence of nevirapine-associated hepatitis in an antenatal clinic. ( Black, V; Rees, H, 2008) |
"Pregnancy has a moderate but significant lowering effect on NVP plasma concentrations." | 1.35 | Steady-state nevirapine plasma concentrations are influenced by pregnancy. ( Boer, K; Burger, DM; Damming, M; de Wolf, F; Godfried, MH; Nellen, JF; Prins, JM; van der Ende, ME; Wit, FW, 2008) |
" The objectives were to compare NVP levels, adverse events, and 36-week efficacy of NVP-based ART between patients who did not receive FLU (group A) and those who received FLU 200 mg/day or 400 mg/day (group B)." | 1.34 | Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. ( Athichathanabadi, C; Manosuthi, W; Phoorisri, T; Sungkanuparph, S; Uttayamakul, S, 2007) |
" Neutropenia (usually transient) was the most common severe adverse event." | 1.34 | Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India. ( Bethel, J; Dharmarajan, S; Jacob, SM; Junankar, V; Parameshwari, S; Read, JS; Samuel, NM; Stoszek, SK; Van Hook, HM; Xu, J, 2007) |
"Nevirapine was quantifiable for up to 17 days after discontinuation of therapy; total nevirapine concentrations remained above the 90% inhibitory concentration for 6 days, and no differences were observed between breasts." | 1.34 | Persistence of nevirapine in breast milk after discontinuation of treatment. ( Acosta, EP; Aldrovandi, GM; Ashouri, N; Bennetto-Hood, C; King, JR; Woodman, K, 2007) |
"Transmission prophylaxis in offspring of HIV-positive mothers may give rise to adverse effects." | 1.34 | [Side effects of antiretroviral treatment for transmission prophylaxis in preterm and near-term infants]. ( Bauer, K; Dunsch, D; Haberl, A; Linde, R; Reitter, A; Schlösser, R, 2007) |
"All nevirapine side effects were developed in less than seven weeks." | 1.34 | Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. ( Carraro, EA; Cornelsen, TC; Dias, JM; Kondo, W; Macedo, RL; Perini, J; Prandel, E; Sasaki, Md; Sbalquiero, R, 2007) |
"Zidovudine (AZT) was provided antenatally from week 34 of gestation and during labour." | 1.33 | Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. ( Abdullah, F; Boulle, A; Coetzee, D; Draper, B; Goemaere, E; Hilderbrand, K, 2005) |
" Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP." | 1.33 | Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. ( Calvet, GA; Cruz, ML; D'Ippolito, MM; João, EC; Matos, HJ; Menezes, JA; Salgado, LA, 2006) |
" In a multivariate model, K103N detection was associated with HIV-1 subtype (C > A), after adjusting for log10 delivery viral load, the number of days between NVP dosing and sample collection, age, and parity." | 1.33 | Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. ( Chen, S; Church, JD; Eshleman, SH; Fiscus, SA; Flys, TS; Guay, LA; Hoover, DR; Jackson, JB; Jones, DC; Kumwenda, N; Mmiro, F; Musoke, P; Mwatha, A; Taha, TE, 2006) |
" A pre-dose to 6 h post-dose steady-state pharmacokinetic analysis (n = 35) of the drugs on the day of the scheduled Caesarean section was performed." | 1.33 | Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. ( Belohradsky, BH; Eberle, J; Friese, K; Gingelmaier, A; Grubert, TA; Kästner, R; Kurowski, M; Mylonas, I, 2006) |
"To assess the incidence and consequences of adverse reactions among African HIV-positive pregnant women treated with fixed-dose combinations of a nevirapine-containing antiretroviral (ARV) triple therapy." | 1.33 | Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. ( da Cruz Gomes, A; Germano, P; Guidotti, G; Liotta, G; Loureiro, S; Mancinelli, S; Marazzi, MC; Narciso, P; Palombi, L; Perno, CF; Valls Blazquez, MC, 2006) |
"To reduce mother-to-child transmission (MTCT) of HIV, we assessed the stability of nevirapine suspension in an oral dosing syringe over a range of storage conditions." | 1.33 | Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission. ( Dreyfuss, ML; Gray, RH; Hamzeh, FM; Li, X; Parsons, TL; Rexroad, VE; Stamper, PD, 2006) |
" The influence of gender, age, body weight and comedication on minimum and maximum concentrations (C(min), C(max)), area under the concentration-time curve (AUC), total clearance (CL(tot)), half-life (t(1/2)) and volume of distribution (V(d)) was analysed by multivariate techniques." | 1.33 | A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. ( Carlebach, A; Gute, P; Haberl, A; Harder, S; Klauke, S; Knecht, G; Kurowski, M; Rohrbacher, M; Staszewski, S; Stocker, H; von Hentig, N, 2006) |
"In HIV-infected women receiving prenatal care and ART, adverse events were uncommon." | 1.32 | Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. ( Balasubramanian, R; Culnane, M; Cunningham, CK; Delfraissy, JF; Delke, I; Dorenbaum, A; Fiore, S; Gelber, RD; Maupin, RT; Mofenson, LM; Newell, ML; Watts, DH, 2004) |
" Labor ward dosing to enhance nevirapine coverage should be considered as an adjunct to antenatal nevirapine administration for prevention of mother-to-child transmission of HIV." | 1.32 | Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. ( Acosta, EP; Aldrovandi, GM; Goldenberg, RL; Kumwenda, R; Sinkala, M; Stout, JP; Stringer, JS; Vermund, SH, 2004) |
"Nevirapine was provided to HIV-1-seropositive women and condoms distributed to all participants." | 1.32 | Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. ( Farquhar, C; John, FN; John-Stewart, GC; Kabura, MN; Kiarie, JN; Mbori-Ngacha, DA; Nduati, RW; Richardson, BA, 2004) |
"Mass treatment of nevirapine would increase access to antiretroviral drugs among pregnant women because they can access nevirapine without volunteer counseling and testing, which 31% of pregnant women in developing countries refused to accept due to the fear of stigmatization." | 1.31 | Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries. ( Hashimoto, H; Kapiga, SH; Murata, Y, 2002) |
" Nevirapine is well absorbed during labor, and sufficient drug for prophylaxis against perinatal transmission crosses the placenta if an oral dose is administered to the mother at least 1 hour before delivery." | 1.31 | Antiretroviral pharmacology in pregnant women and their newborns. ( Mirochnick, M, 2000) |
"Nevirapine is a non-nucleoside HIV reverse transcriptase inhibitor." | 1.29 | Nevirapine: ethical dilemmas and care for HIV-infected mothers. ( Benson, M; Shannon, M, 1995) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 38 (5.70) | 18.2507 |
2000's | 386 (57.87) | 29.6817 |
2010's | 221 (33.13) | 24.3611 |
2020's | 22 (3.30) | 2.80 |
Authors | Studies |
---|---|
Yeh, RF | 1 |
Rezk, NL | 1 |
Kashuba, AD | 2 |
Dumond, JB | 1 |
Tappouni, HL | 1 |
Tien, HC | 1 |
Chen, YC | 1 |
Vourvahis, M | 1 |
Horton, AL | 1 |
Fiscus, SA | 13 |
Patterson, KB | 1 |
Boyce, CL | 1 |
Sils, T | 1 |
Ko, D | 1 |
Wong-On-Wing, A | 1 |
Beck, IA | 5 |
Styrchak, SM | 1 |
DeMarrais, P | 1 |
Tierney, C | 2 |
Stranix-Chibanda, L | 6 |
Flynn, PM | 3 |
Taha, TE | 14 |
Owor, M | 7 |
Fowler, MG | 30 |
Frenkel, LM | 9 |
Chaúque, S | 1 |
Mohole, J | 1 |
Zucula, H | 1 |
Lambo, L | 1 |
Lisboa, A | 1 |
Ferreira, D | 1 |
Nguyen, H | 1 |
Chowdhary, H | 1 |
Macmillian, B | 1 |
Elias, B | 1 |
Seni, A | 1 |
Buck, WC | 1 |
Dollfus, C | 1 |
Le Chenadec, J | 1 |
Mandelbrot, L | 2 |
Tubiana, R | 1 |
Faye, A | 2 |
Brossard, M | 1 |
Frange, P | 1 |
Blanche, S | 5 |
Warszawski, J | 1 |
Cuco, RM | 1 |
Loquiha, O | 1 |
Juga, A | 1 |
Couto, A | 1 |
Meggi, B | 1 |
Vubil, A | 1 |
Sevene, E | 1 |
Osman, N | 2 |
Temermam, M | 1 |
Degomme, O | 1 |
Sidat, M | 2 |
Bhatt, N | 1 |
Stalter, RM | 1 |
Amorim, G | 1 |
Mocello, AR | 1 |
Jakait, B | 2 |
Shepherd, BE | 2 |
Musick, B | 1 |
Bernard, C | 1 |
Bukusi, EA | 3 |
Wools-Kaloustian, K | 2 |
Cohen, CR | 4 |
Yiannoutsos, CT | 1 |
Patel, RC | 4 |
Jao, J | 2 |
Sun, S | 1 |
Bonner, LB | 1 |
Legbedze, J | 1 |
Mmasa, KN | 1 |
Makhema, J | 7 |
Mmalane, M | 1 |
Kgole, S | 1 |
Masasa, G | 1 |
Moyo, S | 4 |
Gerschenson, M | 1 |
Mohammed, T | 1 |
Abrams, EJ | 10 |
Kurland, IJ | 2 |
Geffner, ME | 2 |
Powis, KM | 1 |
Namara-Lugolobi, E | 1 |
Namukwaya, Z | 2 |
Ouma, J | 1 |
Namale-Matovu, J | 1 |
Nakabiito, C | 14 |
Ndugwa, C | 1 |
Musoke, P | 30 |
Penazzato, M | 2 |
Kasirye, I | 1 |
Ruel, T | 1 |
Mukui, I | 1 |
Bekker, A | 1 |
Archary, M | 1 |
Essajee, S | 1 |
Siberry, GK | 2 |
Mahy, M | 1 |
Simnoue, D | 1 |
Simione, B | 1 |
Zech, JM | 1 |
Mushavi, A | 2 |
Larsen, A | 1 |
Magasana, V | 1 |
Dinh, TH | 2 |
Ngandu, N | 1 |
Lombard, C | 3 |
Cheyip, M | 1 |
Ayalew, K | 1 |
Chirinda, W | 1 |
Kindra, G | 1 |
Jackson, D | 2 |
Goga, A | 2 |
Onyango-Makumbi, C | 2 |
Owora, AH | 1 |
Mwiru, RS | 1 |
Mwatha, A | 14 |
Young, AM | 1 |
Moodley, D | 13 |
Coovadia, HM | 5 |
Manji, K | 3 |
Maldonado, Y | 6 |
Richardson, P | 3 |
Andrew, P | 2 |
George, K | 4 |
Fawzi, W | 3 |
Hompe, ED | 1 |
Jacobson, DL | 1 |
Eudailey, JA | 1 |
Butler, K | 2 |
Edwards, W | 1 |
Pollara, J | 1 |
Brummel, SS | 1 |
Fouda, GG | 1 |
Chinula, L | 1 |
Kamanga, M | 1 |
Kinikar, A | 3 |
Permar, SR | 2 |
Engelbrecht, AE | 1 |
Wiesner, L | 2 |
Norman, J | 1 |
Rabie, H | 5 |
Decloedt, EH | 1 |
Venkatesh, KK | 2 |
Farhad, M | 1 |
Fenton, T | 4 |
Naik, S | 1 |
Fairlie, L | 1 |
Stringer, JSA | 1 |
Chi, BH | 14 |
Lallemant, M | 10 |
Amzal, B | 1 |
Sripan, P | 1 |
Urien, S | 4 |
Cressey, TR | 7 |
Ngo-Giang-Huong, N | 9 |
Klinbuayaem, V | 2 |
Rawangban, B | 1 |
Sabsanong, P | 3 |
Siriwachirachai, T | 1 |
Jarupanich, T | 2 |
Kanjanavikai, P | 2 |
Wanasiri, P | 1 |
Koetsawang, S | 4 |
Jourdain, G | 11 |
Le Coeur, S | 7 |
Suryavanshi, N | 5 |
Kadam, A | 1 |
Gupte, N | 7 |
Hegde, A | 1 |
Kanade, S | 1 |
Sivalenka, S | 1 |
Kumar, VS | 1 |
Gupta, A | 8 |
Bollinger, RC | 6 |
Shankar, A | 2 |
McKenzie-White, J | 1 |
Mave, V | 3 |
Napyo, A | 1 |
Tylleskär, T | 1 |
Mukunya, D | 1 |
Tumuhamye, J | 1 |
Musaba, MW | 1 |
Ojok Arach, AA | 1 |
Waako, P | 1 |
Tumwine, JK | 1 |
Ndeezi, G | 1 |
Bhattacharya, D | 1 |
Guo, R | 1 |
Tseng, CH | 1 |
Emel, L | 5 |
Sun, R | 1 |
Chiu, SH | 1 |
Chipato, T | 6 |
Mohtashemi, NZ | 1 |
Kintu, K | 1 |
Manji, KP | 1 |
Thio, CL | 1 |
Currier, JS | 3 |
Waitt, C | 1 |
Myer, L | 1 |
Khoo, S | 3 |
Ruel, TD | 1 |
Capparelli, EV | 4 |
Nelson, BS | 1 |
Coletti, A | 1 |
Bryson, Y | 2 |
Cotton, MF | 6 |
Spector, SA | 3 |
Mirochnick, M | 20 |
LeBlanc, R | 1 |
Reding, C | 1 |
Zimmer, B | 1 |
Persaud, D | 3 |
Bwakura-Dangarembizi, M | 2 |
Naidoo, KL | 1 |
Hazra, R | 1 |
Jean-Philippe, P | 2 |
Chadwick, EG | 1 |
Celerino da Silva, R | 1 |
Segat, L | 1 |
Kuhn, L | 14 |
Chies, JAB | 1 |
Crovella, S | 1 |
Menegotto, M | 1 |
Magdaleno, AM | 1 |
da Silva, CLO | 1 |
Friedrich, L | 1 |
da Silva, CH | 1 |
Aguti, I | 1 |
Kimbugwe, C | 1 |
Apai, P | 1 |
Munyaga, S | 1 |
Nyeko, R | 1 |
Bitarakwate, E | 2 |
Ashburn, K | 1 |
Kazooba, P | 1 |
Khamasi, R | 1 |
Natumanya, E | 1 |
Herrera, N | 1 |
Owomugisha, B | 1 |
Malkin, RA | 2 |
Kisaakye, L | 1 |
Hirt, D | 3 |
Kubota Kilengelela, J | 1 |
Jarreau, PH | 1 |
Tréluyer, JM | 3 |
Marcou, V | 1 |
Kebaya, LMN | 1 |
Wamalwa, D | 1 |
Kariuki, N | 1 |
Admani, B | 1 |
Ayieko, P | 1 |
Nduati, R | 1 |
Cababasay, M | 1 |
Mofenson, LM | 12 |
Fiscus, S | 4 |
Coutsoudis, A | 2 |
Gnanashanmugam, D | 2 |
Chakhtoura, N | 1 |
McCarthy, K | 1 |
Frenkel, L | 4 |
Beck, I | 2 |
Mukuzunga, C | 1 |
Makanani, B | 1 |
Nematadzira, T | 1 |
Kusakara, B | 1 |
Patil, S | 5 |
Vhembo, T | 1 |
Bobat, R | 3 |
Mmbaga, BT | 2 |
Masenya, M | 1 |
Nyati, M | 1 |
Theron, G | 3 |
Mulenga, H | 1 |
Shapiro, DE | 6 |
Girma, M | 1 |
Wendaferash, R | 1 |
Shibru, H | 1 |
Berhane, Y | 1 |
Hoelscher, M | 1 |
Kroidl, A | 1 |
McIlleron, H | 1 |
Denti, P | 1 |
Cohn, S | 1 |
Mashabela, F | 1 |
Hoffmann, JD | 1 |
Shembe, S | 1 |
Msandiwa, R | 1 |
Velaphi, S | 1 |
Lala, SG | 2 |
Chaisson, RE | 1 |
Martinson, N | 7 |
Dooley, KE | 1 |
Punyawudho, B | 1 |
Saenjum, C | 1 |
Jittayanun, K | 1 |
Phanomcheong, S | 1 |
Luvira, A | 1 |
Borkird, T | 1 |
Puangsombat, A | 1 |
Aarons, L | 1 |
Sukrakanchana, PO | 1 |
Bhat, J | 1 |
Bharadwaj, R | 3 |
Kulkarni, V | 4 |
Bhosale, R | 7 |
McIntire, KN | 1 |
Bollinger, R | 2 |
Morroni, C | 1 |
Scarsi, KK | 4 |
Sripipatana, T | 2 |
Kiarie, J | 4 |
Birlie, B | 1 |
Braekers, R | 1 |
Awoke, T | 1 |
Kasim, A | 1 |
Shkedy, Z | 1 |
Mwau, M | 1 |
Bwana, P | 1 |
Kithinji, L | 1 |
Ogollah, F | 1 |
Ochieng, S | 1 |
Akinyi, C | 1 |
Adhiambo, M | 1 |
Ogumbo, F | 1 |
Sirengo, M | 1 |
Boeke, C | 1 |
Cook, RR | 1 |
Peltzer, K | 2 |
Weiss, SM | 1 |
Rodriguez, VJ | 1 |
Jones, DL | 1 |
Veroniki, AA | 1 |
Antony, J | 1 |
Straus, SE | 1 |
Ashoor, HM | 1 |
Finkelstein, Y | 1 |
Khan, PA | 1 |
Ghassemi, M | 1 |
Blondal, E | 1 |
Ivory, JD | 1 |
Hutton, B | 1 |
Gough, K | 1 |
Hemmelgarn, BR | 1 |
Lillie, E | 1 |
Vafaei, A | 1 |
Tricco, AC | 1 |
Nkenfou, CN | 1 |
Temgoua, ES | 1 |
Ndzi, EN | 1 |
Mekue, LCM | 1 |
Ngoufack, MN | 1 |
Dambaya, B | 1 |
Anoubissi, JD | 1 |
Domkam, I | 2 |
Elong, E | 1 |
Fainguem, N | 1 |
Thèze, J | 1 |
Colizzi, V | 2 |
Bissek, ACZK | 1 |
Ndjolo, A | 1 |
Haaland, RE | 1 |
Otieno, K | 1 |
Martin, A | 1 |
Katana, A | 1 |
Dinh, C | 1 |
Slutsker, L | 1 |
Menendez, C | 2 |
Gonzalez, R | 1 |
Williamson, J | 1 |
Heneine, W | 4 |
Desai, M | 1 |
Ogalo, EA | 1 |
Adina, JO | 1 |
Ooko, H | 1 |
Batuka, J | 1 |
Kimaiyo, S | 1 |
Torimiro, JN | 1 |
Nanfack, A | 1 |
Takang, W | 1 |
Keou, CK | 1 |
Joyce, AN | 1 |
Njefi, K | 1 |
Agyingi, K | 1 |
Takou, D | 1 |
Moudourou, S | 1 |
Sosso, S | 1 |
Mbu, RE | 2 |
Liu, JX | 1 |
Shen, J | 1 |
Wilson, N | 1 |
Janumpalli, S | 1 |
Stadler, P | 1 |
Padian, N | 1 |
Wang, X | 2 |
Guo, G | 1 |
Zheng, J | 1 |
Lu, L | 1 |
Potty, RS | 1 |
Sinha, A | 1 |
Sethumadhavan, R | 1 |
Isac, S | 1 |
Washington, R | 1 |
Apangu, P | 1 |
Izudi, J | 1 |
Bajunirwe, F | 2 |
Mulogo, E | 1 |
Batwala, V | 1 |
Strehlau, R | 2 |
Paximadis, M | 1 |
Patel, F | 1 |
Burke, M | 1 |
Technau, KG | 1 |
Shiau, S | 2 |
Sherman, GG | 3 |
Hunt, G | 1 |
Ledwaba, J | 2 |
Mazanderani, AH | 1 |
Tiemessen, CT | 4 |
Thomas, K | 1 |
Yiannoutsos, C | 1 |
Onono, M | 2 |
Wools-Kaloustian, KK | 1 |
Tseng, A | 1 |
Hills-Nieminen, C | 1 |
Ton, Q | 1 |
Frank, M | 2 |
Harms, G | 7 |
Kunz, A | 7 |
Kloft, C | 2 |
Reynolds, HW | 2 |
Gachuno, O | 1 |
Kayita, J | 2 |
Hays, MA | 1 |
Otterness, C | 1 |
Rakwar, J | 1 |
Darak, S | 1 |
Darak, T | 1 |
Kulkarni, S | 3 |
Parchure, R | 1 |
Hutter, I | 1 |
Janssen, F | 1 |
Wang, R | 1 |
Weng, J | 1 |
Pain, D | 1 |
Barr, CD | 1 |
Maruapula, D | 1 |
Mongwato, D | 1 |
Novitsky, V | 3 |
Essex, M | 8 |
Audureau, E | 1 |
Kahn, JG | 5 |
Besson, MH | 1 |
Saba, J | 1 |
Ladner, J | 1 |
Vardhanabhuti, S | 1 |
Acosta, EP | 7 |
Ribaudo, HJ | 2 |
Severe, P | 1 |
Lalloo, U | 1 |
Kumarasamy, N | 2 |
Taulo, F | 2 |
Kabanda, J | 2 |
Oneko, O | 1 |
Ive, P | 1 |
Sambarey, P | 2 |
Chan, ES | 2 |
Hitti, J | 7 |
Hong, F | 2 |
McMahon, D | 1 |
Haas, DW | 1 |
Kourtis, AP | 7 |
Wiener, J | 4 |
Kayira, D | 5 |
Chasela, C | 3 |
Ellington, SR | 3 |
Hyde, L | 1 |
Hosseinipour, M | 1 |
van der Horst, C | 6 |
Jamieson, DJ | 6 |
Werayingyong, P | 1 |
Phanuphak, N | 2 |
Chokephaibulkit, K | 1 |
Tantivess, S | 1 |
Kullert, N | 1 |
Tosanguan, K | 1 |
Butchon, R | 1 |
Voramongkol, N | 1 |
Boonsuk, S | 1 |
Pilasant, S | 1 |
Kulpeng, W | 1 |
Teerawattananon, Y | 1 |
Bendle, M | 1 |
Bajpai, S | 1 |
Choudhary, A | 1 |
Pazare, A | 1 |
Watts, DH | 8 |
Brown, ER | 4 |
Herron, C | 1 |
Reddy, L | 1 |
Zwerski, S | 5 |
Coovadia, H | 7 |
Fowler, M | 1 |
Fillekes, Q | 3 |
Muro, EP | 2 |
Chunda, C | 1 |
Aitken, S | 1 |
Kisanga, ER | 2 |
Kankasa, C | 11 |
Thomason, MJ | 1 |
Gibb, DM | 3 |
Walker, AS | 2 |
Burger, DM | 4 |
Cohan, D | 1 |
Mwesigwa, J | 1 |
Natureeba, P | 1 |
Aliba Luwedde, F | 1 |
Ades, V | 1 |
Plenty, A | 1 |
Kakuru, A | 1 |
Achan, J | 1 |
Clark, T | 1 |
Osterbauer, B | 1 |
Kamya, M | 1 |
Havlir, D | 1 |
Salazar, MG | 1 |
Gao, F | 1 |
Cai, F | 1 |
Learn, GH | 1 |
Kalilani, L | 1 |
Hahn, BH | 1 |
Shaw, GM | 1 |
Salazar-Gonzalez, JF | 1 |
Dube, N | 1 |
Adewusi, E | 1 |
Summers, R | 1 |
Bock, P | 1 |
Fatti, G | 1 |
Grimwood, A | 1 |
Nanda, K | 1 |
Delany-Moretlwe, S | 1 |
Dubé, K | 1 |
Lendvay, A | 1 |
Kwok, C | 1 |
Molife, L | 1 |
Nakubulwa, S | 1 |
Edward, VA | 1 |
Mpairwe, B | 1 |
Mirembe, FM | 1 |
Donnell, D | 5 |
Mmiro, F | 23 |
Allen, M | 4 |
Jackson, JB | 25 |
Guay, LA | 18 |
Sartorius, BK | 1 |
Chersich, MF | 4 |
Mwaura, M | 1 |
Meda, N | 1 |
Temmerman, M | 6 |
Newell, ML | 13 |
Farley, TM | 1 |
Luchters, S | 3 |
Ramokolo, V | 2 |
Fadnes, LT | 1 |
Doherty, T | 3 |
Jackson, DJ | 1 |
Goga, AE | 1 |
Chhagan, M | 1 |
Van den Broeck, J | 1 |
Perry, SH | 1 |
Swamy, P | 1 |
Preidis, GA | 1 |
Mwanyumba, A | 1 |
Motsa, N | 1 |
Sarero, HN | 1 |
Kayentao, K | 1 |
Guirou, EA | 1 |
Doumbo, OK | 1 |
Venkatesan, M | 1 |
Plowe, CV | 1 |
Parsons, TL | 4 |
Hendrix, CW | 1 |
Nyunt, MM | 1 |
Ngemu, EK | 1 |
Khayeka-Wandabwa, C | 1 |
Kweka, EJ | 1 |
Choge, JK | 1 |
Anino, E | 1 |
Oyoo-Okoth, E | 1 |
Buchanan, AM | 1 |
Dow, DE | 2 |
Massambu, CG | 1 |
Nyombi, B | 1 |
Shayo, A | 1 |
Musoke, R | 1 |
Feng, S | 1 |
Bartlett, JA | 1 |
Cunningham, CK | 7 |
Schimana, W | 2 |
Manicklal, S | 1 |
van Niekerk, AM | 1 |
Kroon, SM | 1 |
Hutto, C | 1 |
Novak, Z | 1 |
Pati, SK | 1 |
Chowdhury, N | 1 |
Hsiao, NY | 1 |
Boppana, SB | 1 |
Micek, MA | 3 |
Dross, S | 2 |
Blanco, AJ | 3 |
Matunha, L | 2 |
Seidel, K | 2 |
Montoya, P | 3 |
Matediana, E | 2 |
Gantt, S | 2 |
Gloyd, S | 3 |
Baranyai, D | 1 |
Muro, E | 1 |
Gödtel-Armbrust, U | 1 |
Schirmer, MA | 1 |
Kisanga, E | 1 |
Diczfalusy, U | 1 |
Schuurman, R | 2 |
Burger, D | 1 |
Wojnowski, L | 1 |
O'Brien, L | 1 |
Shaffer, N | 6 |
Sangrujee, N | 1 |
Abimbola, TO | 1 |
Andreotti, M | 5 |
Pirillo, MF | 4 |
Liotta, G | 7 |
Jere, H | 4 |
Maulidi, M | 1 |
Sagno, JB | 3 |
Luhanga, R | 2 |
Amici, R | 6 |
Mancini, MG | 2 |
Gennaro, E | 1 |
Marazzi, MC | 10 |
Vella, S | 6 |
Giuliano, M | 7 |
Palombi, L | 10 |
Mancinelli, S | 6 |
Price, AJ | 1 |
Kayange, M | 1 |
Zaba, B | 1 |
Chimbwandira, FM | 1 |
Jahn, A | 2 |
Chirwa, Z | 2 |
Dasgupta, AN | 1 |
Katundu, C | 1 |
Saul, JL | 1 |
Glynn, JR | 1 |
Koole, O | 1 |
Crampin, AC | 1 |
Chetty, T | 1 |
Carter, RJ | 2 |
Bland, RM | 2 |
Hamela, G | 1 |
Kabondo, C | 1 |
Tembo, T | 1 |
Zimba, C | 1 |
Kamanga, E | 1 |
Mofolo, I | 1 |
Bulla, B | 1 |
Sellers, C | 1 |
Nakanga, RC | 1 |
Lee, C | 1 |
Martinson, F | 3 |
Hoffman, I | 2 |
Hosseinipour, MC | 5 |
Saegusa, T | 1 |
Di, C | 1 |
Chen, YQ | 2 |
Onwuamah, CK | 1 |
Ezechi, OC | 1 |
Herbertson, EC | 1 |
Audu, RA | 2 |
Ujah, IA | 1 |
Odeigah, PG | 1 |
Dross, SE | 1 |
Rossi, SS | 1 |
Seidel, KD | 1 |
Mistry, N | 1 |
Sereboe, L | 1 |
Oakeshott, P | 1 |
Iveli, P | 1 |
Noguera-Julian, A | 1 |
Soler-Palacín, P | 1 |
Martín-Nalda, A | 1 |
Rovira-Girabal, N | 1 |
Fortuny-Guasch, C | 1 |
Figueras-Nadal, C | 1 |
Phan, CT | 1 |
Pham, HV | 1 |
Bi, X | 1 |
Ishizaki, A | 1 |
Saina, M | 1 |
Phung, CD | 1 |
Khu, DT | 1 |
Ichimura, H | 1 |
Desmond, AC | 1 |
Conolly, CA | 1 |
Castel, SA | 1 |
Samuel, R | 2 |
Paredes, R | 3 |
Parboosing, R | 2 |
Moodley, P | 2 |
Singh, L | 2 |
Naidoo, A | 2 |
Gordon, M | 2 |
Dominguez, K | 2 |
Cotton, M | 1 |
Barlow-Mosha, L | 1 |
Ford, N | 2 |
Smith, C | 1 |
Forster, JE | 1 |
Levin, MJ | 1 |
Davies, J | 1 |
Pappas, J | 1 |
Kinzie, K | 1 |
Barr, E | 1 |
Paul, S | 1 |
McFarland, EJ | 1 |
Weinberg, A | 1 |
Galluzzo, CM | 5 |
Kirmse, B | 1 |
Yu, C | 1 |
Qiu, Y | 1 |
Powis, K | 3 |
Nshom, E | 1 |
Epie, F | 1 |
Tih, PM | 3 |
Sperling, RS | 2 |
LeRoith, D | 1 |
Woldesenbet, S | 1 |
Puren, A | 4 |
Sherman, G | 3 |
Mogashoa, M | 1 |
Bhardwaj, S | 1 |
Chopra, M | 2 |
Pillay, Y | 1 |
Knight, L | 1 |
Todd, G | 1 |
Muloiwa, R | 1 |
Matjila, M | 2 |
Lehloenya, RJ | 1 |
Sirirungsi, W | 1 |
Traisathit, P | 1 |
Mcintosh, K | 5 |
Kiweewa, FM | 1 |
Bakaki, PM | 2 |
McConnell, MS | 5 |
Musisi, M | 1 |
Namirembe, C | 1 |
Nakayiwa, F | 1 |
Kusasira, F | 1 |
Nakintu, D | 1 |
Mubiru, MC | 1 |
Chang, TS | 1 |
Dollard, SC | 1 |
Amin, MM | 1 |
Ellington, S | 2 |
Okawa, S | 1 |
Chirwa, M | 1 |
Ishikawa, N | 2 |
Kapyata, H | 1 |
Msiska, CY | 1 |
Syakantu, G | 1 |
Miyano, S | 2 |
Komada, K | 1 |
Jimba, M | 1 |
Yasuoka, J | 1 |
Vogt, F | 1 |
Ferreyra, C | 2 |
Bernasconi, A | 1 |
Ncube, L | 1 |
Taziwa, F | 1 |
Marange, W | 1 |
Wachi, D | 1 |
Becher, H | 1 |
Gandhi, M | 1 |
Blat, C | 1 |
Hagey, J | 1 |
Shade, SB | 1 |
Vittinghoff, E | 1 |
Newmann, SJ | 1 |
De Nardo, P | 1 |
Gentilotti, E | 1 |
Nguhuni, B | 1 |
Vairo, F | 1 |
Chaula, Z | 1 |
Nicastri, E | 2 |
Ippolito, G | 1 |
Baroncelli, S | 2 |
Holgate, S | 1 |
Nelson, A | 1 |
Wedderburn, C | 1 |
Darin, KM | 1 |
Nakalema, S | 1 |
Back, DJ | 3 |
Byakika-Kibwika, P | 2 |
Else, LJ | 2 |
Dilly Penchala, S | 1 |
Buzibye, A | 1 |
Cohn, SE | 1 |
Merry, C | 2 |
Lamorde, M | 2 |
Nakanga, W | 1 |
Patel, P | 1 |
Panjwani, S | 1 |
Kennedy, N | 1 |
Kawaza, K | 1 |
Bolaris, MA | 1 |
Keller, MA | 1 |
Robbins, BL | 1 |
Podany, AT | 1 |
Fletcher, CV | 1 |
Moodley, T | 1 |
Sebitloane, M | 1 |
Maharaj, N | 1 |
Sartorius, B | 1 |
Cha, A | 1 |
Elsamadisi, P | 1 |
Su, CP | 1 |
Phipps, E | 1 |
Birnbaum, JM | 1 |
Scarcella, P | 3 |
Aliyu, MH | 1 |
Blevins, M | 2 |
Audet, CM | 1 |
Kalish, M | 1 |
Gebi, UI | 1 |
Onwujekwe, O | 1 |
Lindegren, ML | 1 |
Wester, CW | 1 |
Vermund, SH | 15 |
Olagunju, A | 1 |
Bolaji, O | 1 |
Neary, M | 1 |
Back, D | 2 |
Owen, A | 1 |
Dahinten, AP | 1 |
Msuya, LJ | 1 |
Capretti, MG | 1 |
Marsico, C | 1 |
Conti, M | 1 |
Corvaglia, LT | 1 |
Arcuri, S | 1 |
Faldella, G | 1 |
Re, MC | 1 |
Julian, MN | 1 |
Stewart, A | 1 |
Lehloenya, R | 1 |
Boulle, A | 3 |
de Waal, R | 1 |
Maartens, G | 1 |
Cohen, K | 1 |
Olana, T | 1 |
Bacha, T | 1 |
Worku, W | 1 |
Tadesse, BT | 1 |
Wang, Q | 2 |
Wang, L | 3 |
Fang, L | 2 |
Wang, A | 1 |
Jin, X | 1 |
Wang, F | 1 |
Qiao, Y | 1 |
Sullivan, SG | 1 |
Rutherford, S | 1 |
Zhang, L | 1 |
De Sousa Mendes, M | 1 |
Lui, G | 1 |
Zheng, Y | 2 |
Pressiat, C | 1 |
Valade, E | 1 |
Bouazza, N | 1 |
Foissac, F | 1 |
Benaboud, S | 2 |
Qin, M | 1 |
McIntyre, J | 14 |
Coletti, AS | 1 |
Klingman, KL | 2 |
Martinson, FE | 1 |
Violari, A | 3 |
Theron, GB | 3 |
Mlay, P | 1 |
Loftis, AJ | 1 |
Browning, R | 1 |
Purdue, L | 2 |
Basar, M | 1 |
Tooke, L | 1 |
Riemer, L | 1 |
Harrison, M | 1 |
Turriziani, O | 1 |
Russo, G | 1 |
Lichtner, M | 1 |
Stano, A | 1 |
Tsague, G | 1 |
Maida, P | 1 |
Vullo, V | 1 |
Antonelli, G | 1 |
Chintu, N | 8 |
Cantrell, RA | 4 |
Kruse, G | 2 |
Mbewe, F | 4 |
Sinkala, M | 27 |
Smith, PJ | 1 |
Stringer, EM | 10 |
Stringer, JS | 25 |
Onah, HE | 1 |
Ibeziako, N | 1 |
Nkwo, PO | 1 |
Obi, SN | 1 |
Nwankwo, TO | 1 |
Kasenga, F | 2 |
Hurtig, AK | 2 |
Emmelin, M | 2 |
Prendergast, A | 1 |
Mphatswe, W | 1 |
Tudor-Williams, G | 2 |
Rakgotho, M | 1 |
Pillay, V | 5 |
Thobakgale, C | 1 |
McCarthy, N | 1 |
Morris, L | 12 |
Walker, BD | 1 |
Goulder, P | 1 |
Hughes, V | 1 |
Lionel, J | 1 |
Aleyamma, TK | 1 |
Varghese, L | 1 |
Buck, J | 1 |
Gopalakrishnan, G | 1 |
Chaguturu, S | 1 |
Cu-Uvin, S | 1 |
Mayer, K | 1 |
Naniche, D | 1 |
Lahuerta, M | 1 |
Bardaji, A | 1 |
Sigauque, B | 1 |
Romagosa, C | 1 |
Berenguera, A | 1 |
Mandomando, I | 1 |
David, C | 1 |
Sanz, S | 1 |
Aponte, J | 1 |
Ordi, J | 1 |
Alonso, P | 1 |
Bedri, A | 2 |
Gudetta, B | 2 |
Isehak, A | 2 |
Kumbi, S | 2 |
Lulseged, S | 2 |
Mengistu, Y | 2 |
Bhore, AV | 2 |
Varadhrajan, V | 1 |
Sastry, J | 6 |
Tripathy, S | 4 |
Mubiru, M | 6 |
Onyango, C | 1 |
Taylor, A | 1 |
Abashawl, A | 2 |
Adamu, R | 2 |
Antelman, G | 2 |
Bright, P | 1 |
Chaudhary, MA | 1 |
Coberly, J | 1 |
Guay, L | 6 |
Hassen, E | 2 |
Moulton, LH | 2 |
Nayak, U | 4 |
Omer, SB | 5 |
Propper, L | 1 |
Ram, M | 3 |
Rexroad, V | 1 |
Ruff, AJ | 1 |
Bae, WH | 1 |
Wester, C | 5 |
Smeaton, LM | 3 |
Shapiro, RL | 6 |
Lockman, S | 11 |
Onyait, K | 1 |
Thior, I | 5 |
Draper, B | 3 |
Abdullah, F | 2 |
Spensley, A | 1 |
Turner, AN | 1 |
Hoblitzelle, C | 1 |
Robinson, J | 1 |
Wilfert, C | 4 |
van Schalkwyk, JE | 1 |
Alimenti, A | 1 |
Khoo, D | 1 |
Maan, E | 1 |
Forbes, JC | 1 |
Burdge, DR | 1 |
Gilgoff, S | 1 |
Money, DM | 1 |
Villani, P | 2 |
Floridia, M | 2 |
Cusato, M | 2 |
Pinnetti, C | 2 |
Sabbatini, F | 1 |
Molinari, A | 2 |
Tamburrini, E | 2 |
Regazzi, M | 2 |
Ekouevi, DK | 15 |
Coffie, PA | 6 |
Becquet, R | 8 |
Tonwe-Gold, B | 7 |
Horo, A | 2 |
Thiebaut, R | 2 |
Leroy, V | 10 |
Dabis, F | 20 |
Chung, MH | 4 |
Kiarie, JN | 6 |
Richardson, BA | 7 |
Lehman, DA | 6 |
Overbaugh, J | 8 |
Kinuthia, J | 2 |
Njiri, F | 2 |
John-Stewart, GC | 9 |
Brown, E | 2 |
Read, JS | 5 |
Sharma, U | 2 |
Hoffman, IF | 2 |
Pikora, C | 1 |
Goldenberg, R | 3 |
Rollins, NC | 1 |
Basson, AE | 1 |
Ntsala, M | 2 |
Tlale, E | 1 |
Corrigan, GE | 1 |
Shao, X | 1 |
Gray, G | 12 |
Shiri, T | 1 |
Welte, A | 1 |
Thomas, T | 1 |
Capparelli, E | 4 |
Zeh, C | 2 |
Holland, D | 1 |
Masaba, R | 2 |
Odhiambo, P | 1 |
Weidle, PJ | 4 |
Thigpen, MC | 6 |
Walter, J | 2 |
Semrau, K | 6 |
Thea, DM | 7 |
Aldrovandi, GM | 11 |
Moorthy, A | 2 |
Thakar, M | 2 |
Kagal, A | 2 |
Venkataramani, V | 1 |
Balasubramaniam, U | 1 |
Ziemniak, C | 2 |
Delvaux, T | 1 |
Elul, B | 1 |
Ndagije, F | 1 |
Munyana, E | 1 |
Roberfroid, D | 1 |
Asiimwe, A | 1 |
Mellors, JW | 4 |
Chow, JY | 2 |
Kondo, W | 2 |
Astori, Ade A | 1 |
Gomes, Sel-K | 1 |
Fernandes, Rde B | 1 |
Sasaki, Md | 2 |
Sbalqueiro, RL | 1 |
Patel, AK | 1 |
Patel, KK | 1 |
Sharma, R | 1 |
Ranjan, RR | 1 |
Shukla, RK | 1 |
Patel, JA | 1 |
Ryan, CT | 1 |
McKoy, JM | 1 |
Bennett, CL | 1 |
Scheetz, MH | 1 |
Differding, V | 1 |
Chandler, KL | 1 |
Yarnold, PR | 1 |
Sutton, S | 1 |
Palella, F | 1 |
Johnson, S | 1 |
Obadina, E | 1 |
Raisch, DW | 1 |
Parada, JP | 1 |
Pornprasert, S | 1 |
Mary, JY | 2 |
Leechanachai, P | 2 |
Limtrakul, A | 1 |
Rugpao, S | 1 |
Sirivatanapa, P | 1 |
Gomuthbutra, V | 1 |
Matanasaravoot, W | 1 |
Barré-Sinoussi, F | 4 |
Menu, E | 2 |
Martinson, NA | 6 |
Johnson, J | 1 |
Gray, GE | 9 |
Dhlamini, P | 3 |
Cohen, S | 2 |
Steyn, J | 2 |
McIntyre, JA | 8 |
Rutta, E | 1 |
Gongo, R | 1 |
Mwansasu, A | 1 |
Mutasingwa, D | 1 |
Rwegasira, V | 1 |
Kishumbu, S | 1 |
Tabayi, J | 1 |
Masini, T | 1 |
Ramadhani, H | 1 |
Han, J | 1 |
Jiang, Y | 1 |
Zhang, Q | 1 |
Yao, J | 1 |
Arrivé, E | 3 |
Chaix, ML | 6 |
Nerrienet, E | 3 |
Rouzioux, C | 7 |
Kruy Leang, S | 1 |
Avit, D | 2 |
Srey, VH | 1 |
N'Dri-Yoman, T | 2 |
Diallo, A | 1 |
Dahl, V | 1 |
Palmer, S | 3 |
Wind-Rotolo, M | 1 |
Durand, C | 1 |
Cranmer, L | 1 |
Reid, A | 1 |
Doherty, M | 1 |
Jilek, BL | 1 |
Kagaayi, J | 2 |
Kizza, A | 1 |
Laeyendecker, O | 1 |
Reynolds, SJ | 1 |
Eshleman, SH | 22 |
Lau, B | 1 |
Ray, SC | 1 |
Siliciano, JD | 1 |
Quinn, TC | 1 |
Siliciano, RF | 1 |
Charurat, M | 1 |
Datong, P | 1 |
Matawal, B | 1 |
Ajene, A | 1 |
Blattner, W | 1 |
Abimiku, A | 1 |
Guidozzi, F | 1 |
Black, V | 2 |
Behets, F | 2 |
Mutombo, GM | 1 |
Edmonds, A | 1 |
Dulli, L | 1 |
Belting, MT | 1 |
Kapinga, M | 1 |
Pantazis, A | 1 |
Tomlin, H | 1 |
Okitolonda, E | 1 |
Foster, C | 1 |
Lyall, H | 1 |
Olmscheid, B | 1 |
Pearce, G | 1 |
Zhang, S | 1 |
Mabuka, JM | 1 |
Ramachandran, S | 1 |
Scott, N | 2 |
Kasonde, P | 7 |
Mwiya, M | 3 |
Decker, D | 1 |
Ammann, AJ | 1 |
Agmon-Levin, N | 1 |
Elbirt, D | 1 |
Asher, I | 1 |
Torten, D | 1 |
Cohen, Y | 1 |
Gradestein, S | 1 |
Werner, B | 1 |
Turner, D | 1 |
Chowers, M | 1 |
Gottesman, G | 1 |
Maayan, S | 1 |
Risenberg, K | 1 |
Levi, I | 1 |
Sthoeger, Z | 1 |
Church, JD | 4 |
Bagenda, D | 6 |
Eure, C | 2 |
Bakaki, P | 4 |
Matovu, F | 3 |
McConnell, M | 2 |
Megazzini, KM | 2 |
Redden, DT | 2 |
Krebs, DW | 2 |
Simwenda, M | 1 |
Tambatamba, B | 1 |
Johnson, N | 2 |
Palmer, P | 3 |
Samuels, LA | 1 |
Morgan, O | 1 |
Onyonyor, A | 1 |
Anderson, M | 1 |
Moore, J | 1 |
Billings, C | 1 |
Harvey, KM | 2 |
Mullings, A | 1 |
McDonald, D | 2 |
Alexander, G | 2 |
Smikle, MF | 3 |
Williams, EW | 1 |
Davis, D | 1 |
Christie, CD | 3 |
Ouyang, DW | 2 |
Lu, M | 2 |
Brogly, SB | 2 |
French, AL | 2 |
Leighty, RM | 2 |
Thompson, B | 2 |
Tuomala, RE | 3 |
Hershow, RC | 2 |
Mmiro, FA | 1 |
Aizire, J | 3 |
Mwatha, AK | 1 |
Musoke, PM | 2 |
Mwinga, K | 1 |
Urassa, W | 1 |
Carpenetti, N | 1 |
Valentine, M | 2 |
Goldenberg, RL | 12 |
Kurewa, EN | 1 |
Gumbo, FZ | 5 |
Munjoma, MW | 3 |
Mapingure, MP | 4 |
Chirenje, MZ | 5 |
Rusakaniko, S | 5 |
Stray-Pedersen, B | 5 |
Galegov, GA | 1 |
Becker, S | 1 |
Mlay, R | 1 |
Schwandt, HM | 1 |
Lyamuya, E | 1 |
Ilboudo, D | 1 |
Simpore, J | 3 |
Sanou, DS | 1 |
Karou, D | 1 |
Sia, DJ | 1 |
Ouermi, D | 1 |
Bisseye, C | 1 |
Sagna, T | 1 |
Odolini, S | 1 |
Buelli, F | 1 |
Pietra, V | 3 |
Pignatelli, S | 2 |
Gnoula, C | 1 |
Nikiema, JB | 2 |
Castelli, F | 2 |
Shalekoff, S | 1 |
Meddows-Taylor, S | 2 |
Schramm, DB | 3 |
Coovadia, A | 1 |
Sim, MS | 1 |
Cumberland, WG | 1 |
Duan, N | 1 |
Bryson, YJ | 2 |
Chantarangsu, S | 1 |
Mahasirimongkol, S | 1 |
Tawon, Y | 1 |
Chantratita, W | 1 |
Kumwenda, J | 1 |
Cole, SR | 1 |
Hoover, DR | 10 |
Kafulafula, G | 3 |
Li, Q | 2 |
Kumwenda, NI | 4 |
Mofenson, L | 9 |
Hopley, M | 1 |
Eklund, M | 1 |
Hall, DB | 2 |
Robinson, P | 3 |
Mayers, D | 2 |
Anzidei, G | 1 |
Tibaldi, C | 1 |
Guaraldi, G | 1 |
Guerra, B | 1 |
Meloni, AM | 1 |
Vimercati, A | 1 |
Dalzero, S | 1 |
Ravizza, M | 1 |
Ellis, GM | 2 |
Warrier, R | 1 |
Nakamura, K | 1 |
Nsibande, D | 1 |
Mngoma, D | 1 |
Cheng, I | 1 |
Kuritzkes, DR | 1 |
Mwanza, J | 1 |
Bulterys, M | 6 |
Ivanovic, J | 1 |
Anceschi, MM | 1 |
Ascenzi, P | 1 |
Signore, F | 1 |
Pisani, G | 1 |
Vallone, C | 1 |
Mattia, E | 1 |
Notari, S | 1 |
Tempestilli, M | 1 |
Pucillo, LP | 1 |
Narciso, P | 3 |
Lidström, J | 1 |
Kumwenda, N | 7 |
Ciccacci, C | 1 |
Borgiani, P | 1 |
Ceffa, S | 3 |
Sirianni, E | 1 |
Altan, AM | 1 |
Paturzo, G | 2 |
Bramanti, P | 1 |
Novelli, G | 1 |
Hudelson, SE | 6 |
Piwowar-Manning, E | 2 |
Nolan, ML | 1 |
Ndirangu, J | 1 |
Tanser, F | 1 |
Herbst, AJ | 1 |
Bland, R | 1 |
van Zyl, GU | 2 |
Traisaithit, P | 1 |
Collins, IJ | 1 |
Sukhumanant, T | 1 |
Achalapong, J | 2 |
Chotivanich, N | 2 |
Winiyakul, N | 1 |
Ariyadej, S | 2 |
Kanjanasing, A | 1 |
Ratanakosol, J | 1 |
Hemvuttiphan, J | 1 |
Kengsakul, K | 1 |
Wannapira, W | 1 |
Sittipiyasakul, V | 1 |
Pornkitprasarn, W | 1 |
Liampongsabuddhi, P | 1 |
Van Dyke, RB | 2 |
Kanchana, S | 1 |
Bolu, O | 2 |
Anekthananon, T | 1 |
Jariyasethpong, T | 1 |
Potter, D | 1 |
Mutsotso, W | 1 |
Borkowf, CB | 1 |
Mbori-Ngacha, D | 1 |
Muiruri, P | 1 |
Ong'ech, JO | 1 |
Zulu, I | 2 |
Njobvu, L | 1 |
Jetsawang, B | 1 |
Pathak, S | 1 |
Wagner, TA | 1 |
Kress, CM | 1 |
Techapornroong, M | 1 |
Wittayapraparat, P | 1 |
Tansuphasawasdikul, S | 1 |
Cohen, J | 3 |
Delva, W | 3 |
Yard, E | 1 |
Muigai, E | 1 |
Oyier, V | 1 |
Conkling, M | 1 |
Shutes, EL | 1 |
Karita, E | 2 |
Chomba, E | 1 |
Tichacek, A | 1 |
Vwalika, B | 1 |
Iwanowski, M | 1 |
Allen, SA | 1 |
Kurewa, NE | 4 |
Kandawasvika, GQ | 2 |
Duri, K | 3 |
Pazvakavambwa, IE | 1 |
Rowley, CF | 2 |
Boutwell, CL | 1 |
Lee, EJ | 2 |
MacLeod, IJ | 2 |
Torpey, K | 2 |
Dirks, R | 2 |
Bweupe, M | 1 |
Kabaso, M | 1 |
Mandala, J | 2 |
Sangiwa, G | 1 |
Kuonza, LR | 1 |
Tshuma, CD | 1 |
Shambira, GN | 1 |
Tshimanga, M | 1 |
Giganti, MJ | 2 |
Putta, NB | 1 |
Sadoki, E | 1 |
Chasela, CS | 2 |
Hudgens, MG | 2 |
Tegha, G | 2 |
Knight, RJ | 2 |
Ahmed, YI | 1 |
Kamwendo, DD | 2 |
Kacheche, Z | 2 |
Soko, A | 2 |
Wiener, JB | 2 |
Kazembe, P | 1 |
Mofolo, IA | 2 |
Chigwenembe, M | 2 |
Sichali, DS | 2 |
van der Horst, CM | 1 |
Hughes, MD | 4 |
Ogwu, A | 2 |
Kitch, D | 1 |
Moffat, C | 4 |
van Widenfelt, E | 3 |
Leidner, J | 2 |
Asmelash, A | 3 |
Tumbare, E | 1 |
Handelsman, E | 1 |
Mburu, K | 1 |
Jayeoba, O | 1 |
Moko, E | 1 |
Souda, S | 1 |
Lubega, E | 1 |
Akhtar, M | 1 |
Tuomola, R | 1 |
Snowden, W | 1 |
Martinez-Tristani, M | 1 |
Mazhani, L | 2 |
O'Gorman, DA | 1 |
Nyirenda, LJ | 1 |
Theobald, SJ | 1 |
Lawson-Evi, K | 1 |
Mouhari-Toure, A | 1 |
Tchama, R | 1 |
Akakpo, SA | 1 |
Atakouma, DY | 2 |
Beauvais, L | 1 |
Pitche, P | 1 |
Kochar, R | 1 |
Nevah, MI | 1 |
Lukens, FJ | 1 |
Fallon, MB | 1 |
Machicao, VI | 1 |
Okaba-Kayom, V | 1 |
Flaherty, JP | 1 |
Boffito, M | 1 |
Namakula, R | 1 |
Ryan, M | 1 |
Kouanda, S | 1 |
Tougri, H | 1 |
Cisse, M | 1 |
Doulougou, B | 1 |
Ouedraogo, G | 1 |
Ouedraogo, CM | 1 |
Soudre, R | 1 |
Sondo, B | 1 |
Coetzee, D | 2 |
Creek, TL | 1 |
Stinson, K | 1 |
Welty, TK | 2 |
Wilfert, CM | 4 |
Bersoff-Matcha, SJ | 1 |
Rourke, D | 1 |
Blank, J | 1 |
Barigye, H | 1 |
Levin, J | 1 |
Maher, D | 1 |
Tindiwegi, G | 1 |
Atuhumuza, E | 1 |
Nakibinge, S | 1 |
Grosskurth, H | 1 |
Gadhamsetty, S | 1 |
Dixit, NM | 1 |
Farr, SL | 1 |
Nelson, JA | 1 |
Ng'ombe, TJ | 1 |
Johnson, JA | 3 |
Tegha, GL | 1 |
Eron, JJ | 1 |
Banda, HN | 1 |
Mpaso, M | 1 |
Lipscomb, J | 1 |
Matiki, C | 1 |
Kristiansen, KI | 1 |
Muller, F | 1 |
Bancheno, WM | 1 |
Mwanyumba, F | 3 |
Mareverwa, J | 1 |
Aaron, E | 1 |
Kempf, MC | 1 |
Criniti, S | 1 |
Tedaldi, E | 1 |
Gracely, E | 1 |
Warriner, A | 1 |
Kumar, R | 1 |
Bachmann, LH | 1 |
Nielsen-Saines, K | 5 |
Haswell, J | 2 |
Magid, NA | 2 |
Buonomo, E | 2 |
Doro Altan, AM | 1 |
Conradie, F | 2 |
Sawe, F | 1 |
Mohapi, L | 1 |
Stringer, E | 2 |
Mngqibisa, R | 1 |
Siika, A | 2 |
Atwine, D | 1 |
Hakim, J | 1 |
Shaffer, D | 1 |
Kanyama, C | 1 |
Salata, RA | 1 |
Hogg, E | 1 |
Alston-Smith, B | 1 |
Walawander, A | 1 |
Purcelle-Smith, E | 1 |
Eshleman, S | 1 |
Rooney, J | 1 |
Rahim, S | 1 |
Schooley, RT | 1 |
Palumbo, P | 1 |
Lindsey, JC | 1 |
Meyers, T | 1 |
Kamthunzi, P | 1 |
Millar, L | 1 |
Petzold, E | 1 |
Lurie, MN | 1 |
Triche, EW | 1 |
De Bruyn, G | 1 |
Harwell, JI | 1 |
McGarvey, ST | 1 |
Rey, E | 1 |
Sim, KL | 1 |
Tattevin, P | 1 |
Arvieux, C | 1 |
Courpotin, C | 1 |
Ouattara, E | 1 |
Moh, R | 1 |
Amani-Bosse, C | 3 |
Messou, E | 1 |
Sissoko, M | 1 |
Anglaret, X | 1 |
Eholié, SP | 1 |
Danel, C | 1 |
Mudiope, P | 2 |
Kekitiinwa, A | 1 |
Matovu, J | 1 |
Kayma, S | 1 |
Salmond, W | 1 |
Maganda, A | 1 |
Galla, M | 1 |
Byamugisha, J | 1 |
Davies, MA | 1 |
Moultrie, H | 1 |
Eley, B | 2 |
Van Cutsem, G | 1 |
Giddy, J | 1 |
Wood, R | 3 |
Technau, K | 1 |
Keiser, O | 1 |
Egger, M | 1 |
Tsague, L | 1 |
Tsiouris, FO | 1 |
Mugisha, V | 1 |
Tene, G | 2 |
Nyankesha, E | 1 |
Koblavi-Deme, S | 1 |
Mugwaneza, P | 1 |
Kayirangwa, E | 1 |
Sahabo, R | 1 |
Huang, S | 3 |
Culnane, M | 4 |
Kaiser, KA | 1 |
Scheuerle, A | 2 |
Stanley, K | 1 |
Delfraissy, JF | 5 |
Rajesh, L | 1 |
Ramesh, K | 1 |
Hanna, LE | 1 |
Narayanan, PR | 1 |
Swaminathan, S | 1 |
van Luin, M | 1 |
Wit, FW | 2 |
Smit, C | 2 |
Rigter, IM | 1 |
Franssen, EJ | 1 |
Richter, C | 1 |
Kroon, F | 1 |
de Wolf, F | 4 |
Dorton, BJ | 1 |
Mulindwa, J | 1 |
Li, MS | 1 |
Chintu, NT | 1 |
Chibwesha, CJ | 1 |
Joshi, S | 1 |
Khandekar, M | 1 |
Karmarkar, A | 1 |
Paranjape, R | 1 |
Jamkar, A | 1 |
de Vincenzi, I | 1 |
Ashworth, R | 1 |
Ruff, A | 1 |
Van Dyke, R | 1 |
Cababasay, MP | 1 |
Louw, J | 1 |
Smith, E | 2 |
Maupin, R | 2 |
Li, JF | 2 |
Lipscomb, JT | 1 |
Wei, X | 1 |
Basu, S | 1 |
Kumar, A | 1 |
Das, BK | 1 |
Ciaranello, AL | 2 |
Freedberg, KA | 2 |
Hughes, M | 1 |
Chu, J | 2 |
Currier, J | 1 |
Holmes, CB | 1 |
Pillay, S | 1 |
Losina, E | 1 |
Walensky, RP | 2 |
Pilger, D | 1 |
Hauser, A | 2 |
Kuecherer, C | 2 |
Mugenyi, K | 4 |
Kabasinguzi, R | 1 |
Somogyi, S | 1 |
Azcoaga-Lorenzo, A | 1 |
Alvarez, A | 1 |
Palma, PP | 1 |
Velilla, E | 1 |
del Amo, J | 1 |
Bolhaar, MG | 1 |
Karstaedt, AS | 1 |
Sikwane, E | 1 |
Majaja, M | 1 |
Parham, L | 1 |
de Rivera, IL | 1 |
Murillo, W | 1 |
Naver, L | 1 |
Largaespada, N | 1 |
Albert, J | 1 |
Karlsson, AC | 1 |
Kieffer, MP | 1 |
Nhlabatsi, B | 1 |
Mahdi, M | 1 |
Hoffman, HJ | 1 |
Kudiabor, K | 1 |
Dolgin, E | 1 |
Ciampa, PJ | 1 |
Burlison, JR | 1 |
Moon, TD | 1 |
Rothman, RL | 1 |
Nathoo, K | 1 |
Perez, F | 2 |
Maruva, M | 1 |
Engelsmann, B | 1 |
Keatinge, J | 1 |
Mugwagwa, R | 1 |
Zimba, I | 1 |
Tudor Car, L | 1 |
van-Velthoven, MH | 1 |
Brusamento, S | 1 |
Elmoniry, H | 1 |
Car, J | 1 |
Majeed, A | 1 |
Atun, R | 2 |
Joseph, O | 1 |
Biodun, O | 1 |
Michael, E | 1 |
Siegfried, N | 1 |
van der Merwe, L | 2 |
Brocklehurst, P | 4 |
Sint, TT | 2 |
Schouten, EJ | 1 |
Midiani, D | 1 |
Makombe, SD | 1 |
Mnthambala, A | 1 |
Harries, AD | 1 |
van Oosterhout, JJ | 1 |
Meguid, T | 1 |
Ben-Smith, A | 1 |
Zachariah, R | 1 |
Lynen, L | 1 |
Zolfo, M | 1 |
Van Damme, W | 1 |
Gilks, CF | 2 |
Shawa, M | 1 |
Chimbwandira, F | 1 |
Wigzell, H | 1 |
Falksveden, L | 1 |
Wahren, B | 1 |
Kanhon, SK | 1 |
Touré, H | 2 |
Ettiegne-Traoré, V | 1 |
Baan, E | 1 |
de Ronde, A | 1 |
Vyankandondera, J | 2 |
Lange, JM | 1 |
Pollakis, G | 1 |
Paxton, WA | 1 |
Mugabo, P | 1 |
Els, I | 1 |
Smith, J | 1 |
Smith, P | 1 |
Steyn, W | 1 |
Hall, D | 2 |
Madsen, R | 1 |
Shah, SK | 1 |
Dawson, L | 1 |
Dixon, DO | 1 |
Lie, RK | 1 |
von Kleist, M | 1 |
Schütte, C | 1 |
Antunes, AM | 1 |
Novais, DA | 1 |
da Silva, JL | 1 |
Santos, PP | 1 |
Oliveira, MC | 1 |
Beland, FA | 1 |
Marques, MM | 1 |
Cecchini, D | 1 |
Urueña, A | 1 |
Trinidad, P | 1 |
Vesperoni, F | 1 |
Mecikovsky, D | 1 |
Wang, J | 1 |
Shetty, AK | 3 |
Kamateeka, M | 1 |
Bolton, SG | 1 |
Ribaudo, H | 1 |
Chen, J | 1 |
Parekh, N | 1 |
L'homme, R | 1 |
Aitken, SC | 1 |
Mariki, G | 1 |
Van der Ven, AJ | 1 |
Dolmans, W | 1 |
Britto, P | 3 |
Roongpisuthipong, A | 1 |
Yuthavisuthi, P | 1 |
Prommas, S | 1 |
Puthanakit, T | 1 |
Rasri, W | 1 |
Drake, AL | 2 |
Roxby, AC | 2 |
Ongecha-Owuor, F | 2 |
John-Stewart, G | 1 |
Wald, A | 2 |
Emery, S | 2 |
Farquhar, C | 4 |
Taylor, S | 1 |
Khoo, SH | 1 |
Chetty, V | 1 |
Msweli, L | 1 |
Kisenge, R | 1 |
Lynn, DJ | 1 |
Schmidt, NC | 1 |
Roman-Pouriet, J | 1 |
Fernandez, AD | 2 |
Beck-Sagué, CM | 1 |
Leonardo-Guerrero, J | 1 |
Nicholas, SW | 1 |
Elbireer, A | 1 |
Nolan, M | 1 |
Janoff, EN | 1 |
Snijdewind, IJ | 1 |
Godfried, MH | 5 |
Nellen, JF | 2 |
Boer, K | 5 |
van der Ende, ME | 4 |
Bentley, ME | 1 |
Mkhomawanthu, C | 1 |
King, CC | 2 |
Chitsulo, P | 1 |
Tembo, M | 1 |
Tohill, B | 1 |
Piwoz, EG | 1 |
Adair, L | 1 |
Mapingure, PM | 1 |
Boltz, VF | 1 |
Hopley, MJ | 1 |
Maldarelli, F | 2 |
Coffin, JM | 1 |
Sewangi, J | 1 |
Mbezi, P | 2 |
Dugange, F | 1 |
Lau, I | 1 |
Ziske, J | 1 |
Theuring, S | 1 |
Wamalwa, DC | 1 |
McCoy, CO | 1 |
Matsen, FA | 1 |
Langat, A | 1 |
Chohan, BH | 1 |
Benki-Nugent, S | 1 |
Custers-Allen, R | 1 |
Bushman, FD | 1 |
van Hoog, S | 1 |
Nellen, J | 2 |
Scherpbier, H | 1 |
Carlsson, J | 1 |
Jamisse, L | 2 |
Adair, LS | 1 |
Sikazwe, I | 1 |
Moyo, T | 1 |
Weaver, M | 1 |
Suzuki, C | 1 |
Hayashi, C | 1 |
Pennings, PS | 1 |
Richardson, B | 1 |
Matemo, DN | 1 |
Veloso, VG | 2 |
Joao, EC | 2 |
Pilotto, JH | 2 |
Santos, B | 1 |
Fonseca, R | 1 |
Kreitchmann, R | 1 |
Pinto, J | 2 |
Mussi-Pinhata, MM | 1 |
Ceriotto, M | 1 |
Machado, D | 1 |
Bethel, J | 2 |
Morgado, MG | 1 |
Dickover, R | 1 |
Camarca, M | 2 |
Siberry, G | 1 |
Grinsztejn, B | 1 |
Moreira, RI | 1 |
Bastos, FI | 1 |
Xu, J | 2 |
Moye, J | 2 |
Minniear, TD | 1 |
Polle, N | 1 |
Peters, PJ | 1 |
Oyaro, B | 1 |
Akoth, B | 1 |
Ndivo, R | 1 |
Angira, F | 1 |
Mills, LA | 1 |
Thomas, TK | 1 |
Ha, TT | 1 |
Anh, NM | 1 |
Bao, NH | 1 |
Tuan, PL | 1 |
Caridha, R | 1 |
Gaseitsiwe, S | 1 |
Hien, NT | 1 |
Cam, PD | 1 |
Ehrnst, A | 1 |
Kinikar, AA | 1 |
Khandave, M | 1 |
Shankar, AV | 1 |
Bera, E | 1 |
Mia, R | 1 |
Rossi, S | 1 |
Moss, M | 1 |
Calmy, A | 1 |
Andrieux-Meyer, I | 1 |
Hargreaves, S | 1 |
Mills, EJ | 1 |
Shubber, Z | 1 |
McMahon, DK | 1 |
Zheng, L | 1 |
Halvas, EK | 1 |
Bonhomme, J | 1 |
Wallis, CL | 1 |
Neubert, J | 1 |
Pfeffer, M | 1 |
Borkhardt, A | 1 |
Niehues, T | 1 |
Adams, O | 1 |
Bolten, M | 1 |
Reuter, S | 1 |
Stannigel, H | 1 |
Laws, HJ | 1 |
Mukherjee, S | 1 |
Ghosh, S | 1 |
Goswami, DN | 1 |
Samanta, A | 1 |
Sidley, P | 2 |
Rekacewicz, C | 3 |
Gelber, RD | 4 |
Dorenbaum, A | 5 |
Bazin, B | 1 |
Sullivan, JL | 7 |
Achmat, Z | 1 |
Baleta, A | 11 |
Woods, D | 1 |
Volmink, J | 7 |
Nachega, J | 1 |
Fleming, T | 9 |
Mracna, M | 3 |
Becker-Pergola, G | 2 |
Kreiss, JK | 1 |
Klosinski, L | 1 |
Hashimoto, H | 1 |
Kapiga, SH | 1 |
Murata, Y | 1 |
Bateman, C | 4 |
Annas, GJ | 1 |
Moodley, J | 4 |
Hofmyer, J | 1 |
Nikodem, C | 1 |
Gigliotti, M | 2 |
Boshoff, L | 1 |
Stout, JP | 4 |
Chapman, V | 2 |
Kumwenda-Phiri, R | 1 |
Marseille, E | 4 |
Laurence, J | 1 |
Boyle, BA | 2 |
Knudtson, E | 1 |
Para, M | 1 |
Boswell, H | 1 |
Fan-Havard, P | 2 |
Blanchard, S | 1 |
Mzyece, E | 1 |
Makuka, I | 1 |
Kwape, P | 1 |
Chilufya, M | 1 |
Quaghebeur, A | 2 |
Mandaliya, K | 2 |
Mudenda, V | 2 |
Kumwenda, R | 2 |
Pillay, C | 2 |
Chezzi, C | 1 |
Lupondwana, P | 1 |
Levin, L | 1 |
Venter, F | 1 |
Das, P | 1 |
Kironde, S | 1 |
Lukwago, J | 1 |
Ssenyonga, R | 1 |
Rely, K | 1 |
Bertozzi, SM | 1 |
Avila-Figueroa, C | 1 |
Guijarro, MT | 1 |
Bruun, JN | 1 |
Vermund, S | 1 |
Acosta, E | 1 |
Beckerman, KP | 2 |
Sherman, J | 2 |
Ducar, C | 2 |
Deseyve, M | 4 |
Duefield, C | 1 |
Miotti, P | 2 |
Bray, D | 2 |
Bertolli, J | 1 |
Hu, DJ | 1 |
Nieburg, P | 1 |
Macalalad, A | 1 |
Simonds, RJ | 2 |
Pittoggi, C | 1 |
Sciamanna, I | 1 |
Mattei, E | 1 |
Beraldi, R | 1 |
Lobascio, AM | 1 |
Mai, A | 1 |
Quaglia, MG | 1 |
Lorenzini, R | 1 |
Spadafora, C | 1 |
Gibbons, A | 2 |
Broadhead, RL | 2 |
Lema, V | 2 |
Liomba, G | 3 |
Nkhoma, C | 2 |
Miotti, PG | 2 |
Kapiriri, L | 1 |
Robberstad, B | 1 |
Robbestad, B | 1 |
Frithjof Norheim, O | 1 |
Ayouba, A | 1 |
Cunin, P | 1 |
Foupouapouognigni, Y | 1 |
Kfutwah, A | 1 |
Thonnon, J | 1 |
Scarlatti, G | 1 |
Monny-Lobé, M | 1 |
Eteki, N | 2 |
Kouanfack, C | 1 |
Tardy, M | 1 |
Leke, R | 1 |
Nkam, M | 2 |
Nlend, AE | 1 |
Martin, PM | 1 |
Rouse, DJ | 3 |
Marseille, EA | 1 |
Mirochnick, MM | 1 |
Katzenstein, DA | 2 |
Wells, J | 2 |
Maponga, CC | 1 |
Jones, SA | 3 |
Abdool Karim, SS | 1 |
Bassett, MT | 1 |
Perez-Then, E | 1 |
Peña, R | 1 |
Tavarez-Rojas, M | 1 |
Peña, C | 1 |
Quiñonez, S | 1 |
Buttler, M | 1 |
Ammann, A | 1 |
Hernández, W | 1 |
Goyanes, M | 1 |
Miguez, MJ | 1 |
Shor-Posner, G | 2 |
Hudson, CP | 5 |
Cooper, E | 1 |
Jackson, B | 2 |
Gerntholtz, L | 1 |
Balasubramanian, R | 1 |
Maupin, RT | 1 |
Delke, I | 1 |
Fiore, S | 1 |
Jaspan, HB | 1 |
Garry, RF | 1 |
Smart, T | 1 |
Servais, J | 1 |
Lambert, C | 1 |
Vanhove, D | 1 |
Fischer, A | 1 |
Baurith, T | 1 |
Schmit, JC | 1 |
Schneider, F | 1 |
Hemmer, R | 1 |
Arendt, V | 1 |
Thompson, CA | 1 |
Coovadia, AH | 2 |
Urban, MF | 2 |
Bolton, KD | 1 |
Rouet, F | 5 |
Inwoley, A | 1 |
Viho, I | 8 |
Bequet, L | 5 |
Chama, CM | 1 |
Audu, BM | 1 |
Kyari, O | 1 |
Urban, M | 2 |
Chersich, M | 1 |
Stek, AM | 1 |
Nachman, SA | 1 |
Baker, D | 1 |
Gonzalez-Garcia, A | 1 |
Provisor, A | 1 |
Thorpe, EM | 2 |
Paul, ME | 1 |
Foca, M | 2 |
Gandia, J | 1 |
Wei, LJ | 1 |
Stevens, LM | 1 |
McNamara, J | 1 |
Mukotekwa, T | 1 |
Miller, A | 1 |
Orne-Gliemann, J | 1 |
Glenshaw, M | 1 |
Chitsike, I | 2 |
Kanshana, S | 1 |
Thaineua, V | 1 |
Bowonwatanuwong, C | 1 |
Kantipong, P | 1 |
Leenasirimakul, P | 1 |
Hammer, S | 2 |
Nour, S | 1 |
Chen, S | 8 |
Check, E | 3 |
Fleming, TR | 1 |
Sweat, MD | 1 |
O'Reilly, KR | 1 |
Schmid, GP | 1 |
Denison, J | 1 |
de Zoysa, I | 1 |
LaFraniere, S | 1 |
Mutunga, L | 1 |
Verhofstede, C | 1 |
Covington, DL | 1 |
Beckerman, K | 2 |
Garcia, P | 1 |
Ross, B | 1 |
Sacks, S | 1 |
Chavers, S | 1 |
Tilson, H | 1 |
Herzmann, C | 1 |
Karcher, H | 4 |
Goulder, PJ | 1 |
Blanckenberg, N | 1 |
Dong, K | 1 |
Feinberg, J | 1 |
Tempelman, C | 2 |
Timmermans, S | 2 |
Dieleman, JP | 1 |
Kabura, MN | 1 |
John, FN | 1 |
Nduati, RW | 1 |
Mbori-Ngacha, DA | 2 |
Mbopi-Keou, FX | 1 |
Alemnji, G | 1 |
Alemdji, G | 1 |
Nkengasong, JN | 2 |
Meli, C | 1 |
Nana, PN | 1 |
Ako, SN | 1 |
Tonye, RN | 1 |
Leke, RJ | 1 |
Lyons, FE | 1 |
Coughlan, S | 1 |
Byrne, CM | 1 |
Hopkins, SM | 1 |
Hall, WW | 1 |
Mulcahy, FM | 2 |
Roehr, B | 1 |
Mullings, AA | 1 |
Williams, E | 1 |
Whorms, S | 2 |
Figueroa, JP | 2 |
Steel-Duncan, JC | 1 |
Pierre, R | 1 |
Evans-Gilbert, T | 1 |
Rodriquez, B | 1 |
Hambleton, I | 1 |
Massaquoi, I | 1 |
Asiimwe, S | 1 |
Kamya, MR | 1 |
Arts, EJ | 1 |
Whalen, CC | 1 |
Sakarovitch, C | 2 |
Fassinou, P | 2 |
Dequae-Merchadou, L | 1 |
Welffens-Ekra, C | 1 |
Lallemant, MJ | 1 |
Kunkeaw, S | 1 |
Lane, HC | 1 |
Folkers, GK | 1 |
Fauci, AS | 1 |
Turner, VF | 1 |
Maclean, CC | 2 |
Thorne, C | 2 |
Kamenga, C | 1 |
de Zoysa, IF | 1 |
Vwalika, C | 3 |
Shutes, E | 1 |
Aldrovandi, G | 1 |
Couzin, J | 1 |
Dreyfuss, ML | 2 |
Kigozi, G | 1 |
Chen, MZ | 1 |
Wabwire-Mangen, F | 1 |
Serwadda, D | 1 |
Wawer, MJ | 1 |
Sewankambo, NK | 1 |
Nalugoda, F | 1 |
Kiwanuka, N | 1 |
Kiddugavu, M | 1 |
Gray, RH | 2 |
Dieleman, J | 1 |
Sprenger, H | 1 |
Schneider, ME | 1 |
Stephenson, J | 2 |
James, JS | 5 |
Hammer, SM | 1 |
Flys, T | 1 |
Nissley, DV | 1 |
Claassen, CW | 1 |
Jones, D | 2 |
Shi, C | 1 |
Strathern, JN | 1 |
Eshleman, JR | 1 |
Taha, T | 2 |
Parkin, N | 2 |
Bolton, C | 1 |
van Niekerk, R | 1 |
Stevens, W | 1 |
Levy, J | 2 |
Degroot, A | 1 |
Urassa, P | 1 |
Gosling, R | 1 |
Pool, R | 1 |
Reyburn, H | 1 |
Mahlat, U | 1 |
Kantor, R | 2 |
Zijenah, L | 2 |
Sheldon, W | 1 |
Mateta, P | 2 |
Johnston, E | 2 |
Contag, CH | 1 |
Bassett, M | 1 |
Hilderbrand, K | 1 |
Goemaere, E | 1 |
Kurowski, M | 4 |
Sheriff, M | 1 |
van't Hoog, AH | 1 |
Marum, LH | 1 |
Otieno, JA | 1 |
Misore, AO | 1 |
Nganga, LW | 1 |
Decock, KM | 1 |
Joy, S | 1 |
Poi, M | 1 |
Hughes, L | 1 |
Brady, MT | 1 |
Koletar, SL | 1 |
Para, MF | 1 |
Welty, ER | 1 |
Ndikintum, G | 1 |
Nkuoh, G | 1 |
Nkfusai, J | 1 |
Clark, R | 1 |
Albrecht, S | 1 |
Quian, J | 1 |
Visconti, A | 1 |
Gutiérrez, S | 1 |
Galli, A | 1 |
Maturo, M | 1 |
Galeano, V | 1 |
Serra, M | 1 |
Lioni, M | 1 |
Savadogo, A | 1 |
Nadembega, WM | 1 |
Yara, J | 1 |
Zoungrana, N | 1 |
Bakouan, D | 1 |
Musumeci, S | 1 |
Toni, TD | 2 |
Masquelier, B | 3 |
Lazaro, E | 1 |
Dore-Mbami, M | 1 |
Ba-Gomis, FO | 1 |
Téa-Diop, Y | 1 |
Kouakou, K | 1 |
Diby, J | 1 |
Sia, E | 1 |
Soppi, S | 1 |
Essien, S | 1 |
Schrive, MH | 1 |
Pinson, P | 1 |
Chenal, H | 1 |
Fleury, HJ | 2 |
Calvet, GA | 1 |
Menezes, JA | 1 |
D'Ippolito, MM | 1 |
Cruz, ML | 1 |
Salgado, LA | 1 |
Matos, HJ | 1 |
Anderson, JR | 1 |
Peytavin, G | 2 |
Menan, H | 2 |
Janowitz, B | 1 |
Homan, R | 1 |
Johnson, L | 1 |
Schmitz, T | 1 |
Kleinkauf, N | 1 |
Klempa, B | 1 |
Ringe, H | 1 |
Varnholt, V | 1 |
Grosch-Wörner, I | 1 |
Parsons, T | 2 |
Smith, DM | 1 |
Koh, MT | 1 |
Loubser, S | 1 |
Balfe, P | 1 |
Oleske, JM | 1 |
Lyons, F | 1 |
Hopkins, S | 1 |
Kelleher, B | 1 |
McGeary, A | 1 |
Sheehan, G | 1 |
Geoghegan, J | 1 |
Bergin, C | 1 |
McCormick, PA | 1 |
Soorapanth, S | 1 |
Sansom, S | 1 |
Besser, M | 1 |
Boltz, V | 1 |
Mellors, J | 1 |
Coffin, J | 1 |
Kouam, L | 1 |
Nsangou, I | 1 |
Mbanya, D | 1 |
Kongnyuy, EJ | 1 |
Ngassa, P | 1 |
Tebeu, PM | 1 |
Elobe, N | 1 |
Kamgaing, NG | 1 |
Zekeng, L | 1 |
Doh, AS | 1 |
Geffen, N | 1 |
Nattrass, N | 2 |
Taiwo, BO | 1 |
Homsy, J | 1 |
Kalamya, JN | 1 |
Obonyo, J | 1 |
Ojwang, J | 1 |
Mugumya, R | 1 |
Opio, C | 1 |
Mermin, J | 1 |
Kankasa, MP | 1 |
Germinario, EA | 1 |
Bassani, L | 1 |
Dehò, L | 1 |
Okong, P | 1 |
Flys, TS | 2 |
Jones, DC | 1 |
Nightingale, S | 1 |
Heymann, SJ | 1 |
Gilbert, PB | 1 |
Stevens, L | 2 |
Peter, T | 1 |
Kim, S | 1 |
Ndase, P | 2 |
Arimi, P | 2 |
Kebaabetswe, P | 1 |
Mazonde, P | 1 |
Lee, TH | 1 |
Marlink, R | 1 |
Lagakos, S | 2 |
Poggensee, G | 1 |
Gingelmaier, A | 1 |
Kästner, R | 1 |
Eberle, J | 1 |
Mylonas, I | 1 |
Belohradsky, BH | 1 |
Friese, K | 1 |
Grubert, TA | 1 |
Germano, P | 2 |
Guidotti, G | 2 |
Loureiro, S | 2 |
da Cruz Gomes, A | 1 |
Valls Blazquez, MC | 1 |
Perno, CF | 1 |
Sagay, AS | 1 |
Musa, J | 1 |
Adewole, AS | 1 |
Imade, GE | 1 |
Ekwempu, CC | 1 |
Kapiga, S | 1 |
Sankale, JL | 2 |
Idoko, J | 2 |
Kanki, P | 1 |
Rexroad, VE | 1 |
Hamzeh, FM | 1 |
Li, X | 1 |
Stamper, PD | 1 |
von Hentig, N | 1 |
Carlebach, A | 1 |
Gute, P | 1 |
Knecht, G | 1 |
Klauke, S | 1 |
Rohrbacher, M | 1 |
Stocker, H | 1 |
Harder, S | 1 |
Staszewski, S | 1 |
Haberl, A | 2 |
Bhayroo, S | 1 |
Thistle, P | 1 |
Spitzer, RF | 1 |
Glazier, RH | 1 |
Pilon, R | 1 |
Arbess, G | 1 |
Simor, A | 1 |
Boyle, E | 1 |
Gottesman, M | 1 |
Silverman, M | 1 |
Gu, SM | 1 |
Giaquinto, C | 1 |
Rampon, O | 1 |
De Rossi, A | 1 |
Mayer, A | 1 |
Simo, S | 1 |
Ali, M | 1 |
Salu, OB | 1 |
Musa, AZ | 1 |
Onyewuche, J | 1 |
Funso-Adebayo, EO | 1 |
Iroha, EO | 1 |
Ezeaka, VC | 1 |
Adetifa, IM | 1 |
Okoeguale, B | 1 |
Idigbe, EO | 1 |
Chand, F | 1 |
Bedikou, G | 1 |
Timite-Konan, M | 1 |
Siegfried, NL | 1 |
Balkus, J | 1 |
Manuel, R | 1 |
Djedje, M | 1 |
Seoighe, C | 1 |
Ketwaroo, F | 1 |
Scheffler, K | 1 |
Wood, N | 1 |
Duffet, R | 1 |
Zvelebil, M | 1 |
Hide, W | 1 |
Westreich, D | 1 |
Eron, J | 1 |
Horst, Cv | 1 |
Van Rie, A | 1 |
Natarajan, U | 1 |
Pym, A | 1 |
McDonald, C | 1 |
Velisetty, P | 1 |
Edwards, SG | 2 |
Hay, P | 2 |
Welch, J | 2 |
de Ruiter, A | 2 |
Taylor, GP | 3 |
Anderson, J | 1 |
Manosuthi, W | 1 |
Athichathanabadi, C | 1 |
Uttayamakul, S | 1 |
Phoorisri, T | 1 |
Sungkanuparph, S | 1 |
Lupodwana, P | 1 |
Steyn, JG | 1 |
Mtonga, V | 1 |
Lee, A | 1 |
Suksomboon, N | 1 |
Poolsup, N | 1 |
Ket-Aim, S | 1 |
Patel, D | 1 |
Cortina-Borja, M | 1 |
Alcorn, K | 1 |
Kurle, SN | 1 |
Gangakhedkar, RR | 1 |
Sen, S | 1 |
Hayatnagarkar, SS | 1 |
Tripathy, SP | 1 |
Paranjape, RS | 1 |
Perre, PV | 1 |
Samuel, NM | 3 |
Parameshwari, S | 1 |
Dharmarajan, S | 1 |
Van Hook, HM | 1 |
Jacob, SM | 1 |
Junankar, V | 1 |
Stoszek, SK | 1 |
Rollins, N | 1 |
Little, K | 1 |
Mzolo, S | 1 |
Horwood, C | 1 |
Basavraj, A | 1 |
Kakrani, A | 1 |
Philip, S | 1 |
Desai, D | 1 |
Manfredi, R | 1 |
Calza, L | 1 |
Bennetto-Hood, C | 1 |
King, JR | 1 |
Woodman, K | 1 |
Ashouri, N | 1 |
Igumbor, OJ | 1 |
Pengpid, S | 1 |
Obi, CL | 1 |
Apornpong, T | 1 |
Teeratakulpisarn, S | 1 |
Chaithongwongwatthana, S | 1 |
Taweepolcharoen, C | 1 |
Mangclaviraj, S | 1 |
Limpongsanurak, S | 1 |
Jadwattanakul, T | 1 |
Eiamapichart, P | 1 |
Luesomboon, W | 1 |
Apisarnthanarak, A | 1 |
Kamudhamas, A | 1 |
Tangsathapornpong, A | 1 |
Vitavasiri, C | 1 |
Singhakowinta, N | 1 |
Attakornwattana, V | 1 |
Kriengsinyot, R | 1 |
Methajittiphun, P | 1 |
Chunloy, K | 1 |
Preetiyathorn, W | 1 |
Aumchantr, T | 1 |
Toro, P | 1 |
El-Sadr, W | 1 |
Phanuphak, P | 1 |
Donninger, S | 1 |
Toure, S | 1 |
El-Sadr, WM | 1 |
Kassaye, S | 1 |
Lee, E | 1 |
Winters, M | 1 |
Katzenstein, D | 1 |
Dao, H | 1 |
Ekpini, R | 1 |
Barnhart, M | 1 |
D'costa, GF | 1 |
Khadke, K | 1 |
Patil, YV | 1 |
Bharucha, KE | 1 |
Kulkarni, P | 1 |
Phadke, M | 1 |
Djadou, KE | 1 |
Ocloo, A | 1 |
Dokounor, D | 1 |
Agbodjan-Djossou, O | 1 |
Akakpossa, A | 1 |
Safrit, JT | 1 |
Shekelle, P | 1 |
Maglione, M | 1 |
Geotz, MB | 1 |
Wagner, G | 1 |
Wang, Z | 1 |
Hilton, L | 1 |
Carter, J | 1 |
Tringle, C | 1 |
Mojica, W | 1 |
Newberry, S | 1 |
Tsai, WY | 1 |
Ly, N | 1 |
Phoung, V | 1 |
Min, DC | 2 |
Srey, C | 1 |
Kruy, LS | 2 |
Koum, K | 1 |
Chhum, V | 1 |
Glaziou, P | 2 |
Reynes, JM | 1 |
Ojesina, AI | 1 |
Mullins, C | 1 |
Imade, G | 1 |
Samuels, J | 1 |
Pam, S | 1 |
Sagay, S | 1 |
Kanki, PJ | 1 |
Downing, R | 1 |
Greenberg, AE | 1 |
Schlösser, R | 1 |
Linde, R | 1 |
Dunsch, D | 1 |
Reitter, A | 1 |
Bauer, K | 1 |
Clarisse, AB | 1 |
Dandona, L | 1 |
Kumar, SG | 1 |
Ramesh, YK | 1 |
Rao, MC | 1 |
Dandona, R | 1 |
Eyakuze, C | 1 |
Jones, DA | 1 |
Starrs, AM | 1 |
Sorkin, N | 1 |
Dube, S | 1 |
Boily, MC | 1 |
Mugurungi, O | 1 |
Mahomva, A | 1 |
Chikhata, F | 1 |
Gregson, S | 1 |
Carraro, EA | 1 |
Prandel, E | 1 |
Dias, JM | 1 |
Perini, J | 1 |
Macedo, RL | 1 |
Cornelsen, TC | 1 |
Sbalquiero, R | 1 |
Rees, H | 1 |
Kirere Mathe, M | 1 |
Sondag-Thull, D | 1 |
Lepage, P | 1 |
Aweeka, F | 1 |
Stek, A | 1 |
Hu, C | 1 |
Burchett, SK | 1 |
Best, B | 1 |
Watts, H | 1 |
Nachman, S | 1 |
Jimenez, E | 3 |
Shearer, WT | 1 |
Damming, M | 1 |
Prins, JM | 1 |
Pérez, H | 1 |
Vignoles, M | 1 |
Laufer, N | 1 |
Gómez, A | 1 |
Coll, P | 1 |
Lottner, J | 1 |
Rolón, M | 1 |
Salomón, H | 1 |
Cahn, P | 1 |
Gomutbutra, V | 1 |
Ghosh, M | 1 |
Bii, SC | 1 |
Otieno-Nyunya, B | 1 |
Rotich, JK | 1 |
Claassen, M | 1 |
Engelbrecht, S | 1 |
Laten, JD | 1 |
Preiser, W | 1 |
Gagnier, P | 1 |
Pav, J | 1 |
Gwynne, M | 1 |
Siminski, S | 2 |
Yogev, R | 1 |
Elliott, T | 1 |
Horton, S | 1 |
Dransfield, K | 2 |
Pav, JW | 1 |
Murarka, A | 1 |
Hom, D | 1 |
McCarthy, M | 1 |
Renault, B | 1 |
Birmingham, K | 2 |
Lurie, P | 1 |
Wolfe, SM | 1 |
Campa, AM | 1 |
Baum, MK | 1 |
Cherry, M | 4 |
Temesgen, Z | 1 |
Wright, AJ | 1 |
Clarke, SM | 1 |
Mulcahy, F | 1 |
Healy, CM | 1 |
Condon, S | 1 |
Butler, KM | 1 |
Masland, T | 1 |
King, P | 1 |
Lyall, EG | 1 |
Ward, C | 1 |
Hayashi, T | 1 |
Chen, F | 1 |
Pau, AK | 1 |
Piscitelli, SC | 1 |
Cooper, PA | 1 |
Jivkov, BI | 1 |
Schorn, MC | 1 |
Stinnett, AA | 1 |
Clarke, DF | 1 |
Akue, JP | 1 |
Babaki, P | 2 |
Charpak, N | 2 |
de Thé, G | 2 |
Rea, MF | 1 |
Huraux, C | 2 |
Ndiaye, B | 2 |
Pratomo, H | 2 |
Zetterström, R | 2 |
Lhotska, L | 1 |
Armstrong, H | 1 |
McNeeley, DF | 1 |
Dovie Akue, JP | 1 |
Ferreira Rea, M | 1 |
Benson, M | 1 |
Shannon, M | 1 |
Bowersox, J | 1 |
Kasper, T | 1 |
Sax, PE | 1 |
Lindsay, MK | 1 |
MacDougall, DS | 1 |
Hankins, C | 1 |
Jones, TT | 2 |
Cunningham, S | 2 |
Smith, AN | 2 |
Glenn Fowler, M | 1 |
Lugo, M | 1 |
Smith, PF | 1 |
DiCenzo, R | 1 |
Morse, GD | 1 |
Larbalestier, N | 1 |
Easterbrook, P | 1 |
Florence, KJ | 1 |
Podzamczer, D | 1 |
Fumero, E | 1 |
Bonard, D | 1 |
Faure, M | 1 |
Huët, C | 1 |
Caumont, A | 1 |
Roques, P | 1 |
Salamon, R | 1 |
Fleury, H | 1 |
Ashraf, H | 1 |
Hoover, D | 1 |
Mukiibi, J | 1 |
Broadhead, R | 1 |
Saman, M | 1 |
Leng, C | 1 |
Huff, B | 1 |
Skordis, J | 1 |
Zuniga, JM | 1 |
Gebbie, KM | 1 |
Cullinan, K | 2 |
Marzolini, C | 1 |
Béguin, A | 1 |
Telenti, A | 1 |
Schreyer, A | 1 |
Buclin, T | 1 |
Biollaz, J | 1 |
Decosterd, LA | 1 |
Cunningham-Schrader, B | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
PHPT-5 Second Phase: Perinatal Antiretroviral Intensification for the Prevention of Mother-to-child Transmission of HIV in Thai Women Having Received Less Than 8 Weeks of HAART During Pregnancy[NCT01511237] | Phase 3 | 379 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study[NCT02140255] | Phase 1/Phase 2 | 905 participants (Anticipated) | Interventional | 2015-01-23 | Recruiting | ||
Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission[NCT00310726] | 1,435 participants (Actual) | Interventional | 2001-05-31 | Completed | |||
Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria[NCT02447159] | 554 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance After a Single Dose Nevirapine (VIramune®), Which is Part of ARV Prophylaxis for PMTCT in Moshi, TAnzania, and in Lusaka, Zambia (VITA2 Trial)[NCT01187719] | Phase 2 | 66 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women[NCT00993031] | Phase 3 | 389 participants (Actual) | Interventional | 2009-12-15 | Completed | ||
Interactions Between Antiretrovirals and Combined Oral Contraceptive Pills[NCT00829114] | Phase 4 | 370 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV[NCT00397150] | 2,579 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
Maternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand.[NCT00409591] | Phase 3 | 435 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Change in National PMTCT guidelines in Thailand) | ||
A Pharmacokinetic Evaluation of Levonorgestrel Implant and Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-infected Ugandan Women[NCT01789879] | Phase 2 | 60 participants (Actual) | Interventional | 2014-03-04 | Completed | ||
Optimizing Integrated PMTCT Services in Rural North-Central Nigeria: A Cluster Randomized Trial[NCT01805752] | 369 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
Role of Pharmacogenetics in Efavirenz and Nevirapine Pharmacokinetics, Efficacy and Safety in Mother-infant Pairs During Pregnancy and Lactation[NCT02269462] | 460 participants (Actual) | Observational | 2012-12-31 | Completed | |||
Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)[NCT01061151] | Phase 3 | 3,747 participants (Actual) | Interventional | 2011-03-01 | Completed | ||
Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission[NCT00204308] | Phase 2 | 400 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women[NCT00209781] | 1,028 participants | Interventional | 2003-08-31 | Active, not recruiting | |||
Prevention of Maternal to Infant HIV Transmission in India[NCT00061321] | Phase 3 | 770 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant[NCT00074399] | Phase 3 | 775 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV[NCT00639938] | Phase 3 | 722 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
Presumptive and Definitive Virologic HIV Diagnosis in Hospitalized Malawian Infants[NCT01388452] | 300 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
ARVs to Prevent Breastmilk HIV:Viral and Immune Responses[NCT00167674] | Phase 2 | 58 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
A Cohort Study To Assess The Impact Of A Breastfeeding Counselling And Support Strategy To Promote Exclusive Breastfeeding On Post-Natal Transmission Of HIV In African Women[NCT01948557] | 3,465 participants (Actual) | Interventional | 2001-10-31 | Completed | |||
Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia[NCT00334256] | Phase 2 | 72 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858] | 1,765 participants (Actual) | Observational | 2011-03-22 | Completed | |||
Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission[NCT00021671] | Phase 3 | 3,720 participants | Interventional | Completed | |||
HIV Exposure, Disease Acquisition and Progression Among Children: Role of Maternal Immunogenetics, Viral Genetic Diversity, HAART Exposure, Co-morbidities and Psycho-Social Status: (UZ-CHS Birth Cohort)[NCT04087239] | 1,200 participants (Actual) | Observational | 2016-01-26 | Active, not recruiting | |||
An Open-label Study Evaluating the Resistance Profile of Single Dose Nevirapine(NVP) When Combined With a 4 or 7 Day Course of Combivir® (ZDV/3TC) Compared to Single Dose Nevirapine for the Prevention of Mother to Child Transmission (pMTCT) of HIV - Treat[NCT00144183] | Phase 3 | 407 participants | Interventional | 2003-01-31 | Completed | ||
Optimizing the Delivery of Maternal and Child Health Services to Strengthen the Primary Health Care System in Rural South Africa[NCT02626351] | 3,172 participants (Actual) | Interventional | 2015-07-15 | Completed | |||
A Phase 2, One Arm, Open Label, Feasibility Study Assessing One Month Zidovudine/Didanosine Postpartum Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine to Prevent Mother to Child Transmission of HIV[NCT00142337] | Phase 2 | 244 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand[NCT00433030] | 2,816 participants (Actual) | Observational | 2007-01-31 | Completed | |||
HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health[NCT00164736] | Phase 3 | 2,369 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants[NCT04862975] | 200 participants (Anticipated) | Observational | 2024-01-08 | Not yet recruiting | |||
Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana[NCT00270296] | Phase 2 | 730 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
Z 1303 - Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children[NCT02682810] | 4,000 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
Nevirapine Pharmacodynamics and Resistance Among HIV-Infected Mothers in Lilongwe, Malawi[NCT00164762] | 126 participants (Actual) | Observational | 2005-06-30 | Completed | |||
Optimal Combination Therapy After Nevirapine Exposure[NCT00089505] | Phase 3 | 745 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-t[NCT00307151] | Phase 2 | 452 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years[NCT01504841] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | 2013-03-14 | Completed | ||
The Effect of Single Dose Carbamazepine on the Pharmacokinetics of Single Dose Nevirapine (Viramune, NVP) and Development of NVP Resistance, PMTCT Program of Moshi, Tanzania (VITA1)[NCT00294892] | Phase 2 | 144 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
[NCT00398684] | Phase 3 | 1,792 participants | Interventional | 2001-01-31 | Completed | ||
Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Di[NCT00109590] | Phase 2 | 175 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding[NCT00530777] | Phase 2 | 148 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission[NCT00099359] | Phase 3 | 1,735 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection[NCT01780831] | Phase 1 | 52 participants (Actual) | Interventional | 2014-01-28 | Completed | ||
Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine[NCT00099632] | Phase 2 | 484 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00000869] | Phase 3 | 2,009 participants | Interventional | Completed | |||
A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates[NCT00006396] | Phase 3 | 1,500 participants | Interventional | Completed | |||
A Phase III Randomized Trial of the Safety and Antiretroviral Effects of Zidovudine/Lamivudine/Abacavir Versus Zidovudine/Lamivudine/Lopinavir/Ritonavir in the Prevention of Perinatal Transmission of HIV[NCT00086359] | Phase 3 | 19 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
Assessment of Safety and Toxicity Among Infants Born to HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World[NCT00100867] | 236 participants (Actual) | Observational | 2006-06-30 | Completed | |||
Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum[NCT00042289] | 1,578 participants (Actual) | Observational | 2003-06-09 | Completed | |||
Phase I/II Study to Assess the Safety and Plasma Concentrations of Nevirapine Given Daily, Twice a Week or Weekly as Prophylaxis in Breastfeeding Infants From Birth to 6 Months[NCT00006279] | Phase 1 | 75 participants | Interventional | Completed | |||
A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00001135] | Phase 3 | 2,009 participants | Interventional | Completed | |||
A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00000942] | Phase 3 | 1,244 participants | Interventional | Completed | |||
Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy[NCT00017719] | Phase 3 | 440 participants | Interventional | 2002-05-31 | Completed | ||
An Open-Label, Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Pre-menopausal Women[NCT00961272] | 6 participants (Actual) | Observational | 2009-07-31 | Completed | |||
A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women[NCT00774683] | 1 participants (Actual) | Observational | 2008-08-31 | Completed | |||
A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers[NCT01325051] | Phase 1 | 15 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants[NCT00076791] | Phase 1 | 66 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
"Prevention of Milk-Borne Transmission of HIV-1C in Botswana (Mashi)"[NCT00197587] | 1,200 participants (Actual) | Interventional | 2002-08-31 | Completed | |||
ART Readiness in HIV-infected Pregnant Women: From Formative Qualitative Research to Individual Randomized Trial[NCT02459678] | 454 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
Pilot Evaluation of Pulmonary Tuberculosis Screening in Antenatal Clinics in Lusaka, Zambia[NCT02053129] | 5,033 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers[NCT00000808] | Phase 1 | 49 participants | Interventional | Completed | |||
Mother-Infant Rapid Intervention at Delivery (MIRIAD)[NCT00046436] | 7,500 participants | Observational | Terminated | ||||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
Intervention | Number of Adverse Events (Number) | ||||
---|---|---|---|---|---|
Death | Life-Threatening | Severe | Moderate | Mild | |
Nevirapine | 26 | 87 | 375 | 694 | 832 |
Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
Intervention | participants (Number) | |
---|---|---|
# of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
Nevirapine | 8 | 700 |
Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
Intervention | participants (Number) | |
---|---|---|
# Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
Nevirapine | 26 | 678 |
Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
Intervention | participants (Number) | |
---|---|---|
Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
Nevirapine | 689 | 629 |
Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
Intervention | participants (Number) | |
---|---|---|
# of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
Nevirapine | 16 | 664 |
Placebo | 23 | 663 |
antiretroviral hair concentrations (per doubling) (NCT00993031)
Timeframe: delivery
Intervention | antiretroviral hair concentration(ng/mg) (Mean) |
---|---|
Without Protease Inhibitor | 5.7 |
With Protease Inhibitor | 6.6 |
CD4 cell count recovery efavirenz at delivery (NCT00993031)
Timeframe: Time of randomization to delivery, an average of 20 weeks
Intervention | CD4 cell count (Median) |
---|---|
Without Protease Inhibitor | -7 |
With Protease Inhibitor | 57 |
Pre-eclampsia Defined by Hypertension > 140/90 on Two Occasions Measured > 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick (NCT00993031)
Timeframe: Time from randomization until delivery
Intervention | Participants (Count of Participants) |
---|---|
Without Protease Inhibitor | 0 |
With Protease Inhibitor | 0 |
(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from delivery until 24 months after delivery or cessation of breastfeeding
Intervention | treatments (Number) |
---|---|
Group A | 21 |
Group B | 13 |
(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from randomization until 24 months after delivery or cessation of breastfeeding
Intervention | treatments (Number) |
---|---|
With Protease Inhibitor | 17 |
Without Protease Inhibitor | 17 |
(NCT00993031)
Timeframe: Randomization to one month postpartum
Intervention | Participants (Count of Participants) |
---|---|
Without Protease Inhibitor | 12 |
With Protease Inhibitor | 8 |
Virologic suppression was defined as plasma HIV-1 RNA 400 copies/ml or less based on the lower limit of detection of the available test. (NCT00993031)
Timeframe: Time from randomization until delivery, an average of 20 weeks
Intervention | Participants (Count of Participants) |
---|---|
Without Protease Inhibitor | 166 |
With Protease Inhibitor | 153 |
HIV tested by DNA PCR (NCT00993031)
Timeframe: Delivery to 48 weeks postpartum
Intervention | Participants (Count of Participants) |
---|---|
Without Protease Inhibitor | 0 |
With Protease Inhibitor | 2 |
Proportion of women with severe maternal Anemia (hemoglobin < 8g/dl by hemacue or CBC) at any point during the trial in Each Treatment Group (NCT00993031)
Timeframe: Time from randomization until one year follow up
Intervention | Participants (Count of Participants) |
---|---|
Without Protease Inhibitor | 11 |
With Protease Inhibitor | 11 |
Number of participants with positive placental RDT for malaria. Malaria rapid diagnostic tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood. RDTs permit a reliable detection of malaria infections particularly in remote areas with limited access to good quality microscopy services. (NCT00993031)
Timeframe: Delivery
Intervention | participants (Number) |
---|---|
With Protease Inhibitor | 6 |
Without Protease Inhibitor | 7 |
Number of participants with positive placental histopathology slide for malaria (NCT00993031)
Timeframe: Delivery
Intervention | participants (Number) |
---|---|
With Protease Inhibitor | 62 |
Without Protease Inhibitor | 47 |
Percent of evaluated participants with composite clinical outcome defined by LBW, stillbirth (intrauterine fetal demise >20wks GA), late spontaneous abortion(miscarriage 12-20wks GA), preterm delivery(<37wks gestation), neonatal death(death of live-born infant within first 28 days) (NCT00993031)
Timeframe: Time from randomization until 24 months postpartum or cessation of breastfeeding
Intervention | % of evaluated participants with outcome (Number) |
---|---|
With Protease Inhibitor | 33.9 |
Without Protease Inhibitor | 27.8 |
Number of participants with positive placental blood PCR for malaria (NCT00993031)
Timeframe: Delivery
Intervention | participants (Number) |
---|---|
With Protease Inhibitor | 6 |
Without Protease Inhibitor | 7 |
Number of participants with positive placental blood smear for malaria (NCT00993031)
Timeframe: Delivery
Intervention | participants (Number) |
---|---|
With Protease Inhibitor | 5 |
Without Protease Inhibitor | 6 |
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
Intervention | participants (Number) |
---|---|
Intervention | 310 |
No Intervention | 161 |
The EBF prevalences based on 24-h recall at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
Intervention | participants (Number) |
---|---|
Intervention | 56 |
No Intervention | 30 |
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
Intervention | participants (Number) |
---|---|
Intervention | 323 |
No Intervention | 161 |
(NCT00397150)
Timeframe: at 3 months of age
Intervention | participants (Number) |
---|---|
Intervention | 104 |
No Intervention | 101 |
Defined as HIV nucleic acid test (NAT) positivity of the specimen drawn at either the birth (Day 0-5) or Week 1 (Day 6-14) visit, confirmed by HIV NAT positivity of a second specimen collected at a different time point (NCT01061151)
Timeframe: Measured at birth or Week 1 study visit
Intervention | Participants (Count of Participants) |
---|---|
Antepartum Arm A | 25 |
Antepartum Arm B | 7 |
Antepartum Arm C | 2 |
Detected by HIV NAT positivity (NCT01061151)
Timeframe: Measured at the birth (<= 3 days postpartum) visit
Intervention | Participants (Count of Participants) |
---|---|
Antepartum Arm A | 22 |
Antepartum Arm B | 4 |
Antepartum Arm C | 2 |
"AIDS-defining illness refers to the WHO Clinical Stage 4 illnesses listed in Appendix IV. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | New cases per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 0.08 |
Maternal Health Arm B (Discontinue Triple ARVs) | 0.25 |
Number of women who died during the maternal health component; that is, who had been randomized to either continue or discontinue ART after risk of HIV vertical transmission through breastfeeding was over. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | New cases per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 0.24 |
Maternal Health Arm B (Discontinue Triple ARVs) | 0.43 |
"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | New cases per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 1.30 |
Maternal Health Arm B (Discontinue Triple ARVs) | 1.43 |
"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | New cases per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 3.47 |
Maternal Health Arm B (Discontinue Triple ARVs) | 5.61 |
"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | New cases per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 1.14 |
Maternal Health Arm B (Discontinue Triple ARVs) | 1.24 |
AIDS-defining illness refers to the WHO Clinical Stage 4 illnesses in Appendix IV of the protocol. These events were reviewed and confirmed by an Endpoint review group. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | New cases per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 0.24 |
Maternal Health Arm B (Discontinue Triple ARVs) | 0.49 |
Incidence of tuberculosis. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | New cases per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 0.40 |
Maternal Health Arm B (Discontinue Triple ARVs) | 0.31 |
"Cardiovascular or metabolic events of particular concern were included in this analysis. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates.~Metabolic events considered were diabetes mellitus, lipodystrophy, or dyslipidemia. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | events per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 2.9 |
Maternal Health Arm B (Discontinue Triple ARVs) | 5.7 |
Particular events were targeted as those of particular concern. This outcome considered all such events: death, events defining WHO stages II, III, or IV, targeted cardiovascular adverse events, other targeted adverse events, or cancers which were not AIDS-defining. A complete list can be found in Appendix IV of the Protocol. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | events per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 9.0 |
Maternal Health Arm B (Discontinue Triple ARVs) | 14.0 |
"This outcome included AIDS-defining illnesses or cardiovascular, hepatic, or renal adverse events of particular concern which were evaluated as serious. Serious outcomes were both those defined as serious according to the International Conference on Harmonization (ICH) definition, or outcomes with grades equal to or worse than 3 (Severe). A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy. Hepatic events considered were cirrhosis and idiopathic sclerosing cholangitis. Renal events considered were renal insufficiency, acute or chronic." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | events per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 0.5 |
Maternal Health Arm B (Discontinue Triple ARVs) | 0.9 |
Other (non-cardiologic) medical conditions of particular concern were included in this outcome. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Events included were metabolic events, hepatic events, renal events, infections such as pulmonary tuberculosis, malaria, or other serious bacterial infections, and others. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | events per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 4.0 |
Maternal Health Arm B (Discontinue Triple ARVs) | 4.6 |
The maternal safety endpoints summarized include grade 2, 3 or 4 hematologies (hemoglobin (Hb), White Blood Cells (WBC), Absolute Neutrophil Count (ANC), platelet count), chemistries (Alanine Aminotransferase (ALT or SGPT), serum creatinine), and grade 3 or 4 signs and symptoms that occurred post-randomization. These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
Intervention | New cases per 100 person-years (Number) |
---|---|
Maternal Health Arm A (Continue Triple ARVs) | 15.3 |
Maternal Health Arm B (Discontinue Triple ARVs) | 13.9 |
Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit (i.e., any visit after the Week 1 [Day 6-14] visit), confirmed by HIV NAT positivity of a second specimen drawn at a different time point. Analyses were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event. (NCT01061151)
Timeframe: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first
Intervention | New cases per 100 person-years (Number) |
---|---|
Postpartum Arm A (Maternal Prophylaxis) | 0.56 |
Postpartum Arm B (Infant Prophylaxis) | 0.55 |
These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first
Intervention | New cases per 100 person-years (Number) |
---|---|
Postpartum Arm A (Maternal Prophylaxis) | 14.4 |
Postpartum Arm B (Infant Prophylaxis) | 14.1 |
Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit, confirmed by HIV NAT positivity of a second specimen drawn at a different time point, or infant death. Analyses (Kaplan-Meier probabilities) were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event. (NCT01061151)
Timeframe: Measured through 24 months post-delivery
Intervention | Probability (Number) |
---|---|
Postpartum Arm A (Maternal Prophylaxis) | 0.971 |
Postpartum Arm B (Infant Prophylaxis) | 0.977 |
Composite outcome (NCT01061151)
Timeframe: Measured at birth
Intervention | Participants (Count of Participants) |
---|---|
Period 2 | |
Antepartum Arm C | 111 |
Composite outcome (NCT01061151)
Timeframe: Measured at birth
Intervention | Participants (Count of Participants) | |
---|---|---|
Periods 1 and 2 | Period 2 | |
Antepartum Arm A | 389 | 91 |
Antepartum Arm B | 563 | 123 |
These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit
Intervention | Participants (Count of Participants) |
---|---|
Period 2 | |
Antepartum Arm C | 60 |
These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit
Intervention | Participants (Count of Participants) | |
---|---|---|
Periods 1 and 2 | Period 2 | |
Antepartum Arm A | 261 | 59 |
Antepartum Arm B | 318 | 61 |
"Complications included deaths, diagnoses, signs/symptoms, chemistry lab tests, or hematological lab tests, with grades of 3 (Severe) or worse. Obstetrical complications were those classified by the MedDra coding system as Pregnancy, puerperium and perinatal conditions, except if the condition was the death of the fetus: Abortions not specified as induced or spontaneous, Abortions spontaneous, or Stillbirth and foetal death." (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit
Intervention | Participants (Count of Participants) |
---|---|
Period 2 | |
Antepartum Arm C | 23 |
"Complications included deaths, diagnoses, signs/symptoms, chemistry lab tests, or hematological lab tests, with grades of 3 (Severe) or worse. Obstetrical complications were those classified by the MedDra coding system as Pregnancy, puerperium and perinatal conditions, except if the condition was the death of the fetus: Abortions not specified as induced or spontaneous, Abortions spontaneous, or Stillbirth and foetal death." (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit
Intervention | Participants (Count of Participants) | |
---|---|---|
Periods 1 and 2 | Period 2 | |
Antepartum Arm A | 89 | 20 |
Antepartum Arm B | 75 | 12 |
For overall survival, failure was defined to be death. For HIV-free survival, failure was defined to be either death or developing HIV. The probability of living, or living without HIV infection, at 104 weeks was calculated by Kaplan-Meier estimation of the survival function. (NCT01061151)
Timeframe: Measured from birth through 104 weeks of age
Intervention | Proportional probability (Number) | |
---|---|---|
Overall survival, period 2 group | HIV-free survival, period 2 group | |
Antepartum Arm C | 0.942 | 0.921 |
For overall survival, failure was defined to be death. For HIV-free survival, failure was defined to be either death or developing HIV. The probability of living, or living without HIV infection, at 104 weeks was calculated by Kaplan-Meier estimation of the survival function. (NCT01061151)
Timeframe: Measured from birth through 104 weeks of age
Intervention | Proportional probability (Number) | |||
---|---|---|---|---|
Overall survival, Periods 1 & 2 group (arms A & B only) | Overall survival, period 2 group | HIV-free survival, Periods 1&2 group (arms A&B only) | HIV-free survival, period 2 group | |
Antepartum Arm A | 0.959 | 0.951 | 0.937 | 0.936 |
Antepartum Arm B | 0.967 | 0.982 | 0.947 | 0.940 |
Analyses (Kaplan-Meier probabilities) conducted for all individual infants (rather than M-I pair) (NCT01061151)
Timeframe: Measured at 12 and 24 months post-delivery
Intervention | Probability (Number) | |
---|---|---|
12 months post delivery | 24 months post delivery | |
Postpartum Arm A (Maternal Prophylaxis) | 0.988 | 0.978 |
Postpartum Arm B (Infant Prophylaxis) | 0.989 | 0.987 |
Analysis used the principle of intent to treat. (NCT01061151)
Timeframe: Measured at the time of delivery
Intervention | Participants (Count of Participants) | Participants (Count of Participants) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Periods 1 and 272329519 | Periods 1 and 272329520 | Period 272329520 | Period 272329519 | Period 272329521 | ||||||
HIV RNA < 400 copies/mL | HIV RNA >= 400 copies/mL | |||||||||
Antepartum Arm A | 415 | |||||||||
Antepartum Arm B | 1092 | |||||||||
Antepartum Arm A | 929 | |||||||||
Antepartum Arm B | 275 | |||||||||
Antepartum Arm A | 102 | |||||||||
Antepartum Arm B | 259 | |||||||||
Antepartum Arm C | 225 | |||||||||
Antepartum Arm A | 210 | |||||||||
Antepartum Arm B | 62 | |||||||||
Antepartum Arm C | 79 |
"Adherence is by maternal report; adherence through hair analysis is not included here.~The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since adherence was not a focus of the study." (NCT01061151)
Timeframe: Week 6 visit (14 days - 9 weeks postpartum); Week 14 visit (10-19 weeks postpartum); Week 26 visit (20 to 31 weeks postpartum); Week 50 visit (44 to 55 weeks postpartum); and Week 74 visit (68 to 80 weeks postpartum).
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 6 visit72329524 | Week 6 visit72329525 | Week 14 visit72329524 | Week 14 visit72329525 | Week 26 visit72329524 | Week 26 visit72329525 | Week 50 visit72329524 | Week 50 visit72329525 | Week 74 visit72329524 | Week 74 visit72329525 | |||||||||||||||||||||||||||||||
Missed dose over 1 month ago | Never missed a dose | Missed dose 2-4 weeks ago | Missed dose within last 2 weeks | |||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 1003 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 1104 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 12 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 17 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 4 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 140 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 74 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 956 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 1081 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 20 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 0 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 35 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 112 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 50 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 888 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 1035 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 48 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 31 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 8 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 103 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 47 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 716 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 841 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 37 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 34 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 7 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 64 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 30 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 311 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 377 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm A (Maternal Prophylaxis) | 15 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 2 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 1 | |||||||||||||||||||||||||||||||||||||||
Postpartum Arm B (Infant Prophylaxis) | 9 |
Number of infants with HIV-positive status (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months
Intervention | Infants (Number) |
---|---|
TZV Arm | 6 |
Kaletra Arm | 1 |
NVP Arm | 1 |
Suppression of the plasma HIV-1 RNA level to less than 400 copies per milliliter (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months
Intervention | Participants (Count of Participants) |
---|---|
TZV Arm | 274 |
Kaletra Arm | 256 |
NVP Arm | 160 |
Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 6 |
NVP/LPV_r | 4 |
NoNVP/NVP | 19 |
NoNVP/LPV_r | 26 |
The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 15 |
NVP/LPV_r | 0 |
NoNVP/NVP | 35 |
NoNVP/LPV_r | 0 |
Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 32 |
NVP/LPV_r | 10 |
NoNVP/NVP | 42 |
NoNVP/LPV_r | 50 |
Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.
Intervention | participants (Number) |
---|---|
NVP/NVP | 20 |
NoNVP/NVP | 51 |
Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.
Intervention | cells/mm^3 (Median) | |
---|---|---|
Week 48 CD4 count change from randomization | Week 96 CD4 count change from randomization | |
NoNVP/LPV_r | 172 | 256 |
NoNVP/NVP | 172 | 223 |
NVP/LPV_r | 201 | 278 |
NVP/NVP | 191 | 291 |
Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
Intervention | Percent of participants (Number) | |
---|---|---|
week 48 percent of virologic failure or death | week 96 percent of virologic failure or death | |
NoNVP/LPV_r | 14 | 20 |
NoNVP/NVP | 14 | 17 |
NVP/LPV_r | 4 | 12 |
NVP/NVP | 23 | 31 |
Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
Intervention | percent of participants (Number) | |
---|---|---|
week 48 percent of full adherence in past month | week 96 percent of full adherence in past month | |
NoNVP/LPV_r | 86 | 87 |
NoNVP/NVP | 90 | 93 |
NVP/LPV_r | 88 | 95 |
NVP/NVP | 89 | 94 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.
Intervention | weeks (Number) | ||
---|---|---|---|
5th percentile | 10th percentile | 25th percentile | |
NVP/LPV_r | 60 | 84 | NA |
NVP/NVP | 12 | 12 | 60 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.
Intervention | weeks (Number) | ||
---|---|---|---|
5th percentile | 10th percentile | 25th percentile | |
NoNVP/LPV_r | 12 | 36 | 132 |
NoNVP/NVP | 24 | 36 | NA |
Change was calculated as CD4 percent at week 48 minus entry CD4 percent (last CD4 percent before randomization date). Only subjects who reached 48 weeks of follow-up before DSMB decisions to unblind each Cohort were included in summary. (NCT00307151)
Timeframe: 48 weeks if before date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)
Intervention | Percent of CD4 (Mean) |
---|---|
Coh I: NVP | 13.9 |
Coh I: LPV/r | 12.0 |
Coh II: NVP | 15.2 |
Coh II: LPV/r | 14.3 |
Numbers of participants developing new NRTI, NNRTI or PI-resistant virus after reaching a virologic failure endpoint (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
Intervention | participants (Number) |
---|---|
Coh I: NVP | 16 |
Coh I: LPV/r | 1 |
Coh II: NVP | 10 |
Coh II: LPV/r | 4 |
Virologic failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR death on or before 24 weeks. Results report percent of participants reaching a virologic failure endpoint by week 24 calculated using the Kaplan-Meier method. (NCT00307151)
Timeframe: Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)
Intervention | Percent of participants (Number) |
---|---|
Coh I: NVP | 27.4 |
Coh I: LPV/r | 10.4 |
Coh II: NVP | 28.6 |
Coh II: LPV/r | 12.9 |
Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR permanent discontinuation of the randomized NNRTI or PI component of study treatment at or prior to 24 weeks of treatment for any reason including death. Results report percent of participants reaching a treatment failure endpoint by week 24 calculated using the Kaplan-Meier method. (NCT00307151)
Timeframe: Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)
Intervention | Percent of participants (Number) |
---|---|
Coh I: NVP | 39.6 |
Coh I: LPV/r | 21.7 |
Coh II: NVP | 40.8 |
Coh II: LPV/r | 19.3 |
Results report 2nd percentile of time from randomization to death (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
Intervention | Weeks (Number) |
---|---|
Coh I: NVP | 11 |
Coh I: LPV/r | 3 |
Coh II: NVP | 2 |
Coh II: LPV/r | 83 |
HIV-related disease progression was defined as progression in WHO clinical stage from stage at entry or death. For subjects in WHO Stage IV at entry, disease progression was defined as death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
Intervention | Weeks (Number) | |
---|---|---|
5th percentile | 10th percentile | |
Coh I: LPV/r | 2 | 4 |
Coh I: NVP | 11 | 17 |
Coh II: LPV/r | 35 | 132 |
Coh II: NVP | 8 | 35 |
Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR a confirmed viral rebound >4000 copies/mL after week 24 OR permanent discontinuation of the randomized NNRTI or PI component of study treatment for any reason including death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
Intervention | Weeks (Number) | |
---|---|---|
10th percentile | 25th percentile | |
Coh I: LPV/r | 4 | 36 |
Coh I: NVP | 12 | 16 |
Coh II: LPV/r | 14 | 36 |
Coh II: NVP | 4 | 16 |
Virologic failure is defined as the earlier of a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR a confirmed viral rebound >4000 copies/mL after week 24 OR death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
Intervention | Weeks (Number) | |
---|---|---|
5th percentile | 10th percentile | |
Coh I: LPV/r | 16 | 24 |
Coh I: NVP | 12 | 12 |
Coh II: LPV/r | 16 | 24 |
Coh II: NVP | 12 | 16 |
Safety events include lab abnormalities, signs or symptoms of grade 3 or higher. Events were graded according to the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events, Version 1.0. Events defined as new if first occurrence was after initiation of study treatment or if severity increased from entry and while on the NNRTI or PI component of study treatment. (NCT00307151)
Timeframe: On randomized NNRTI or PI component of study treatment and until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)
Intervention | Weeks (Number) | |
---|---|---|
10th percentile | 25th percentile | |
Coh I: LPV/r | 8 | 36 |
Coh I: NVP | 4 | 24 |
Coh II: LPV/r | 4 | 12 |
Coh II: NVP | 3 | 4 |
Geometric Mean (Standard Deviation) of the area under the plasma concentration-time curve over 12 hours (AUC12h) of ETR. (NCT01504841)
Timeframe: Pre-dose, 1, 2, 4, 6, 9, and 12 hours post-dose measured at intensive PK visit (within 7-10 days after last dose of study drug administration)
Intervention | ng*h/mL (Geometric Mean) |
---|---|
Cohort I: Treatment Experienced, 2 to 6 Years of Age | 5512.85 |
Cohort II: Treatment Experienced, 1 to 2 Years of Age | 4821.76 |
Number (%) of participants with a >5% decline in absolute CD4 percent from baseline at weeks 12, 24, and 48, by Cohort, including Clopper-Pearson confidence intervals. (NCT01504841)
Timeframe: Measured at baseline and at Weeks 12, 24, and 48
Intervention | Participants (Count of Participants) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 1272045667 | Week 1272045668 | Week 2472045667 | Week 2472045668 | Week 4872045667 | Week 4872045668 | |||||||
>5% decline in CD4 % from baseline | Increase or <5% decline in CD4 % from baseline | |||||||||||
Cohort I: Treatment Experienced, 2 to 6 Years of Age | 1 | |||||||||||
Cohort II: Treatment Experienced, 1 to 2 Years of Age | 2 | |||||||||||
Cohort I: Treatment Experienced, 2 to 6 Years of Age | 10 | |||||||||||
Cohort II: Treatment Experienced, 1 to 2 Years of Age | 1 | |||||||||||
Cohort II: Treatment Experienced, 1 to 2 Years of Age | 3 | |||||||||||
Cohort I: Treatment Experienced, 2 to 6 Years of Age | 2 | |||||||||||
Cohort I: Treatment Experienced, 2 to 6 Years of Age | 9 |
Number (%) of participants with confirmed Virologic Failure, defined as: failure to suppress plasma HIV-1 RNA to fewer than 400 copies/ml and failure to achieve at least a 2-log10 reduction (from baseline) in HIV-1 RNA at Weeks 24 or 48, by Cohort, with Clopper-Pearson confidence intervals. The initial HIV-1 RNA results that met the Virologic Failure definition were each confirmed by a second result obtained within 1 to 4 weeks of the initial result obtained at Week 24 and/or 48. (NCT01504841)
Timeframe: Baseline, Week 24, and Week 48
Intervention | Participants (Count of Participants) | |||||||
---|---|---|---|---|---|---|---|---|
Week 2472045667 | Week 2472045668 | Week 4872045667 | Week 4872045668 | |||||
Virologic Failure | No Virologic Failure | |||||||
Cohort I: Treatment Experienced, 2 to 6 Years of Age | 2 | |||||||
Cohort I: Treatment Experienced, 2 to 6 Years of Age | 9 | |||||||
Cohort I: Treatment Experienced, 2 to 6 Years of Age | 3 | |||||||
Cohort II: Treatment Experienced, 1 to 2 Years of Age | 3 | |||||||
Cohort I: Treatment Experienced, 2 to 6 Years of Age | 8 | |||||||
Cohort II: Treatment Experienced, 1 to 2 Years of Age | 1 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
Intervention | ug*hr/mL (Median) |
---|---|
Within 72 Hrs Ppm | 99.7 |
At Day 30 Ppm | NA |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
Intervention | ug/mL (Median) |
---|---|
Within 72 Hrs Ppm | 10.78 |
At Day 30 Ppm | 12.96 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
Intervention | ug/mL (Median) |
---|---|
Within 72 Hrs Ppm | 11.2 |
At Day 30 Ppm | NA |
(NCT00109590)
Timeframe: at 24 weeks postpartum
Intervention | log10 copies/mL (Median) |
---|---|
Arm A : LPV/r x 7d | 4.3 |
Arm B : no LPV/r | 3.9 |
Arm C: LPV/r x 30d | 4.0 |
Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading > the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities (and events of any grade that led to a change in study treatment) were included. (NCT00109590)
Timeframe: After start of study Treatment (postpartum)
Intervention | participants (Number) |
---|---|
Arm A : LPV/r x 7d | 2 |
Arm B : no LPV/r | 0 |
Arm C: LPV/r x 30d | 2 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
Intervention | ug/mL (Median) |
---|---|
Within 72 Hrs Ppm | 6.08 |
At Day 30 Ppm | 9.17 |
Resistance mutations as identified by consensus sequencing or OLA (NCT00109590)
Timeframe: 24 weeks postpartum
Intervention | participants (Number) |
---|---|
Arm B : no LPV/r | 0 |
Arm C: LPV/r x 30d | 0 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
Intervention | percent of participants (Number) |
---|---|
Arm A : LPV/r x 7d | 3.6 |
Arm B : no LPV/r | 7.1 |
Arm C : LPV/r x 30d | 5.3 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
Intervention | percent of participants (Number) |
---|---|
Arm A: LPV/r x 7d | 4.9 |
Arm B: no LPV/r | 9.5 |
Arm C : LPV/r x 30d | 7.0 |
The incidence of new NVP resistance mutation in plasma HIV within 8 weeks postpartum in each randomized arm was estimated using an exact binomial confidence interval. If a resistance mutation was detected at any of the timepoints then an endpoint was met. Samples with VL <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml (e.g.missed visit), it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: within 8 weeks postpartum.
Intervention | percent of participants (Number) |
---|---|
Arm A : LPV/r x 7d | 7.1 |
Arm B : no LPV/r | 12.5 |
Arm C: LPV/r x 30d | 5.3 |
Resistance mutations as identified by OLA in plasma samples or PBMC at 72 weeks postpartum amongst women who had new NVP resistance mutations within 8 weeks postpatrum. These results were based on the 13 women who developed a new NVP resistance mutation in the first 8 weeks postpartum. For the primary outcome measure 1, one particpant in arm A was unavailable for follow-up after week 5 and was conservatively imputed to have developed resistance mutation. (NCT00109590)
Timeframe: within 72 weeks postpartum
Intervention | participants (Number) | |
---|---|---|
OLA in plasma samples | OLA in PBMC | |
Arm A : LPV/r x 7d | 0 | 0 |
Arm B : no LPV/r | 0 | 0 |
Arm C: LPV/r x 30d | 0 | 1 |
(NCT00109590)
Timeframe: At Week 5 postpartum (ZDV) and at the first timepoint with viral load >=500 copies/ml after treatment discontinuation (ddI and LPV/r).
Intervention | percent of participants (Number) | ||
---|---|---|---|
The proportion of women with new ZDV resistance | The proportion of women with new ddI resistance | The proportion of women with new LPV/r resistance | |
Arm A : LPV/r x 7d | 0 | 0 | 0 |
Arm B : no LPV/r | 1.78 | 0 | 0 |
Arm C: LPV/r x 30d | 0 | 0 | 0 |
Calculated as log10 plasma viral load at 34 weeks gestation - log10 plasma viral load at 38 weeks gestation (NCT00530777)
Timeframe: 4 weeks
Intervention | log10 copies/mL (Mean) |
---|---|
Valacyclovir | -0.53 |
Placebo | 0.03 |
Mother-to-child HIV transmission (NCT00530777)
Timeframe: 1 year postpartum
Intervention | Participants (Number) |
---|---|
Valacyclovir | 6 |
Placebo | 4 |
Intrapartum HIV infection at 3 Months (NCT00099359)
Timeframe: 3 months
Intervention | participants (Number) |
---|---|
ARM A (ZDV - Standard of Care) | 24 |
ARM B (ZDV + NVP) | 11 |
ARM C (ZDV +3TC+NFV) | 12 |
In utero HIV-1 infection rate (NCT00099359)
Timeframe: birth
Intervention | participants (Number) |
---|---|
Arm A (ZDV Only) | 37 |
ARM B (ZDV + NVP) | 28 |
ARM C (ZDV + 3TC + NFV) | 28 |
(NCT00099359)
Timeframe: through age 6 months
Intervention | participants (Number) |
---|---|
Arm A (ZDV Only) | 11 |
ARM B (ZDV + NVP) | 15 |
ARM C (ZDV + 3TC + NFV) | 17 |
Serious Adverse Events by System Organ Class=Blood and lymphatic system disorders (NCT00099359)
Timeframe: through age 6 months.
Intervention | participants (Number) |
---|---|
ARM A (ZDV Only) | 86 |
ARM B (ZDV + NVP) | 59 |
ARM C (ZDV + 3TC/NFV) | 110 |
Descriptive study of 3TC and NFV pharmacokinetics during first two weeks of life using weight band dosing regimen in a subset of enrolled infants. (NCT00099359)
Timeframe: through age 14 days
Intervention | ug*h/mL (Median) | |||
---|---|---|---|---|
(NFV-AUC-12h) 4-7 day | (NFV-AUC-12h) 10-14 day | (3TC-AUC-12 h) 4-7 day | (3TC-AUC-12h) 10-14 day | |
ARM C (ZDV + 3TC/NFV) | 20.7 | 25.5 | 4.0 | 7.9 |
Descriptive study of NVP pharmacokinetics during first two weeks of life using weight band dosing in a subset of enrolled infants. (NCT00099359)
Timeframe: 14 days
Intervention | ng/mL (Median) | |||
---|---|---|---|---|
NVP conc prior to 3rd dose | NVP peak conc (Cmax) post 3rd dose | NVP conc 3-5 day post 3rd dose | NVP conc 7 day post 3rd dose | |
ARM B (ZDV + NVP) | 362 | 2286 | 459 | 76 |
Risk factors to be assessed include maternal HIV-1 RNA levels at delivery, maternal syphilis and other infections, obstetrical factors such as duration of membrane rupture, and adherence to neonatal medication. (NCT00099359)
Timeframe: through age 3 months
Intervention | participants (Number) | |||
---|---|---|---|---|
Treatment Arm C (ZDV+3TC/NFV) | Treatment Arm B (ZDV+NFV) | Treatment Arm A (ZDV only) | Illegal Substance Abuse during pregnancy | |
Infected | 12 | 11 | 24 | 7 |
Uninfected | 516 | 523 | 505 | 130 |
Area Under the Concentration-time Curve at 24-hour interval (AUC24) based on intensive PK sampling around Cohort 1 RAL dose #1 (within 48 hours of birth) (NCT01780831)
Timeframe: Cohort 1 RAL dose #1 (within 48 hours of birth) intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12 (±1), 24 (±1) hours post-dose.
Intervention | mg*h/L (Geometric Mean) |
---|---|
Cohort 1 RAL-naive: 3 mg/kg for First Dose | 53.88 |
Cohort 1 RAL-naive: 2 mg/kg for First Dose | 44.26 |
Cohort 1 RAL-exposed 1.5 mg/kg | 37.42 |
Area Under the Concentration-time Curve at the 24-hour interval (AUC24) for Cohort 2 initial RAL dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed, respectively). (NCT01780831)
Timeframe: Cohort 2 initial dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed, respectively) intensive PK sampling: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose.
Intervention | mg*h/L (Geometric Mean) |
---|---|
Cohort 2 RAL-naive: 1.5 mg/kg Once Daily on Days 1-7 of Life | 38.2 |
Cohort 2 RAL-exposed: 1.5mg/kg Once Daily on Days 1-7 of Life | 42.89 |
Last concentration of the drug (Clast) at 24 hour interval post dosing for the Cohort 2 initial RAL dose (within 48 and at 12-60 hours of birth for RAL-naive and RAL-exposed, respectively). This is the plasma RAL concentration from a sample collected at or close to 24 hours post dose. (NCT01780831)
Timeframe: Cohort 2 initial dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed groups, respectively) intensive PK sampling: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose.
Intervention | ng/mL (Geometric Mean) |
---|---|
Cohort 2 RAL-naive: 1.5 mg/kg Once Daily on Days 1-7 of Life | 947.90 |
Cohort 2 RAL-exposed: 1.5 mg/kg Once Daily on Days 1-7 of Life | 946.24 |
Maximum concentration (Cmax) for Cohort 1 dose #1 (within 48 hours of birth) (NCT01780831)
Timeframe: Cohort 1 dose #1(within 48 hours of birth) intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12 (±1), 24 (±1) hours post-dose.
Intervention | ng/mL (Geometric Mean) |
---|---|
Cohort 1 RAL-naive: 3 mg/kg for First Dose | 3360.89 |
Cohort 1 RAL-naive: 2 mg/kg for First Dose | 3405.24 |
Cohort 1 RAL-exposed: 1.5 mg/kg for First Dose | 2188.82 |
Cohort 1 Dose #1 neonatal RAL elimination was represented by Clearance (CL/F), which is the volume of plasma cleared of the drug per unit time. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians (i.e. genotyping was optional) . (NCT01780831)
Timeframe: Cohort 1 Dose #1 Intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12, 24 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.
Intervention | L/hr (Median) |
---|---|
(TA)6(TA)6 | 0.11 |
(TA)6(TA)7 | 0.06 |
Cohort 2 initial dose neonatal RAL elimination was represented by Clearance (CL/F), which is defined as the volume of plasma cleared of the drug per unit time. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians (i.e. genotyping was optional) . (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 initial dose: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.
Intervention | L/hr (Median) |
---|---|
(TA)6(TA)6 Wildtype | 0.1 |
Mutation | 0.1 |
Cohort 2 15-18 days of life dose neonatal RAL elimination was represented by Clearance (CL/F), which is defined as the volume of plasma cleared of the drug per unit time at 15-18 days of life when RAL dosing would have been 3 mg/kg twice daily. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians(i.e. genotyping was optional) . (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2 hours post-dose, 4-6, 8-12 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.
Intervention | L/hr (Median) |
---|---|
(TA)6(TA)6 Wildtype | 0.5 |
Mutation | 0.5 |
Number of infants who died or had adverse events (AEs) of Grade 3 or 4 as defined in DAIDS AE Grading Table. Events with onset dates prior to first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. (NCT01780831)
Timeframe: From first RAL dose through 24 weeks of life
Intervention | Participants (Count of Participants) |
---|---|
Cohort 1 RAL-naive | 2 |
Cohort 1 RAL-exposed | 2 |
Cohort 1 Total | 4 |
Cohort 2 RAL-naive | 11 |
Cohort 2 RAL-exposed | 4 |
Cohort 2 Total | 15 |
Number of infants who died or had adverse events (AEs) of Grade 3 or 4 as defined in DAIDS AE Grading Table. Events with onset dates prior to first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. (NCT01780831)
Timeframe: From first dosing of RAL through 6 weeks of life
Intervention | Participants (Count of Participants) |
---|---|
Cohort 1 RAL-naive | 2 |
Cohort 1 RAL-exposed | 2 |
Cohort 1 Total | 4 |
Cohort 2 RAL-naive | 7 |
Cohort 2 RAL-exposed | 4 |
Cohort 2 Total | 11 |
"Number of infants who died or had Suspected Adverse Drug Reaction (SADR) of Grade 3 or 4 as defined in DAIDS AE Grading Table.~Events with onset dates prior to the first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. SADRs are AEs assessed as definitely related, probably related or possibly related to RAL." (NCT01780831)
Timeframe: From first RAL dose through 24 weeks of life
Intervention | Participants (Count of Participants) |
---|---|
Cohort 1 RAL-naive | 1 |
Cohort 1 RAL-exposed | 0 |
Cohort 1 Total | 1 |
Cohort 2 RAL-naive | 0 |
Cohort 2 RAL-exposed | 0 |
Cohort 2 Total | 0 |
"Number of infants who died or had Suspected Adverse Drug Reaction (SADR) of Grade 3 or 4 as defined in DAIDS AE Grading Table.~Events with onset dates prior to the first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. SADRs are AEs assessed as definitely related, probably related or possibly related to RAL." (NCT01780831)
Timeframe: From first RAL dose through 6 weeks of life
Intervention | Participants (Count of Participants) |
---|---|
Cohort 1 RAL-naive | 1 |
Cohort 1 RAL-exposed | 0 |
Cohort 1 Total | 1 |
Cohort 2 RAL-naive | 0 |
Cohort 2 RAL-exposed | 0 |
Cohort 2 Total | 0 |
Area Under the Concentration-time Curve at 12-hour interval (AUC12) of RAL for Cohort 2 at 15-18 days of life. (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2, 4-6, 8-12 hours post-dose.
Intervention | mg*h/L (Geometric Mean) |
---|---|
Cohort 2 RAL-naive: 3 mg/kg Twice Daily on Days 8-18 of Life | 14.3 |
Cohort 2 RAL-exposed: 3 mg/kg Twice Daily on Days 8-28 of Life | 18.25 |
RAL concentration at 12 hours (C12) for Cohort 2 at 15-18 days of life. (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2, 4-6, 8-12 hours post-dose.
Intervention | mg*h/L (Geometric Mean) |
---|---|
Cohort 2 RAL-naive: 3 mg/kg Twice Daily on Days 8-28 of Life | 176.11 |
Cohort 2 RAL-exposed: 3 mg/kg Twice Daily on Days 8-28 of Life | 273.59 |
participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively. (NCT00099632)
Timeframe: From first day of study treatment to last day of study treatment (up to 21 days)
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 2 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
7-day Lopinavir/Ritonavir (LPV/r) | 0 |
21-day Lopinavir/Ritonavir (LPV/r) | 5 |
"For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.~10 participants who did not have resistance samples available were excluded from the primary endpoint analysis." (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
7-day Lopinavir/Ritonavir (LPV/r) | 3 |
21-day Lopinavir/Ritonavir (LPV/r) | 1 |
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
7-day Lopinavir/Ritonavir (LPV/r) | 1 |
21-day Lopinavir/Ritonavir (LPV/r) | 0 |
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
7-day Lopinavir/Ritonavir (LPV/r) | 0 |
21-day Lopinavir/Ritonavir (LPV/r) | 0 |
"Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.~Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death" (NCT00099632)
Timeframe: From first day of study treatment to week 12
Intervention | participants (Number) |
---|---|
7-day Lamivudine/Zidovudine (3TC/ZDV) | 5 |
21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
7-day Lopinavir/Ritonavir (LPV/r) | 2 |
21-day Lopinavir/Ritonavir (LPV/r) | 2 |
Infant plasma concentrations were collected and measured during the first 9 days of life. Half-life is defined as 0.693/k, where k, the elimination rate constant, is the slope of the decline in concentrations. (NCT00042289)
Timeframe: Infant plasma samples at 2-10, 18-28, 36-72 hours and 5-9 days after birth.
Intervention | hour (Median) |
---|---|
DTG 50mg q.d. | 32.8 |
EVG/COBI 150/150mg q.d. | 7.6 |
DRV/COBI 800/150 mg q.d. | NA |
EFV 600 mg q.d. (Outside THA) | 65.6 |
Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.
Intervention | unitless (Median) |
---|---|
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 0.15 |
DTG 50mg q.d. | 1.25 |
EVG/COBI 150/150mg q.d. | 0.91 |
DRV/COBI 800/150 mg q.d. | 0.07 |
ATV/COBI 300/150 mg q.d. | 0.07 |
TFV 300mg q.d. | 0.88 |
Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. For arms with zero overall participants analyzed, samples were below the limit of quantification and ratios could not be calculated. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.
Intervention | unitless (Median) |
---|---|
TAF 10mg q.d. w/COBI | 0.97 |
EFV 600 mg q.d. (Outside THA) | 0.67 |
EFV 600mg q.d. | 0.49 |
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 0.2 |
RAL 400mg b.i.d. | 1.5 |
ETR 200mg b.i.d. | 0.52 |
MVC 150 or 300mg b.i.d. | 0.33 |
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 0.14 |
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 0.16 |
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | 0.19 |
IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 0.12 |
RPV 25mg q.d. | 0.55 |
ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d. | 0.18 |
DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d. | 0.18 |
Serum concentrations of the contraceptives. Note that no historical controls were provided by team pharmacologists and thus no comparisons were done for contraceptive concentrations in women using hormonal contraceptives and selected ARV drugs as compared to historical controls not using those ARV drugs. (NCT00042289)
Timeframe: Measured at 6-7 weeks after contraceptive initiation postpartum
Intervention | pg/mL (Median) |
---|---|
ATV/RTV/TFV 300/100/300mg q.d. With ENG | 604 |
LPV/RTV 400/100 b.i.d. With ENG | 428 |
EFV 600mg q.d. With ENG | 125 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.
Intervention | mcg*hr/mL (Median) | |
---|---|---|
Before contraceptive initiation | After contraceptive initiation | |
LPV/RTV 400/100 b.i.d. With ENG | 115.97 | 100.20 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.
Intervention | mcg*hr/mL (Median) | |
---|---|---|
Before contraceptive initiation | After contraceptive initiation | |
ATV/RTV/TFV 300/100/300mg q.d. With ENG | 53.96 | 55.25 |
EFV 600mg q.d. With ENG | 53.64 | 56.65 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
Intervention | Participants (Count of Participants) | |
---|---|---|
3rd Trimester | Postpartum | |
EFV 600mg q.d. | 20 | 21 |
MVC 150 or 300mg b.i.d. | 8 | 7 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
ATV/RTV Arm 1: 300/100mg q.d. | 1 | 12 | 12 |
DRV/COBI 800/150 mg q.d. | 3 | 4 | 14 |
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 7 | 16 | 22 |
DRV/RTV 600/100mg b.i.d. | 7 | 19 | 22 |
DRV/RTV 800/100mg q.d. | 9 | 19 | 22 |
DTG 50mg q.d. | 9 | 20 | 23 |
EFV 600 mg q.d. (Outside THA) | 12 | 33 | 34 |
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 8 | 29 | 27 |
ETR 200mg b.i.d. | 5 | 13 | 7 |
EVG/COBI 150/150mg q.d. | 8 | 10 | 18 |
FPV/RTV 700/100mg b.i.d. | 8 | 26 | 22 |
IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 10 | 19 | 26 |
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 9 | 30 | 27 |
ATV/COBI 300/150 mg q.d. | 1 | 2 | 5 |
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 15 | 14 |
RAL 400mg b.i.d. | 11 | 33 | 30 |
RPV 25mg q.d. | 14 | 26 | 25 |
TAF 10mg q.d. w/COBI | 15 | 23 | 22 |
TAF 25mg q.d. | 13 | 23 | 24 |
TAF 25mg q.d. w/COBI or RTV Boosting | 10 | 24 | 18 |
TFV 300mg q.d. | 2 | 27 | 27 |
TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 1 | 11 | 12 |
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 7 | 23 | 32 |
Infant plasma concentrations were collected and measured during the first 9 days of life. (NCT00042289)
Timeframe: Blood samples were collected at 2-10, 18-28, 36-72 hours and 5-9 days after birth.
Intervention | mcg/mL (Median) | |||
---|---|---|---|---|
2-10 hours after birth | 18-28 hours after birth | 36-72 hours after birth | 5-9 days after birth | |
DRV/COBI 800/150 mg q.d. | 0.35 | 1.43 | 1.87 | 1.72 |
DTG 50mg q.d. | 1.73 | 1.53 | 1.00 | 0.06 |
EFV 600 mg q.d. (Outside THA) | 1.1 | 1.0 | 0.9 | 0.4 |
EVG/COBI 150/150mg q.d. | 0.132 | 0.032 | 0.005 | 0.005 |
Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
Intervention | ng*hour/mL (Geometric Mean) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
MVC 150 or 300mg b.i.d. | NA | 2717 | 3645 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
Intervention | mg*hour/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 55.1 | 51.8 | 79.6 |
DRV/RTV 600/100mg b.i.d. | 45.8 | 45.9 | 61.7 |
FPV/RTV 700/100mg b.i.d. | 43.50 | 32.15 | 51.60 |
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 34.2 | 33.5 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
Intervention | mg*hour/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
ETR 200mg b.i.d. | 4.5 | 8.3 | 5.3 |
IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 14.9 | 16.1 | 27.1 |
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 72 | 96 | 133 |
RAL 400mg b.i.d. | 6.6 | 5.4 | 11.6 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24 (area under the curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
Intervention | mg*hour/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
ATV/COBI 300/150 mg q.d. | 25.33 | 18.85 | 36.20 |
ATV/RTV Arm 1: 300/100mg q.d. | 88.2 | 41.9 | 57.9 |
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 30.6 | 45.7 | 48.8 |
DRV/COBI 800/150 mg q.d. | 50.00 | 42.05 | 95.55 |
DRV/RTV 800/100mg q.d. | 64.6 | 63.5 | 103.9 |
DTG 50mg q.d. | 47.6 | 49.2 | 65.0 |
EFV 600 mg q.d. (Outside THA) | 47.30 | 60.02 | 62.70 |
EVG/COBI 150/150mg q.d. | 15.3 | 14.0 | 21.0 |
TAF 10mg q.d. w/COBI | 0.197 | 0.206 | 0.216 |
TAF 25mg q.d. | 0.171 | 0.212 | 0.271 |
TAF 25mg q.d. w/COBI or RTV Boosting | 0.181 | 0.257 | 0.283 |
TFV 300mg q.d. | 1.9 | 2.4 | 3.0 |
TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 14.5 | 28.8 | 39.6 |
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 26.2 | 37.7 | 58.7 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
Intervention | mg*hour/L (Median) | |
---|---|---|
3rd Trimester | Postpartum | |
EFV 600mg q.d. | 55.4 | 58.3 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
Intervention | mg*hour/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
RPV 25mg q.d. | 1.969 | 1.669 | 2.387 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
Intervention | mg/L (Median) | |
---|---|---|
3rd Trimester | Postpartum | |
EFV 600mg q.d. | 5.44 | 5.10 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
Intervention | mg/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
ATV/COBI 300/150 mg q.d. | 2.82 | 2.20 | 3.90 |
ATV/RTV Arm 1: 300/100mg q.d. | NA | 3.6 | 4.1 |
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 3.11 | 4.51 | 4.52 |
DRV/COBI 800/150 mg q.d. | 4.59 | 3.67 | 7.04 |
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 6.22 | 6.55 | 8.96 |
DRV/RTV 600/100mg b.i.d. | 5.64 | 5.53 | 7.78 |
DRV/RTV 800/100mg q.d. | 6.77 | 5.78 | 8.11 |
DTG 50mg q.d. | 3.62 | 3.54 | 4.85 |
EFV 600 mg q.d. (Outside THA) | 3.87 | 5.13 | 4.41 |
FPV/RTV 700/100mg b.i.d. | 5.61 | 5.12 | 6.75 |
IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 3.89 | 3.62 | 5.37 |
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 5.1 | 5.0 |
TFV 300mg q.d. | 0.250 | 0.245 | 0.298 |
TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 1.2 | 2.5 | 4.1 |
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 2.73 | 3.56 | 5.43 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
Intervention | mg/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
ETR 200mg b.i.d. | 0.70 | 1.01 | 0.63 |
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 8.4 | 10.7 | 14.6 |
RAL 400mg b.i.d. | 2.250 | 1.770 | 3.035 |
RPV 25mg q.d. | 0.145 | 0.134 | 0.134 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
Intervention | ng/mL (Median) | |
---|---|---|
3rd Trimester | Postpartum | |
MVC 150 or 300mg b.i.d. | 448 | 647 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
Intervention | ng/mL (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
EVG/COBI 150/150mg q.d. | 1447.1 | 1432.8 | 1713.1 |
TAF 10mg q.d. w/COBI | 80.4 | 91.2 | 98.2 |
TAF 25mg q.d. | 69.7 | 96 | 133 |
TAF 25mg q.d. w/COBI or RTV Boosting | 87.8 | 107 | 141 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
Intervention | ng/mL (Geometric Mean) | |
---|---|---|
3rd Trimester | Postpartum | |
MVC 150 or 300mg b.i.d. | 108 | 128 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
Intervention | mg/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 2.84 | 2.52 | 4.51 |
DRV/RTV 600/100mg b.i.d. | 2.12 | 2.22 | 2.51 |
FPV/RTV 700/100mg b.i.d. | 2.12 | 1.64 | 2.87 |
NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 0.47 | 0.52 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
Intervention | mg/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
ETR 200mg b.i.d. | 0.36 | 0.48 | 0.38 |
IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 0.13 | 0.13 | 0.28 |
LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 3.7 | 5.1 | 7.2 |
RAL 400mg b.i.d. | 0.0621 | 0.064 | 0.0797 |
"Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose.~For the TAF 25 mg q.d., 10 mg q.d. w/COBI, and 25 mg q.d. w/COBI or RTV boosting arms, samples were all below the limit of quantification and statistical analyses were not conducted." (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
Intervention | mg/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
ATV/COBI 300/150 mg q.d. | 0.21 | 0.21 | 0.61 |
ATV/RTV Arm 1: 300/100mg q.d. | 2.0 | 0.7 | 1.2 |
ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 0.49 | 0.71 | 0.90 |
DRV/COBI 800/150 mg q.d. | 0.33 | 0.27 | 1.43 |
DRV/RTV 800/100mg q.d. | 0.99 | 1.17 | 2.78 |
DTG 50mg q.d. | 0.73 | 0.93 | 1.28 |
EFV 600 mg q.d. (Outside THA) | 1.49 | 1.48 | 1.94 |
EVG/COBI 150/150mg q.d. | 0.0258 | 0.0487 | 0.3771 |
TAF 10mg q.d. w/COBI | 0.00195 | 0.00195 | 0.00195 |
TAF 25mg q.d. | 0.00195 | 0.00195 | 0.00195 |
TAF 25mg q.d. w/COBI or RTV Boosting | 0.00195 | 0.00195 | 0.00195 |
TFV 300mg q.d. | 0.039 | 0.054 | 0.061 |
TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 0.3 | 0.5 | 0.8 |
TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 0.44 | 0.57 | 1.26 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
Intervention | mg/L (Median) | |
---|---|---|
3rd Trimester | Postpartum | |
EFV 600mg q.d. | 1.60 | 2.05 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
Intervention | mg/L (Median) | ||
---|---|---|---|
2nd Trimester | 3rd Trimester | Postpartum | |
RPV 25mg q.d. | 0.063 | 0.056 | 0.081 |
51 reviews available for nevirapine and Pregnancy
Article | Year |
---|---|
Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.
Topics: Adult; Alkynes; Benzoxazines; Contraception; Contraceptive Agents; Counseling; Cyclopropanes; Drug I | 2017 |
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities | 2018 |
Drug interactions between antiretrovirals and hormonal contraceptives.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Drug Interactio | 2013 |
HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission.
Topics: Alkynes; Anti-HIV Agents; Aptamers, Nucleotide; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; D | 2013 |
Prevention of perinatal HIV I transmission by protease inhibitor based triple drug antiretroviral therapy versus nevirapine as single dose at the time of delivery.
Topics: Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV Proteas | 2012 |
Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.
Topics: Age Factors; Anti-HIV Agents; Clinical Protocols; Female; HIV Infections; Humans; Infant; Infant, Ne | 2014 |
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; Fem | 2015 |
Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents; Cyclopropanes; Drug | 2015 |
Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?
Topics: Adult; Africa South of the Sahara; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; D | 2016 |
Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2009 |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2009 |
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.
Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV | 2009 |
[Highly efficient chemoprophylaxis of perinatal transmission of HIV 1 infection in HIV-infected pregnant women].
Topics: Animals; Anti-HIV Agents; Azides; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, | 2009 |
Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries.
Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infectious Disease Transmissi | 2011 |
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudi | 2011 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fet | 2011 |
Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Female; HIV Infections; Humans; Nevirapine | 2012 |
Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Seropositivity; Humans; Nevirapine; Pregna | 2013 |
Mother to child transmission of HIV.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections | 2002 |
Mother to child transmission of HIV.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections | 2002 |
HIV: mother to child transmission.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Issues in antiretroviral toxicity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Exanthema; Female; HIV | 2003 |
Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus.
Topics: Africa; AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disea | 2003 |
Preventing neonatal HIV: a review.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious | 2003 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
Nevirapine toxicity--implications for management of South African patients.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV-1; Humans; Infectious Disease | 2005 |
Preventing mother-to-child transmission of HIV: successes and challenges.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Drug Resistance, Viral; Fema | 2005 |
HIV: mother to child transmission.
Topics: Administration, Intravaginal; Anti-HIV Agents; Breast Feeding; Cesarean Section; Female; HIV Infecti | 2005 |
Sex differences in antiretroviral therapy-associated intolerance and adverse events.
Topics: Acidosis, Lactic; Anti-Retroviral Agents; Didanosine; Exanthema; Female; HIV Infections; Humans; Liv | 2005 |
Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV.
Topics: Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Dis | 2006 |
Nevirapine toxicity.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Liver; Nevirapine; Pregnancy; Pregnancy Complicatio | 2006 |
Evidence behind the WHO guidelines: hospital care for children: what antiretroviral agents and regimens are effective in the prevention of mother-to-child transmission of HIV?
Topics: Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; I | 2006 |
Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious | 2006 |
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2007 |
Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infectio | 2007 |
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1 | 2007 |
International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Clinical Trials as Topic; Drug Administrati | 2007 |
Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Female; HIV Infections; Humans; Infectious | 2007 |
Antiretroviral (ARV) drug resistance in the developing world.
Topics: Africa; Anti-HIV Agents; Asia; Child; Developing Countries; Drug Resistance, Viral; Female; HIV; HIV | 2007 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; D | 1999 |
[New therapy reduces AIDS passed to fetuses and costs less].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Developing Countries; Female; Health Care Costs | 2000 |
Update on preventing vertical transmission of HIV type 1.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; | 2000 |
Nevirapine: pharmacokinetic considerations in children and pregnant women.
Topics: Adult; Area Under Curve; Child; Drug Administration Schedule; Drug Interactions; Female; Half-Life; | 2000 |
Management of the infant born to a mother infected with human immunodeficiency virus type 1 (HIV-1): current concepts.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Female; HIV In | 2000 |
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Benzoxazines; Biological Availability; Cyclopropanes; Delavirdine; Drug Interactions; Femal | 2001 |
Prevention of mother-to-child transmission of HIV: challenges for the current decade.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Resistance, Microbial; Female; Health Resour | 2001 |
The role of nevirapine in the treatment of HIV-1 disease.
Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Interac | 2001 |
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2002 |
HIV-1 drug resistance and mother-to-child transmission.
Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans | 2001 |
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2002 |
136 trials available for nevirapine and Pregnancy
Article | Year |
---|---|
Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Female; HIV Infections; Humans; Infant; Infant, N | 2022 |
Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; Breast Feeding; Coh | 2019 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; | 2019 |
A mobile health-facilitated behavioural intervention for community health workers improves exclusive breastfeeding and early infant HIV diagnosis in India: a cluster randomized trial.
Topics: Adult; Anti-HIV Agents; Behavior Therapy; Breast Feeding; Cluster Analysis; Community Health Workers | 2020 |
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi | 2021 |
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.
Topics: Anti-HIV Agents; Female; Gestational Age; HIV Infections; Humans; Infant; Infant, Newborn; Infectiou | 2021 |
Efficacy of Mobile phone use on adherence to Nevirapine prophylaxis and retention in care among the HIV-exposed infants in prevention of mother to child transmission of HIV: a randomized controlled trial.
Topics: Anti-HIV Agents; Cell Phone Use; Child; Female; HIV Infections; Humans; Infant; Infectious Disease T | 2021 |
Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component.
Topics: Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV Seropositivity; H | 2021 |
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Clinical Protocols; Dose-Response Relationship, Dr | 2017 |
Conditional cash transfers to prevent mother-to-child transmission in low facility-delivery settings: evidence from a randomised controlled trial in Nigeria.
Topics: Adult; Delivery, Obstetric; Female; HIV Infections; Hospitals, Public; Humans; Infant, Newborn; Infa | 2019 |
Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dise | 2013 |
Cluster randomised trial of the uptake of a take-home infant dose of nevirapine in Kenya.
Topics: Adolescent; Adult; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, | 2010 |
Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; HIV Antibodies; HIV Infections; HIV-1; | 2013 |
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Chemoprevention; Cytochrome P-450 CYP2B6; Fem | 2013 |
Health outcomes of HIV-exposed uninfected African infants.
Topics: Anti-Retroviral Agents; Antiviral Agents; Breast Feeding; Cause of Death; Drug Therapy, Combination; | 2013 |
HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Disease Progression; Doubl | 2013 |
Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
Topics: Adult; Anti-HIV Agents; Anticonvulsants; Drug Interactions; Drug Resistance, Viral; Female; Half-Lif | 2013 |
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort S | 2013 |
Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyc | 2013 |
Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Contraceptives, Oral; Dru | 2013 |
Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.
Topics: Anthropometry; Anti-HIV Agents; Body Height; Body Weight; Chemoprevention; Child, Preschool; Female; | 2013 |
Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries.
Topics: Adult; Africa South of the Sahara; Anemia; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; I | 2013 |
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 | 2014 |
Hypothesis testing for an extended cox model with time-varying coefficients.
Topics: Algorithms; Biometry; Computer Simulation; Data Interpretation, Statistical; Female; HIV Infections; | 2014 |
Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infant, | 2015 |
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.
Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA, Viral; Double-Blind Method; Female; HIV Infections; Hu | 2015 |
Cytomegalovirus IgG Level and Avidity in Breastfeeding Infants of HIV-Infected Mothers in Malawi.
Topics: Anti-HIV Agents; Antibodies, Viral; Antibody Affinity; Breast Feeding; Cytomegalovirus; Cytomegalovi | 2015 |
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Co | 2016 |
Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delive | 2016 |
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
Topics: Adult; Anti-Retroviral Agents; Black or African American; CD4 Lymphocyte Count; Drug Therapy, Combin | 2016 |
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine | 2008 |
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru | 2008 |
Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria.
Topics: Adult; Anemia; Anti-HIV Agents; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; HIV | 2008 |
Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
Topics: Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active | 2008 |
Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Seroposit | 2008 |
Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Developing Countries; Female; HIV Infections; H | 2008 |
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Huma | 2009 |
Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
Topics: Adult; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combinatio | 2009 |
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Administration Schedul | 2009 |
Timing and determinants of mother-to-child transmission of HIV in Nigeria.
Topics: Adult; Anti-HIV Agents; Birth Weight; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hum | 2009 |
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Base Sequence; DNA | 2009 |
Predictors of rapid HIV testing acceptance and successful nevirapine administration in Zambian labor wards.
Topics: Anti-HIV Agents; Chemoprevention; Clinical Laboratory Techniques; Female; HIV Infections; Humans; In | 2009 |
Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious | 2009 |
Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol.
Topics: Adult; Anti-HIV Agents; Blood Cell Count; Double-Blind Method; Female; Follow-Up Studies; Gestationa | 2009 |
Comparing couples' and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial.
Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Counseling; Family Characteristics; Female; HIV Infectio | 2010 |
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressu | 2009 |
Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte | 2009 |
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2009 |
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Sched | 2009 |
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
Topics: Adult; Anti-HIV Agents; Female; Fetal Blood; Health Services Accessibility; HIV Infections; Humans; | 2010 |
Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia.
Topics: Anti-HIV Agents; Clinical Protocols; Developing Countries; Disease Transmission, Infectious; Drug Re | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
Topics: Africa, Eastern; Africa, Southern; Africa, Western; Anti-Retroviral Agents; Breast Feeding; Child, P | 2011 |
Antiretroviral therapies in women after single-dose nevirapine exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug T | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
Topics: Adult; Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Epidemiologic Methods; Femal | 2010 |
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Infan | 2011 |
Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Congenital Abnormalities; Double-Blind Method; Female; Heart | 2011 |
CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Seroposit | 2011 |
Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2011 |
Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Thera | 2011 |
Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
Topics: Base Sequence; Breast Feeding; Child; Drug Administration Schedule; Drug Resistance, Viral; Ethiopia | 2011 |
Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Cluster Analysis; Feasibility Studies; Female; HIV Infections; H | 2011 |
Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female | 2011 |
Improved detection of incident HIV infection and uptake of PMTCT services in labor and delivery in a high HIV prevalence setting.
Topics: Anti-HIV Agents; Eswatini; Female; Fetal Blood; HIV Antibodies; HIV Infections; Humans; Incidence; I | 2011 |
Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).
Topics: Adolescent; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Immunoglobulins, Intravenous; In | 2011 |
Extended prophylaxis with nevirapine and cotrimoxazole among HIV-exposed uninfected infants is well tolerated.
Topics: Adult; Anemia; Anti-HIV Agents; Blotting, Western; Breast Feeding; Drug Administration Schedule; Dru | 2012 |
Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
Topics: Adolescent; Adult; Carbamazepine; CD4 Lymphocyte Count; Chi-Square Distribution; Drug Interactions; | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
Topics: Acyclovir; Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; HIV-1; H | 2012 |
Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Hi | 2012 |
A lipid-based nutrient supplement mitigates weight loss among HIV-infected women in a factorial randomized trial to prevent mother-to-child transmission during exclusive breastfeeding.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Dietary Supplements; Female; HIV Infections; HIV-1; H | 2012 |
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; HIV Infections; Humans | 2012 |
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; HIV-1; Hum | 2012 |
Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
Topics: Acyclovir; Antiviral Agents; Biomarkers; CD4 Antigens; Disease Progression; Female; Herpes Genitalis | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2012 |
Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India.
Topics: Adult; Anthropometry; Female; HIV Infections; HIV Seropositivity; Humans; India; Infant; Infant, New | 2012 |
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucl | 2013 |
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; | 2013 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 3
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; | 2002 |
Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya.
Topics: Adult; Anti-HIV Agents; Female; Focus Groups; Follow-Up Studies; Health Knowledge, Attitudes, Practi | 2003 |
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Topics: Adult; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV- | 2003 |
Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N | 2003 |
Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose.
Topics: Adult; Anti-HIV Agents; Bahamas; Brazil; Double-Blind Method; Europe; Female; Fetal Blood; HIV Infec | 2003 |
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.
Topics: Adolescent; Adult; Breast Feeding; Drug Administration Schedule; Female; HIV Infections; HIV Seropos | 2003 |
Feeding risk cut for HIV-infected women.
Topics: Anti-HIV Agents; Breast Feeding; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial.
Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infan | 2003 |
Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon.
Topics: Anti-HIV Agents; Cameroon; Female; HIV Infections; HIV-1; Humans; Immunoenzyme Techniques; Infant; I | 2003 |
Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Epidemiologi | 2003 |
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Inf | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; | 2004 |
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, | 2005 |
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, | 2005 |
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, | 2005 |
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, | 2005 |
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers.
Topics: Anti-HIV Agents; Bottle Feeding; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infa | 2005 |
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant | 2005 |
Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease T | 2005 |
Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024.
Topics: Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans; | 2005 |
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newb | 2005 |
Reduction of mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso.
Topics: Adolescent; Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Burkina Faso; Drug Administratio | 2006 |
Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission.
Topics: Acute Disease; Adult; Anti-HIV Agents; Chorioamnionitis; Chronic Disease; Female; Fetal Blood; HIV I | 2006 |
Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; HIV Infections; HIV-1; Hu | 2006 |
Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
Topics: Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Infant, Newborn | 2006 |
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Disease-Free Survi | 2006 |
A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV- | 2007 |
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infectio | 2007 |
Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human | 2007 |
Intrapartum transmission after mucosal exposure to HIV was not observed with single-dose nevirapine for mother and child.
Topics: Adult; Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn | 2007 |
Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
Topics: Adult; Anti-Retroviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combinatio | 2007 |
Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Côte d'Ivoire.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cohort Studies; Cote d'Ivoir | 2007 |
Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
Topics: Adult; Alanine Transaminase; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparta | 2007 |
Safety of nevirapine in pregnancy.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Exanthema | 2007 |
Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Drug Administration Schedule; Female; HIV Infections; Humans; | 2007 |
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci | 2007 |
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci | 2007 |
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci | 2007 |
Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
Topics: Age Distribution; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Inci | 2007 |
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D.
Topics: Africa; Anti-HIV Agents; Black People; DNA Mutational Analysis; Drug Administration Schedule; Drug R | 2007 |
Pathology of placenta in HIV infection.
Topics: Anti-HIV Agents; Chorioamnionitis; Female; Fetal Death; HIV Infections; Humans; Hyperplasia; Infant, | 2007 |
Mother-to-child transmission of HIV among women who chose not to exclusively breastfeed their infants in Pune, India.
Topics: Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cohort Studies; Drug Administration Schedule | 2007 |
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV | 2007 |
Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transm | 2007 |
High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission.
Topics: Breast Feeding; Female; HIV Infections; Humans; Infant; Infant Food; Infant, Newborn; Infectious Dis | 2007 |
Temporal and lateral dynamics of HIV shedding and elevated sodium in breast milk among HIV-positive mothers during the first 4 months of breast-feeding.
Topics: Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn | 2008 |
Nevirapine concentrations in newborns receiving an extended prophylactic regimen.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; HIV | 2008 |
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; In | 1998 |
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).
Topics: Anti-HIV Agents; Consumer Product Safety; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Inf | 1999 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H | 1999 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H | 1999 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H | 1999 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H | 1999 |
[Encouraging study results. HIV from birth on--virostatic drugs can decrease the risk].
Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infant, Newborn; Infectious Dise | 1999 |
South Africa's Medicines Control Council contradicts Health Minister.
Topics: Adverse Drug Reaction Reporting Systems; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Inf | 2000 |
Nevirapine and perinatal transmission.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe | 2000 |
Major advance in protecting newborns: one Nevirapine dose cuts infection in half.
Topics: Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Dis | 1999 |
Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Female; HIV Infections; HIV-1; Humans; Infant; Infectio | 2001 |
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2001 |
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2001 |
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2001 |
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2001 |
Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T | 2001 |
Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants.
Topics: Alanine Transaminase; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newb | 2002 |
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cesarean Section; Drug | 2002 |
480 other studies available for nevirapine and Pregnancy
Article | Year |
---|---|
Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.
Topics: Acquired Immunodeficiency Syndrome; Adult; Amniotic Fluid; Anti-HIV Agents; Cytochrome P-450 CYP3A; | 2009 |
Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants.
Topics: Anti-HIV Agents; Breast Feeding; Case-Control Studies; Drug Resistance; Female; HIV; HIV Infections; | 2022 |
HIV Encephalopathy in ART-Naïve, Hospitalized Infants in Mozambique.
Topics: AIDS Dementia Complex; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Di | 2021 |
Improved Hematologic Outcomes in HIV1-Exposed Infants Receiving Nevirapine Compared With Zidovudine for Postnatal Prophylaxis in a High Resource Setting.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; | 2022 |
Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
Topics: Adolescent; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; Hair; HI | 2022 |
Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Contraceptive Agents; Cyclopropanes; Female; HIV Infection | 2022 |
Twenty years of Prevention of Mother to Child HIV Transmission: research to implementation at a national referral hospital in Uganda.
Topics: Anti-HIV Agents; Child; Female; HIV Infections; Hospitals; Humans; Infant, Newborn; Infectious Disea | 2022 |
Antiretroviral postnatal prophylaxis to prevent HIV vertical transmission: present and future strategies.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Inf | 2023 |
Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; Follow-Up Studi | 2019 |
Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.
Topics: Anti-HIV Agents; Child Development; Female; Growth; HIV Infections; Humans; Infant; Infectious Disea | 2019 |
Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch | 2020 |
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Combinations; Female; HIV Infections; Humans; Infant, Ne | 2020 |
Barriers and enablers of adherence to infant nevirapine prophylaxis against HIV 1 transmission among 6-week-old HIV exposed infants: A prospective cohort study in Northern Uganda.
Topics: Adult; Age Factors; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disea | 2020 |
Advancing knowledge in perinatal HIV treatment.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2021 |
Association of SNPs in HLA-C and ZNRD1 Genes With HIV-1 Mother-to-Child Transmission in Zambia Population.
Topics: Adult; Anti-HIV Agents; DNA-Binding Proteins; Female; Genetic Predisposition to Disease; Genotype; H | 2021 |
Mother-to-Child HIV Transmission among Pregnant Women in a City with the Highest Rates of HIV in Brazil.
Topics: Brazil; Child; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmiss | 2022 |
HIV-free survival among breastfed infants born to HIV-positive women in northern Uganda: a facility-based retrospective study.
Topics: Anti-HIV Agents; Breast Feeding; Cohort Studies; Female; HIV Infections; Humans; Infant; Infant, New | 2020 |
Effects of the Pratt pouch model of dispensing nevirapine prophylaxis on HIV exposed infant completion of 6 weeks of prophylaxis in Uganda.
Topics: Adult; Anti-HIV Agents; Drug Implants; Drug Packaging; Female; HIV Infections; Humans; Infant; Infan | 2021 |
Nevirapine Pharmacokinetics in Neonates Between 25 and 32 Weeks Gestational Age for the Prevention of Mother-to-Child Transmission of HIV.
Topics: Administration, Oral; Anti-HIV Agents; Female; Gestational Age; HIV Infections; HIV-1; Humans; Infan | 2021 |
Uptake and performance of prevention of mother-to-child transmission and early infant diagnosis in pregnant HIV-infected women and their exposed infants at seven health centres in Addis Ababa, Ethiopia.
Topics: Adolescent; Adult; Anti-HIV Agents; Ethiopia; Female; Follow-Up Studies; Guideline Adherence; Health | 2017 |
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Breast Feeding; Case-Control Studies; Drug Therapy, C | 2017 |
Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cost-Benefit Anal | 2017 |
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Co | 2017 |
Mother-to-child transmission of HIV in Kenya: A cross-sectional analysis of the national database over nine years.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Databases, Factual; | 2017 |
A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Bayes Theorem; Depression; Depression, Postpartum; Disclosure; F | 2018 |
Maternal age, infant age, feeding options, single/multiple pregnancy, type of twin sets and mother-to-child transmission of HIV.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cameroon; Female; HIV | 2019 |
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy.
Topics: Adult; Anti-HIV Agents; Antimalarials; Cross-Sectional Studies; Drug Interactions; Female; Fetal Blo | 2018 |
Mother-baby dyads enrolled in PMTCT care in western Kenya: characteristics and implications for ART programmes.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Diseas | 2018 |
Rates of HBV, HCV, HDV and HIV type 1 among pregnant women and HIV type 1 drug resistance-associated mutations in breastfeeding women on antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cameroon; Coinfection; Drug Resistance, Viral; F | 2018 |
Programmes for the prevention of mother-to-child HIV infection transmission have made progress in Yunnan Province, China, from 2006 to 2015: a cost effective and cost-benefit evaluation.
Topics: Adult; China; Cost-Benefit Analysis; Delivery of Health Care; Female; Health Expenditures; HIV; HIV | 2019 |
Incidence, prevalence and associated factors of mother-to-child transmission of HIV, among children exposed to maternal HIV, in Belgaum district, Karnataka, India.
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Breast Feeding; Child, Preschool; Female; HIV; HIV | 2019 |
Retention of HIV exposed infants in care at Arua regional referral hospital, Uganda: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Chi-Square Distribution; Female; HIV; HIV Infections; Humans; Infant, Newbor | 2019 |
HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy.
Topics: Anti-HIV Agents; Breast Feeding; Early Diagnosis; Female; HIV Infections; HIV Seronegativity; Humans | 2019 |
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cohort Stud | 2019 |
Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Fem | 2013 |
Scaling up prevention of mother-to-child HIV transmission programs in sub-Saharan African countries: a multilevel assessment of site-, program- and country-level determinants of performance.
Topics: Africa South of the Sahara; Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infe | 2013 |
Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cyclopro | 2015 |
Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.
Topics: Anti-HIV Agents; Chemoprevention; Cluster Analysis; Drug Resistance, Viral; Female; Genotype; HIV In | 2013 |
Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; Humans; Logistic Models; Nevir | 2013 |
HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants.
Topics: Adolescent; Adult; Anti-HIV Agents; Black People; Female; Growth Disorders; HIV; HIV Infections; HIV | 2014 |
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraceptive Agents, Female; Cycl | 2014 |
Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection.
Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Coinfection; Drug Inte | 2014 |
Toxicology and Carcinogenesis Studies of Mixtures of 3'-Azido-3'-Deoxythymidine (AZT), Lamivudine (3TC), and Nevirapine (NVP) (CAS Nos. 30516-87-1, 134678-17-4, 129618-40-2) in Genetically Modified C3B6.129F1-Trp53(tm1Brd) N12 Haploinsufficient Mice (in u
Topics: Animals; Animals, Genetically Modified; Animals, Newborn; Anti-HIV Agents; Body Weight; Chemistry, P | 2013 |
Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dried Blood Spot Testing; Female; HIV Infect | 2014 |
Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2014 |
Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique.
Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infe | 2014 |
Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity.
Topics: Anti-HIV Agents; Carbamazepine; Chemoprevention; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Indu | 2014 |
The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cost- | 2014 |
The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; Hepatitis B; He | 2014 |
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemo | 2014 |
HIV status, breastfeeding modality at 5 months and postpartum maternal weight changes over 24 months in rural South Africa.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; Humans; Infant; I | 2014 |
Evaluating the benefits of incorporating traditional birth attendants in HIV prevention of mother to child transmission service delivery in Lilongwe, Malawi.
Topics: Adult; Anti-HIV Agents; Feasibility Studies; Female; Focus Groups; HIV Infections; Humans; Infant, N | 2014 |
Foetal loss and enhanced fertility observed in mice treated with Zidovudine or Nevirapine.
Topics: Animals; Anti-HIV Agents; Female; Fertility; Fetal Death; Male; Mice; Nevirapine; Pregnancy; Sex Rat | 2014 |
Variable and suboptimal nevirapine levels in infants given single-dose nevirapine at birth without maternal prophylaxis.
Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Nevirapine; Plasma | 2014 |
HIV testing in pregnancy.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmiss | 2014 |
[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy].
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cross-Sectional Studies; Female; HIV Infect | 2016 |
Genetic Analyses of HIV-1 Strains Transmitted from Mother to Child in Northern Vietnam.
Topics: Anti-HIV Agents; Cluster Analysis; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variat | 2015 |
A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Deoxycytidine; Drug Administra | 2015 |
Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review.
Topics: Anemia; Anti-HIV Agents; Drug Therapy, Combination; Female; Humans; Infant; Infant, Newborn; Infecti | 2015 |
Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; | 2015 |
Lower Preprandial Insulin and Altered Fuel Use in HIV/Antiretroviral-Exposed Infants in Cameroon.
Topics: Amino Acids, Branched-Chain; Anti-Retroviral Agents; Cameroon; Energy Metabolism; Female; HIV Infect | 2015 |
Missed Opportunities along the Prevention of Mother-to-Child Transmission Services Cascade in South Africa: Uptake, Determinants, and Attributable Risk (the SAPMTCTE).
Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studie | 2015 |
Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.
Topics: Anti-HIV Agents; Female; Fetus; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Outcome; St | 2015 |
A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study".
Topics: Adult; Cross-Sectional Studies; Disclosure; Fear; Female; HIV Infections; HIV-1; Humans; Mass Screen | 2015 |
Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2015 |
Tracing defaulters in HIV prevention of mother-to-child transmission programmes through community health workers: results from a rural setting in Zimbabwe.
Topics: Adult; Cohort Studies; Community Health Workers; Female; HIV Infections; Humans; Infant, Newborn; In | 2015 |
Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children.
Topics: Adult; Anti-HIV Agents; Bacterial Capsules; Child, Preschool; Female; HIV Infections; Humans; Immuno | 2016 |
The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.
Topics: Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature | 2015 |
Supra-treatment threshold neonatal jaundice: Incidence in HIV-exposed compared to non-exposed neonates at Queen Elizabeth Central Hospital in Blantyre, Malawi.
Topics: Anti-HIV Agents; Bilirubin; Breast Feeding; Comorbidity; Female; Gestational Age; HIV Infections; Hu | 2015 |
Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen.
Topics: Adult; Anti-Retroviral Agents; Drug Therapy, Combination; False Positive Reactions; Female; HIV; HIV | 2017 |
Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate D | 2016 |
Prevention of perinatal transmission of zidovudine- and nevirapine-resistant HIV.
Topics: Adolescent; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infectio | 2016 |
Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance | 2016 |
Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.
Topics: Adult; Anti-HIV Agents; Biomarkers; Constitutive Androstane Receptor; Cytochrome P-450 CYP2B6; Femal | 2016 |
Providing Safe and Effective Preventative Antiretroviral Prophylaxis to HIV-exposed Newborns via a Novel Drug Delivery System in Tanzania.
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Dried Blood Spot Testing; Drug Delivery Systems; Female; HI | 2016 |
Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infant, Premature; Infectio | 2016 |
HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infec | 2016 |
Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Drug Therapy, Combination; Female; HIV | 2016 |
Early infant diagnosis of HIV infection using DNA-PCR at a referral center: an 8 years retrospective analysis.
Topics: Anti-HIV Agents; DNA, Viral; Early Diagnosis; Ethiopia; Female; HIV; HIV Infections; Humans; Infant; | 2016 |
Timely antiretroviral prophylaxis during pregnancy effectively reduces HIV mother-to-child transmission in eight counties in China: a prospective study during 2004-2011.
Topics: Adult; Anti-HIV Agents; China; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmissio | 2016 |
A Physiologically-Based Pharmacokinetic Model to Predict Human Fetal Exposure for a Drug Metabolized by Several CYP450 Pathways.
Topics: Cytochrome P-450 Enzyme System; Female; Fetus; Forecasting; Humans; Male; Models, Biological; Nevira | 2017 |
Antiretrovirals causing severe pre-eclampsia.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delivery, Obstetric; F | 2016 |
Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; Child; Child, Preschool; Cohort Studies; Drug Resistance, Multiple | 2008 |
Voluntary counselling and testing (VCT) uptake, nevirapine use and infant feeding options at the University of Nigeria Teaching Hospital.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS Serodiagnosis; Ambulatory Care; Breast F | 2008 |
HIV-positive women's experiences of a PMTCT programme in rural Malawi.
Topics: Anti-HIV Agents; Choice Behavior; Disclosure; Female; Health Knowledge, Attitudes, Practice; Health | 2010 |
Extra drugs and slower weaning lowers HIV risk for newborns.
Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Case-Control Studies; Female; HIV Infec | 2008 |
HIV and obstetric complications and fetal outcomes in Vellore, India.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seronegativity; Humans; India; Infan | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
A review of the prevention of mother-to-child transmission programme of the Western Cape provincial government, 2003 - 2004.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infectious Disease Transmissi | 2008 |
Preventing mother-to-child transmission of HIV in resource-limited settings: the Elizabeth Glaser Pediatric AIDS Foundation experience.
Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; Foundations; Health Education; HIV Infect | 2009 |
Serious toxicity associated with continuous nevirapine-based HAART in pregnancy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Multivariate | 2008 |
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination; | 2008 |
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; | 2008 |
Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritization within programmes.
Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Choice | 2008 |
Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti | 2008 |
Transient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations.
Topics: Antiviral Agents; Female; Genome; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Ve | 2008 |
Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood; Breast Feeding; Cl | 2009 |
Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV; HIV Infections; Humans; I | 2008 |
Determinants of nonadherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Rwanda.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newborn | 2009 |
Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis | 2009 |
[Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital].
Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Female; HIV Infections; Hospitals, University; Humans; N | 2008 |
Prevention of mother-to-child HIV transmission using 3-drug combination antiretroviral treatment: observational cohort in clinical practice setting in India.
Topics: Adolescent; Adult; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV | 2009 |
Which ART regimen is best after receipt of single-dose nevirapine?
Topics: Disease Transmission, Infectious; Female; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy C | 2009 |
Higher placental anti-inflammatory IL-10 cytokine expression in HIV-1 infected women receiving longer zidovudine prophylaxis associated with nevirapine.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Interleukin-10; Nevirapine; Placenta; | 2009 |
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV | 2009 |
Prevention of mother-to-child transmission of HIV in a refugee camp setting in Tanzania.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn; Infecti | 2008 |
Establishment of drug-resistant HIV-1 in latent reservoirs.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Breast Feeding; Developing Countries; Disease R | 2009 |
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Reservoirs; Drug Resistance, Viral; Female; HIV Infec | 2009 |
The obstetric face and challenge of HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Inf | 2009 |
Reducing vertical HIV transmission in Kinshasa, Democratic Republic of Congo: trends in HIV prevalence and service delivery.
Topics: Anti-HIV Agents; Delivery of Health Care; Democratic Republic of the Congo; Female; HIV Infections; | 2009 |
Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hu | 2009 |
Prevention of human immunodeficiency virus mother-to-child transmission in Israel.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emigrants and Immigrants; | 2009 |
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Administration Schedule; Drug | 2009 |
Evolving care of HIV-infected pregnant women in Jamaica--from nevirapine to HAART.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; H | 2008 |
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infecti | 2009 |
Effect of maternal HIV status on infant mortality: evidence from a 9-month follow-up of mothers and their infants in Zimbabwe.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; Drug Administration Schedule; Female; Foll | 2010 |
Mother-to-child HIV and HHV-8 transmission in neonates at Saint Camille Medical Centre in Burkina Faso.
Topics: Adult; Anti-HIV Agents; Burkina Faso; CD4 Lymphocyte Count; DNA, Viral; Female; Herpesviridae Infect | 2009 |
Single-dose nevirapine exposure affects T cell response and cytokine levels in HIV type 1-infected women.
Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Cytokines; Female; HIV Infections; Humans; Infa | 2009 |
Modeling vertical transmission of HIV: imperfect vaccines can be of benefit.
Topics: AIDS Vaccines; Anti-HIV Agents; Antibodies, Monoclonal; Breast Feeding; Child, Preschool; Female; HI | 2009 |
Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infectio | 2009 |
Plasma lipid profile in pregnant women with HIV receiving nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Cholesterol; Drug Therapy, Combination; Female; HIV Infections; | 2009 |
Improving the coverage of the PMTCT programme through a participatory quality improvement intervention in South Africa.
Topics: Anti-HIV Agents; Continuity of Patient Care; Female; HIV Infections; Humans; Infant, Newborn; Infect | 2009 |
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Inf | 2010 |
Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Indu | 2010 |
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birt | 2009 |
Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infectious D | 2010 |
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
Topics: Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily | 2010 |
Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Chromatography, Liquid; Drug Resistanc | 2010 |
Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact?
Topics: Adult; Anti-HIV Agents; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; In | 2010 |
Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; | 2010 |
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Female; HIV Infect | 2010 |
Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.
Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Ke | 2010 |
Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA Primers; DNA, Viral; Drug Resistance, Viral; Female; HI | 2010 |
17th Conference on Retroviruses and Opportunistic Infections, 16-19 February, San Francisco, CA. Limits of success.
Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infectious Disease Tr | 2010 |
A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Health Knowledge, Attitudes, Practice; HIV Infect | 2010 |
Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study.
Topics: Adult; Cohort Studies; Counseling; Family Characteristics; Female; HIV Infections; Humans; Infectiou | 2010 |
Rising mother-to-child HIV transmission in a resource-limited breastfeeding population.
Topics: Adult; Breast Feeding; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Inf | 2010 |
Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.
Topics: Botswana; Drug Resistance, Viral; Female; Gene Frequency; Genetic Variation; HIV Infections; HIV-1; | 2010 |
Non-adherence to the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV in Bindura town, Zimbabwe: a cross-sectional analytic study.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Delivery, Obstetric; Educational Status; Female; He | 2010 |
Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.
Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Re | 2010 |
Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Epidemi | 2010 |
Prevention of mother-to-child transmission of HIV infection: views and perceptions about swallowing nevirapine in rural Lilongwe, Malawi.
Topics: Administration, Oral; Adult; Aged; Anti-HIV Agents; Attitude to Health; Female; Focus Groups; Health | 2010 |
[Fate of children born to HIV positive mothers followed in the context of preventing mother-to-child transmission of HIV in Togo. Study of 1042 infants].
Topics: Anti-HIV Agents; Breast Feeding; Delivery, Obstetric; Female; HIV Infections; HIV Seropositivity; Hu | 2010 |
Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited.
Topics: Adult; Anti-HIV Agents; Bile Duct Diseases; Bile Ducts, Intrahepatic; Cholestasis, Intrahepatic; Fem | 2010 |
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Nev | 2010 |
Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Burkina Faso; Cohort Stud | 2010 |
Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries.
Topics: Adult; Africa; Anti-HIV Agents; Cross-Sectional Studies; Female; Fetal Blood; HIV Infections; Humans | 2010 |
Evaluation of the safety of nevirapine therapy during pregnancy.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; HI | 2010 |
Operational evaluation of a service for prevention of mother-to-child transmission of HIV in rural Uganda: barriers to uptake of single-dose nevirapine and the role of birth reporting.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Infectious | 2010 |
Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.
Topics: Drug Resistance, Viral; Evolution, Molecular; Female; Genome, Viral; HIV Infections; HIV-1; Humans; | 2010 |
Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; | 2010 |
Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control study in a resource poor setting.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cohort Studies; Female; HIV Infections; HIV-1; Humans; | 2010 |
Outcomes and challenges of scaling up comprehensive PMTCT services in rural Swaziland, Southern Africa.
Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Eswatini; Female; HIV Infections; Humans; Infant; Infant | 2010 |
Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infecti | 2010 |
Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life.
Topics: Adult; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Female; H | 2010 |
Preventing mother-to-child transmission of HIV—protecting this generation and the next.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Infectious Disease Transmis | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infe | 2010 |
Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Africa, Western; Alkynes; Anti-HIV Agents; Benzoxaz | 2011 |
The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 20
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Confidence Intervals; Female; HIV Inf | 2011 |
Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschoo | 2011 |
Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens.
Topics: Adolescent; Adult; Africa South of the Sahara; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinica | 2010 |
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte C | 2011 |
Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India.
Topics: Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; India | 2010 |
Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Ther | 2011 |
Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.
Topics: Anti-HIV Agents; Disease Transmission, Infectious; DNA Primers; Female; HIV Infections; HIV-1; Human | 2011 |
Perinatal tuberculosis: two unusual cases.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Antimalarials; Drug Therapy, Combination; Endometritis; F | 2011 |
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Infant, Newborn; Infe | 2011 |
Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec | 2011 |
Study leads to revision in WHO guidelines for HIV women.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Practice Guid | 2010 |
Effectiveness of a PMTCT programme in rural Western Kenya.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Epidemiologic Methods; Fe | 2011 |
Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2011 |
Factors associated with short-course antiretroviral prophylaxis (dual therapy) adherence for PMTCT in Nkangala district, South Africa.
Topics: Anti-HIV Agents; Chi-Square Distribution; Depression, Postpartum; Directive Counseling; Female; Heal | 2011 |
Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004.
Topics: Anti-HIV Agents; Base Sequence; Belize; Cohort Studies; Drug Resistance, Multiple, Viral; Female; HI | 2011 |
Trial in youngest group points to HIV treatment overhaul.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV Protease Inhibitors; Humans; | 2011 |
Improving retention in the early infant diagnosis of HIV program in rural Mozambique by better service integration.
Topics: Adult; Anti-HIV Agents; Delivery of Health Care; Drug Therapy, Combination; Female; HIV Infections; | 2011 |
Reduced HIV transmission at subsequent pregnancy in a resource-poor setting.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newb | 2011 |
WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers.
Topics: Anti-HIV Agents; Breast Feeding; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious | 2011 |
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Lo | 2011 |
Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Cesarean Section; Chi-Sq | 2011 |
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach.
Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Administration Schedule; Drug The | 2011 |
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Inf | 2011 |
Nevirapine for the prevention of mother-to-child transmission of HIV: a nation-wide coverage survey in Côte d'Ivoire.
Topics: Adult; Cote d'Ivoire; Disease Transmission, Infectious; Female; HIV Infections; Humans; Multivariate | 2011 |
HIV type 1 mother-to-child transmission facilitated by distinctive glycosylation sites in the gp120 envelope glycoprotein.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Cohort Studies; Female; Glycosylation; HIV Envelope Protein | 2012 |
Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1.
Topics: Anti-HIV Agents; Female; HIV-1; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2011 |
Should sponsors and DSMBs share interim results across trials?
Topics: Anti-HIV Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiali | 2011 |
Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; HIV-1; Humans; Infant, | 2011 |
Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine.
Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Revers | 2011 |
HIV and pregnancy: maternal and neonatal evolution.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Female; Follow-Up Studies; | 2011 |
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; N | 2012 |
Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis | 2012 |
Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious D | 2012 |
Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Drug Th | 2012 |
Predictors of attrition among children born in a PMTCT programme in Zimbabwe followed up over 5 years.
Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; Female; Follow-Up Studies; Forecasting; HIV Infecti | 2012 |
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
Topics: Adult; Alleles; Anti-Retroviral Agents; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec | 2012 |
Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.
Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; D | 2012 |
Transplacental passage of nevirapine, nelfinavir and lopinavir.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; Fetal Blood; HIV Infections; Humans; | 2012 |
Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human | 2012 |
Policy. 3 steps can drastically reduce mother-to-child transmission.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi | 2012 |
Nevirapine prophylaxis during breastfeeding.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss | 2012 |
Use of service data to inform pediatric HIV-free survival following prevention of mother-to-child transmission programs in rural Malawi.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Disease-Free Survival; Female; Follow-Up Studies; Health Ser | 2012 |
Standing genetic variation and the evolution of drug resistance in HIV.
Topics: Anti-HIV Agents; Computational Biology; Computer Simulation; Drug Resistance, Viral; Evolution, Mole | 2012 |
Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.
Topics: Adult; Aging, Premature; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Fe | 2012 |
HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective observational study.
Topics: Anti-Retroviral Agents; Antibiotic Prophylaxis; Counseling; Delivery, Obstetric; Drug Resistance, Vi | 2012 |
Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HI | 2013 |
Infant feeding and transmission of human immunodeficiency virus in the United States.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cooperative Behavior; Developin | 2013 |
Toxicology and carcinogenesis studies of mixtures of 3'-azido-3'-deoxythymidine (AZT), lamivudine (3TC), nevirapine (NVP), and nelfinavir mesylate (NFV) (Cas Nos. 30516-87-1, 134678-17-4, 129618-40-2, 159989-65-8) in B6C3F1 Mice (transplacental exposure s
Topics: Administration, Oral; Animals; Anti-Retroviral Agents; DNA; Drug Therapy, Combination; Escherichia c | 2013 |
Performance evaluation of PPTCT (Prevention of parent to child transmission of HIV) programme: an experience from West Bengal.
Topics: Adult; Female; Focus Groups; HIV Infections; Humans; India; Infant; Infectious Disease Transmission, | 2012 |
South African government forced to give mothers antiretroviral drug.
Topics: Anti-HIV Agents; Female; HIV Seropositivity; Humans; Legislation, Drug; Nevirapine; Pregnancy; Rever | 2002 |
South Africans win MTCT court case.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi | 2002 |
South Africa shifts position on antiretroviral drugs.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2002 |
An interim plan to reduce mother-to-child HIV infection in South Africa.
Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Female; Health Promotion; HIV Infections; Humans; | 2002 |
Nevirapine warning on post-exposure prophylaxis.
Topics: Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; Humans; Infectious Disease | 2001 |
Antiretroviral treatment in developing countries.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Fe | 2002 |
Two drugs reduce transmission.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2002 |
Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012).
Topics: Cohort Studies; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmis | 2002 |
Hope emerges for controlling perinatal HIV transmission.
Topics: Developing Countries; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Diseas | 1999 |
Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infa | 2002 |
Nevirapine all set to succeed in Gauteng.
Topics: Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra | 2002 |
The right to health and the nevirapine case in South Africa.
Topics: Anti-HIV Agents; Child Advocacy; Female; Health Care Costs; Health Policy; Health Services Accessibi | 2003 |
A saga in international HIV policy modeling: preventing mother-to-child HIV transmission.
Topics: Africa; Antiretroviral Therapy, Highly Active; Female; Fetus; Health Policy; HIV Infections; Humans; | 2002 |
Preventing mother-to-infant transmission of HIV in the developing world.
Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infe | 1999 |
More good news on reducing the incidence of maternal-fetal transmission of HIV and simplifying HAART.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Developing Countri | 1999 |
Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2003 |
Resistant HIV in breast milk.
Topics: Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Milk, Human; Nevirapine; Pregnancy | 2003 |
Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia.
Topics: Antiviral Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Drug Costs; Female; HIV I | 2003 |
Mother-to-child HIV transmission in resource poor settings: how to improve coverage?
Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Humans; Infant, Newborn; | 2003 |
Nevirapine: an option for preventing as well as treating paediatric HIV infection.
Topics: Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease | 2001 |
Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.
Topics: Adult; Developing Countries; Drug Resistance, Viral; Female; Gene Frequency; HIV Infections; HIV-1; | 2003 |
South African government to withdraw antiretrovirals for pregnant mothers.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Approval; Female; Humans; Nevirapine; Preg | 2003 |
Scaling the frontier--should traditional birth attendants also be used to provide nevirapine for PMTCT in Uganda?
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver | 2003 |
Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Cesarean Section; Cost of Illness; Cost-Benefit | 2003 |
South African government threatens to ban nevirapine. Move would take away option for treating vertical HIV transmission.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Disease Outbreaks; Dr | 2003 |
[Antiviral agents for reduction of mother-to-child transmission of HIV infection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Evidence-Based Medicine; Female; HIV Infecti | 2003 |
Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1.
Topics: Anti-HIV Agents; Antibodies, Viral; Child; Developed Countries; Female; Fetal Blood; HIV Infections; | 2003 |
Long-term findings of HIVNET 012: the next steps.
Topics: Anti-HIV Agents; Clinical Protocols; Disease Outbreaks; Disease-Free Survival; Drug Administration S | 2003 |
Decision analysis to guide choice of interventions to reduce mother-to-child transmission of HIV.
Topics: Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Decision Support Techniques; Decision Tree | 2003 |
Role of endogenous reverse transcriptase in murine early embryo development.
Topics: Animals; Antibodies; Cell-Free System; Embryonic and Fetal Development; Embryonic Development; Femal | 2003 |
The relationship between prevention of mother to child transmission of HIV and stakeholder decision making in Uganda: implications for health policy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Attitude to Health; Cost-Benefit Analysis; E | 2003 |
Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience.
Topics: Bottle Feeding; Delivery, Obstetric; Developing Countries; Dominican Republic; Female; HIV Infection | 2003 |
Nevirapine reduced mother-to-child transmission better than AZT--at 70 times less the cost.
Topics: Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertic | 2003 |
HIVNET 012 and Petra.
Topics: Anti-HIV Agents; Counseling; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant, Newbo | 2004 |
HIVNET 012 and Petra.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; I | 2004 |
HIVNET 012 and Petra.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variation; HIV Infection | 2004 |
HIVNET 012 and Petra.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; | 2004 |
Nurses in Zambia gain access to antiretroviral treatment.
Topics: Anti-HIV Agents; Female; Health Policy; Health Services Accessibility; HIV Infections; Humans; Mater | 2004 |
Preventing mother-to-child transmission: landmark decision by South African court.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr | 2002 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.
Topics: Adult; Anti-HIV Agents; Developing Countries; Directly Observed Therapy; Female; HIV Infections; Hum | 2004 |
Mother-to-child transmission. How will AZT and nevirapine use for MTCT affect future treatment? Two studies provide clues.
Topics: CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmissi | 2004 |
HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
Topics: Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV Protease; HIV Reverse Transcriptase; | 2004 |
Retrovirus conferees discuss new strategies.
Topics: Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant, Newborn; | 2004 |
PMTCT from research to reality--results from a routine service.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2004 |
Nevirapine warning.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Nevirapine; | 2004 |
Nevirapine may promote resistance.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis | 2004 |
Immune status and uptake of antiretroviral interventions to prevent mother-to-child transmission of HIV-1 in Africa.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Female; HIV Infections; HIV-1; Humans; | 2004 |
Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2004 |
Risk of archived resistance after intrapartum nevirapine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans; | 2004 |
Nevirapine-induced resistance is a problem.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans; | 2004 |
Acceptability and utilisation of voluntary HIV testing and nevirapine to reduce mother-to-child transmission of HIV-1 integrated into routine clinical care.
Topics: Anti-HIV Agents; Diagnostic Tests, Routine; Female; HIV Infections; HIV-1; Humans; Infant Welfare; I | 2004 |
Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience.
Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious D | 2004 |
Antiretroviral agents--how best to protect infants from HIV and save their mothers from AIDS.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Drug Resistance | 2004 |
Health minister ignites row over drugs for HIV mothers.
Topics: Congresses as Topic; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; I | 2004 |
Some design issues in trials of microbicides for the prevention of HIV infection.
Topics: Anti-HIV Agents; Anti-Infective Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase I | 2004 |
Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries.
Topics: Adult; Anti-HIV Agents; Botswana; Cost-Benefit Analysis; Cote d'Ivoire; Female; HIV Infections; Huma | 2004 |
South Africa rejects use of AIDS drug for women.
Topics: Acquired Immunodeficiency Syndrome; Female; Health Policy; HIV Infections; Humans; Infectious Diseas | 2004 |
Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnancy; Pregnancy Complicatio | 2004 |
Mutations correlated to NVP concentrations.
Topics: Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2004 |
Assessing the risk of birth defects associated with antiretroviral exposure during pregnancy.
Topics: Abnormalities, Drug-Induced; Anti-Retroviral Agents; Female; Gestational Age; Humans; Lamivudine; Ma | 2004 |
Perinatal HIV research unit clarifies nevirapine resistance and transmission issues.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; H | 2004 |
Decreased likelihood [correction of likelyhood] of infants contracting HIV when taking nevirapine.
Topics: Female; HIV Infections; Humans; Infant; Infant, Newborn; Nevirapine; Pregnancy | 2003 |
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2004 |
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
Topics: Anti-Retroviral Agents; DNA, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; Infectious | 2004 |
The efficacy-effectiveness gap in PMTCT.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2004 |
Meeting report from the XV International AIDS Conference. Perinatal transmission.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi | 2004 |
[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; F | 2004 |
Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission.
Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Condoms; Contact Tracing; Counseling; Fa | 2004 |
Reduction of materno-fetal transmission of HIV by improved delivery techniques combined with nevirapine treatment in women attending two family planning clinics in Yaounde, Cameroon.
Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Delivery, Obstetric; Family Planning Services; Female; | 2004 |
Activists and researchers rally behind AIDS drug for mothers.
Topics: Acquired Immunodeficiency Syndrome; Africa; Clinical Trials as Topic; Female; Humans; Infant, Newbor | 2004 |
HIV transmission. Allegations raise fears of backlash against AIDS prevention strategy.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infant, Newborn; | 2004 |
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther | 2005 |
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther | 2005 |
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther | 2005 |
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther | 2005 |
Articles criticising nevirapine trial may endanger babies' lives.
Topics: Anti-HIV Agents; Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newbor | 2005 |
HIV seroprevalence, uptake of interventions to reduce mother-to-child transmission and birth outcomes in greater Kingston, Jamaica.
Topics: Adolescent; Adult; Female; HIV Infections; HIV Seropositivity; HIV Seroprevalence; Humans; Infectiou | 2004 |
Uptake of interventions, outcomes and challenges in caring for HIV-exposed infants in Kingston, Jamaica.
Topics: Antibiotic Prophylaxis; Female; HIV Infections; Humans; Infant; Infant Care; Infant, Newborn; Infect | 2004 |
Zidovudine monotherapy and the prevention of mother-to-child HIV-1 transmission.
Topics: Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2005 |
Recent advances in prevention of mother to child (PMTCT) of HIV.
Topics: Africa; Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; Humans; Infant, | 2004 |
Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda.
Topics: Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Disease Outbreaks; Female; HIV Infections; | 2004 |
Top stories of 2004. Perinatal transmission interventions: the benefits come with resistance.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr | 2005 |
Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Developing Countries; Drug Therapy, Combination; Female; HIV | 2005 |
Activists angry at fallout from AIDS drug trial allegations.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Female; Humans; Infan | 2005 |
Reports on nevirapine threaten public health.
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Female; Government Publications as Topic; HIV Infe | 2005 |
HIV drug remains unproven without placebo trial.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2005 |
FDA advisory on nevirapine.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan | 2005 |
Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.
Topics: Anti-HIV Agents; Breast Feeding; Costs and Cost Analysis; Female; HIV Infections; HIV Seroprevalence | 2005 |
Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?
Topics: Anti-HIV Agents; Female; Health Status; HIV Infections; HIV Seropositivity; Humans; Infectious Disea | 2005 |
Routine provision of nevirapine to women of unknown serostatus: at best a temporary solution to prevent MTCT.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infe | 2005 |
Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Cohort Studies; Counseling; Disclosure; Divorce; Domestic Vi | 2005 |
AIDS research. IOM panel clears HIV prevention study.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio | 2005 |
Nevirapine-related death draws attention.
Topics: Clinical Trials as Topic; Fatal Outcome; Female; HIV Infections; Humans; Liver Failure; National Ins | 2005 |
Resistance with short-course nevirapine.
Topics: Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV Infections; Humans; Nevirapine; Pregna | 2005 |
Averting drug resistance while preventing MTCT.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human | 2005 |
Maternal self-medication and provision of nevirapine to newborns by women in Rakai, Uganda.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2005 |
A drug is effective if better than a harmless control.
Topics: Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dis | 2005 |
Nelfinavir and nevirapine side effects during pregnancy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymp | 2005 |
Reducing HIV vertical transmission scrutinized.
Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; Humans; Infan | 2005 |
Nevirapine misinformation: will it kill?
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi | 2004 |
IOM: nevirapine study is reliable.
Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, V | 2005 |
Single-dose nevirapine and drug resistance: the more you look, the more you find.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human | 2005 |
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1 | 2005 |
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti | 2005 |
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV | 2005 |
Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Protea | 2005 |
Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; Genotype; HIV Infections; HIV-1; Humans; Infectious D | 2005 |
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Fetal Blood; HIV Infections; Humans; Infant, Newb | 2005 |
Roundtable. Revisiting the role of single-dose nevirapine for preventing perinatal HIV transmission.
Topics: Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tr | 2005 |
Attitudes to voluntary counselling and testing prior to the offer of Nevirapine to prevent vertical transmission of HIV in northern Tanzania.
Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Counseling; Female; Focus Groups; HIV Infect | 2005 |
Addressing the paediatric HIV epidemic: a perspective from the Western Cape Region of South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Disease Outbreaks; Female; HIV Infections; Humans; Infant | 2006 |
Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; HIV Infections; Humans; Inf | 2005 |
Nevirapine concentration in cervicovaginal and oropharyngeal secretions after single-dose administration to the mother.
Topics: Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Di | 2005 |
Preventing mother-to-child transmission of HIV in Western Kenya: operational issues.
Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Hospitals, General; Hospi | 2005 |
Third-trimester maternal toxicity with nevirapine use in pregnancy.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnanc | 2005 |
Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon.
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Cameroon; Counseling; Female; HIV Infections; Human | 2005 |
Predictors of nonadherence to single-dose nevirapine therapy for the prevention of mother-to-child HIV transmission.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Home Childbirth; Humans; Infant, Low Birth Wei | 2006 |
[Detection of HIV infection in pregnant women by rapid testing: a successful strategy to reduce its vertical transmission].
Topics: Adolescent; Adult; Anti-HIV Agents; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; HI | 2005 |
Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Female; | 2005 |
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholestasis; Cohort Studies; Female; Hepatitis B; Hepa | 2006 |
HIV and pregnancy at the 12 CROI.
Topics: AIDS Serodiagnosis; Diabetes, Gestational; Drug Resistance, Viral; Female; HIV Infections; HIV Prote | 2005 |
Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2006 |
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
Topics: Cote d'Ivoire; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hum | 2006 |
The value of contraception to prevent perinatal HIV transmission.
Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Contraception; Cost-Benefit Analysis | 2006 |
Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Fatal Outcome; Female; HIV Infections; HIV-1; Humans; Infan | 2006 |
The controversies of nevirapine for preventing mother-to-child HIV transmission.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2006 |
Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Lactates; Lamivudine; Male; Mitoch | 2007 |
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
Topics: Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Gene Freq | 2006 |
This is no time to stop use of nevarapine to prevent mother-to-child transmission of HIV.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious | 2006 |
Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Chemical and Drug | 2006 |
Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings.
Topics: Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Female; HIV Infection | 2006 |
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
Topics: Adult; Alleles; Anti-HIV Agents; Child; Drug Resistance, Microbial; Female; Genotype; HIV Infections | 2006 |
Prevention of mother-to-child transmission of HIV in Cameroon: experiences from the University Teaching Hospital in Yaounde (Cameroon).
Topics: Administration, Oral; Anti-HIV Agents; Cameroon; Developing Countries; Female; Follow-Up Studies; HI | 2006 |
HIV denialists ignore large gap in the study they cite.
Topics: Clinical Trials as Topic; Denial, Psychological; Female; History, 20th Century; HIV Infections; HIV | 2006 |
Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital.
Topics: Anti-HIV Agents; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropositivity; Humans | 2006 |
Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Revers | 2006 |
Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; | 2006 |
Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D.
Topics: Black People; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vert | 2006 |
In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers.
Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Blood Chemical Analysis; Female; Fetal Blo | 2006 |
Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N | 2006 |
Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
Topics: Amniotic Fluid; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Interactions; Female; | 2006 |
Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.
Topics: Adult; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Cohort Studies; Fe | 2006 |
Rapid HIV testing and counselling in labour in a northern Nigerian setting.
Topics: Adolescent; Adult; Anti-HIV Agents; Counseling; Cross-Sectional Studies; Female; HIV Infections; HIV | 2006 |
Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission.
Topics: Administration, Oral; Anti-HIV Agents; Drug Packaging; Drug Stability; Drug Storage; Female; HIV Inf | 2006 |
Implementation of single-dose nevirapine for prevention of MTCT of HIV--lessons from Cape Town.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Guideline Adherence; Health Planning; HIV Inf | 2006 |
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pregnancy; Pr | 2006 |
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV; HIV Infections | 2007 |
The ethics of placebo-controlled studies on perinatal HIV transmission and its treatment in the developing world.
Topics: Anti-HIV Agents; Breast Feeding; Control Groups; Controlled Clinical Trials as Topic; Developing Cou | 2006 |
Estimation of the rate of mother to child transmission of HIV in Nigeria.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Female; HIV Infecti | 2006 |
A model of directional selection applied to the evolution of drug resistance in HIV-1.
Topics: Anti-HIV Agents; Codon; Computer Simulation; Drug Resistance, Viral; Evolution, Molecular; Female; G | 2007 |
Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model.
Topics: Africa South of the Sahara; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infect | 2007 |
Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
Topics: Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru | 2007 |
Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administra | 2007 |
Expanded services for the prevention of mother-to-child HIV transmission: field acceptability of a pilot program in Lusaka, Zambia.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cities; Drug Therapy, Combination; Female; HIV Infections; Hu | 2007 |
Home deliveries: implications for adherence to nevirapine in a PMTCT programme in rural Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Delivery, Obstetric; Female; HIV Infections; Home Childbi | 2007 |
Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
Topics: Adolescent; Adult; Africa, Western; Antiretroviral Therapy, Highly Active; Europe; Female; HIV Infec | 2007 |
Delaying maternal NVP-based ART more effective.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr | 2007 |
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Feasibility Studies; Fema | 2007 |
Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India.
Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss | 2007 |
Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Anti-HIV Agents; Drug Administration Schedule; Female | 2007 |
Safety issues about nevirapine administration in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Bilirubin; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Con | 2007 |
Persistence of nevirapine in breast milk after discontinuation of treatment.
Topics: Anti-HIV Agents; Female; Functional Laterality; HIV Infections; Humans; Milk, Human; Nevirapine; Pre | 2007 |
Effect of exposure to clinic-based health education interventions on behavioural intention to prevent mother-to-child transmission of HIV infection.
Topics: Adolescent; Adult; Catchment Area, Health; Condoms; Cross-Sectional Studies; Female; Health Behavior | 2006 |
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Topics: Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Infectious Di | 2007 |
African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Chemok | 2007 |
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Cohort | 2007 |
Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; M | 2007 |
Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine.
Topics: Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease | 2007 |
[Treatment of children born of AIDS mothers in Tsevie hospital regional center, Togo].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Breast Feeding; Child Health Services; Femal | 2007 |
Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine.
Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; I | 2007 |
Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication.
Topics: Adult; Anti-Retroviral Agents; Dandy-Walker Syndrome; Female; Heart Ventricles; HIV Infections; Huma | 2007 |
Reverse transcriptase mutations in Cambodian CRF01_AE isolates after antiretroviral prophylaxis against HIV Type 1 perinatal transmission.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Female; HIV Infections; HIV Revers | 2007 |
Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria.
Topics: Amino Acid Sequence; Anti-HIV Agents; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Huma | 2007 |
Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda.
Topics: Anti-HIV Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; HIV; HIV Infections; Humans; | 2007 |
[Side effects of antiretroviral treatment for transmission prophylaxis in preterm and near-term infants].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cesarean Section; Female; Gestational Age; HIV | 2007 |
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Drug Resistance, Viral; Female; HIV Inf | 2008 |
Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India.
Topics: Abortion, Induced; AIDS Serodiagnosis; Anti-HIV Agents; Costs and Cost Analysis; Counseling; Deliver | 2008 |
A grave delay for South Africa's mothers and infants.
Topics: Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine | 2008 |
From PMTCT to a more comprehensive AIDS response for women: a much-needed shift.
Topics: Abortion, Induced; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Developing Countries; | 2008 |
Estimating vertically acquired HIV infections and the impact of the prevention of mother-to-child transmission program in Zimbabwe: insights from decision analysis models.
Topics: Decision Support Techniques; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra | 2008 |
Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Eruptions | 2007 |
Incidence of nevirapine-associated hepatitis in an antenatal clinic.
Topics: Adult; Alanine Transaminase; Ambulatory Care Facilities; Chemical and Drug Induced Liver Injury; Fem | 2008 |
Feasibility of prevention of perinatal HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 2002-2004.
Topics: Chemoprevention; Democratic Republic of the Congo; Female; HIV Infections; Humans; Infant, Newborn; | 2008 |
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy; | 2008 |
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy; | 2008 |
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy; | 2008 |
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy; | 2008 |
Steady-state nevirapine plasma concentrations are influenced by pregnancy.
Topics: Adult; Africa; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Trans | 2008 |
Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral; | 2008 |
Characteristics of pregnancy with human immuno-deficiency virus (HIV) and perinatal transmission in Nakornping Hospital.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Female; HIV Infections; Humans; Incidence; Infant, Newbor | 2008 |
Self-reported adherence to single dose nevirapine in the prevention of mother to child transmission of HIV at Kitale District Hospital.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child Welfare; Cross-Sectional Studies; Female; Health Su | 2007 |
Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2008 |
[Nevirapine: a new principle of action against HIV].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Do | 1996 |
Low-cost drug cuts perinatal HIV-transmission rate.
Topics: Anti-HIV Agents; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra | 1999 |
Uganda gives lessons in stemming the AIDS epidemic.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Disease Outbreaks; Female; Government; Health P | 1999 |
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
Topics: Africa South of the Sahara; Anti-HIV Agents; Cost-Benefit Analysis; Drug Administration Schedule; Fe | 1999 |
Call to buy nevirapine for developing countries.
Topics: Africa; Congresses as Topic; Developing Countries; Female; HIV Infections; Humans; India; Infectious | 1999 |
Perinatal HIV prevention.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 1999 |
AIDS drug trials in Thailand and Uganda.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio | 1999 |
HIVNET nevirapine trials.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newbor | 1999 |
HIVNET nevirapine trials.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Female; HIV Infections; HI | 1999 |
HIVNET nevirapine trials.
Topics: Anti-HIV Agents; Counseling; Ethics, Medical; Female; HIV Infections; HIV-1; Humans; Infectious Dise | 1999 |
Concern at cheap AIDS drug fears.
Topics: Acquired Immunodeficiency Syndrome; Africa, Southern; Anti-HIV Agents; Costs and Cost Analysis; Fema | 1999 |
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease | 2000 |
Deaths bring South African HIV drug trials to a premature halt.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Drug T | 2000 |
Flirting with strange ideas. Mbeki reaches out to a controversial AIDS researcher.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Biochemistry; Clinical Trials as Topic; | 2000 |
Beanie Baby profits support AIDS foundation.
Topics: Acquired Immunodeficiency Syndrome; Female; Foundations; Humans; Infectious Disease Transmission, Ve | 2000 |
The mother of all HIV challenges.
Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Clinical Trials as | 2000 |
Pharmacological implications of lengthened in-utero exposure to nevirapine.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; Half-Life; HIV Infections; HIV-1 | 2000 |
Mbeki gives AIDS scientists the cold shoulder.
Topics: Acquired Immunodeficiency Syndrome; Adult; Breast Feeding; Enzyme-Linked Immunosorbent Assay; Female | 2000 |
Diplomatic Mandela calls for action on HIV...as South Africa considers its options after free drugs offer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Child; Drug Costs; Drug Industry; Female | 2000 |
South African government continues policy of inactivity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Female; HIV Infections; Humans; Maternal-Fetal | 2000 |
AZT blues.
Topics: Anti-HIV Agents; Counseling; Female; Foster Home Care; HIV Infections; HIV-1; Humans; Infant, Newbor | 2000 |
Prevention of mother-child HIV transmission: progress and problems.
Topics: Africa; Antiviral Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Cohort Studies | 2000 |
Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa.
Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Cost-Benefit Analysis; Decision Sup | 2000 |
Inexpensive AIDS drug still reduces HIV transmission from mother to child after 1 year.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Follow-Up Studies | 2000 |
No turning back now.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis | 2000 |
Human immunodeficiency virus type-1: mother-to-child transmission. Meeting of World Federation of Scientists in Erice, Italy, August 2000. Joint report of AIDS/Infectious Diseases PMP and Mother and Child PMP.
Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Age Factors; Anti-HIV Agents; Breast | 2000 |
Future directions.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Counseling; Fem | 2000 |
Antiretroviral pharmacology in pregnant women and their newborns.
Topics: Administration, Oral; Anti-HIV Agents; Delivery, Obstetric; Female; HIV Infections; Humans; Infant; | 2000 |
The cost effectiveness of a single-dose nevirapine regimen to mother and infant to reduce vertical HIV-1 transmission in sub-Saharan Africa.
Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Anti-HIV Agents; Computer Simulation | 2000 |
Further views by the Erice working group on mother-to-child transmission of HIV type 1.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T | 2001 |
South Africa's AIDS activists say new neviripine programme is not enough.
Topics: Anti-HIV Agents; Costs and Cost Analysis; Female; Financing, Government; Health Care Rationing; HIV | 2001 |
South Africa cuts agreement for one AIDS drug but ignores another.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cost Savings; Drug Indust | 2001 |
Two studies suggest nevirapine benefit for children.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Female; HIV Infect | 1997 |
Nevirapine: ethical dilemmas and care for HIV-infected mothers.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Counseling; Ethics, Medical; F | 1995 |
Nevirapine approved by FDA. Food and Drug Administration.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Th | 1996 |
Pregnant women eligible for single-dose nevirapine study.
Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm | 1997 |
Perinatal HIV down as treatment increases.
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant, | 1997 |
Preventing HIV infection in infants in developing countries: NIAID's role. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Developing Countries; Ethiopia; | 1997 |
Thai study success affects ongoing placebo trials.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio | 1998 |
Unequal care sustains vertical transmission rate.
Topics: Anti-HIV Agents; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 1999 |
Single-dose Nevirapine during pregnancy.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis | 1999 |
Prevention of perinatal HIV infection: cause for optimism.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Cesarean Section; Clinical Trials as Topic; Drug Therapy, Combi | 1999 |
Perinatal transmission.
Topics: Anti-HIV Agents; Developing Countries; Female; Foundations; HIV Infections; Humans; Infant, Newborn; | 1999 |
Hope for Africa's next generation.
Topics: Administration, Oral; Clinical Trials as Topic; Drug Administration Schedule; Female; HIV Infections | 1999 |
Study offers hope for Africa's next generation.
Topics: Administration, Oral; Anti-HIV Agents; Breast Feeding; Clinical Trials as Topic; Drug Administration | 1999 |
Can a $4 drug stop vertical HIV transmission?
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Health Services Accessibility; HIV Infections | 1999 |
Perinatal transmission.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe | 1999 |
Global strategies for the prevention of HIV transmission from mothers to infants: the second conference.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Congresses as Topic; De | 1999 |
Simpler regimens for preventing mother-to-child HIV transmission.
Topics: Delivery, Obstetric; Developing Countries; Drug Administration Schedule; Female; HIV Infections; Hum | 1999 |
Preventing mother-to-child transmission of HIV in developing countries: recent developments and ethical implications.
Topics: Anti-HIV Agents; Developing Countries; Ethics, Medical; Female; HIV Infections; Humans; Infant, Newb | 2000 |
Rwanda to receive cheaper anti-HIV drugs for chronic treatment and free viramune to prevent viral transmission from mother to child.
Topics: Anti-HIV Agents; Chronic Disease; Developing Countries; Drug Costs; Drug Industry; Female; HIV Infec | 2001 |
South Africa in crisis on HIV/AIDS treatment.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Industry; Female; Health Policy; Health Se | 2001 |
New drug regimen helps prevent HIV infection in infants.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 1999 |
Taking HIV to court.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2001 |
To test or not to test--ethical dilemmas and practical realities in the use of co-trimoxazole and nevirapine in HIV-infected adults.
Topics: Adult; AIDS Serodiagnosis; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Developing Countr | 2001 |
South Africa's stance on nevirapine on trial.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant; Infant, Newborn; Infectious | 2001 |
Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV.
Topics: Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious Disease Transmission | 2001 |
Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV-1; Humans; | 2001 |
I want to see them grow up.
Topics: Anecdotes as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission | 2001 |
The faces of AIDS in Uganda: Mulago Hospital.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan | 2001 |
South Africa: activists, physicians sue government to prevent maternal transmission, ask international support.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Internat | 2001 |
Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cote d'Ivoire; Drug Resistance, Viral; Female; Genotype; HIV | 2002 |
S Africa state offers HIV drug to pregnant women.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2002 |
South African government procrastinates over policy on HIV drug.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2002 |
South African President hints at expansion of HIV-drug pilot programmes.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2002 |
Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies.
Topics: Anti-HIV Agents; Cohort Studies; Decision Support Techniques; Female; Fetal Death; HIV Infections; H | 2002 |
Confusion over Mandela's "support" of ANC HIV policy.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver | 2002 |
A South African perspective on 2001.
Topics: Anti-HIV Agents; Drug Industry; Female; HIV Infections; Humans; Infant; Infectious Disease Transmiss | 2002 |
Stage of the epidemic and viral phenotype should influence recommendations regarding mother-to-child transmission of HIV-1.
Topics: Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; HIV-1; Humans; Infant; I | 2002 |
South African judge reaffirms judgement to expand access to AIDS drug.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infectious Disease Transmission | 2002 |
Feasibility of antenatal and late HIV testing in pregnant women in Phnom Penh Cambodia: the PERIKAM/ANRS1205 study.
Topics: AIDS Serodiagnosis; Cambodia; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropreva | 2002 |
Enough time wasted in South Africa.
Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Legislation, Drug; Nevirapine; | 2002 |
South African court again tells government to increase access to AIDS drug.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn; | 2002 |
South African nevirapine policy faces growing pressure.
Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnan | 2002 |
Mothers, orphans, and prevention of paediatric AIDS.
Topics: Anti-HIV Agents; Female; Foster Home Care; HIV Infections; Humans; Infant, Newborn; Infectious Disea | 2002 |
South African leader relents in storm over HIV drugs for women.
Topics: Anti-HIV Agents; Female; Government; HIV Infections; Humans; Infectious Disease Transmission, Vertic | 2002 |
FDA application withdrawn to market Viramune for new use.
Topics: Drug Approval; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine | 2002 |
Let nevirapine do what it does best.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr | 2002 |
Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa.
Topics: Adult; Anti-HIV Agents; Child Welfare; Child, Preschool; Cost of Illness; Cost-Benefit Analysis; Fem | 2002 |
Judasa, HPCSA and CMSA take up cudgels.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Patient Advocacy; Pregnancy; Pregnancy | 2002 |
PMTCT--who decides on the right to life?
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Male; Nevirapine; Practice | 2002 |
No acceptable excuse for inaction.
Topics: Acquired Immunodeficiency Syndrome; Female; Health Priorities; Health Services Accessibility; Humans | 2002 |
Policy watch. Good news, bad news.
Topics: Anti-HIV Agents; Bioterrorism; Budgets; Female; Health Policy; HIV Infections; Humans; Infant, Newbo | 2002 |
Court orders South Africa to treat pregnant HIV-positive women with nevirapine.
Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp | 2002 |
Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery.
Topics: Calibration; Chromatography, High Pressure Liquid; Female; HIV Protease Inhibitors; Humans; Lopinavi | 2002 |
HIV does cause AIDS but it's hard to prescribe the drugs, says South Africa's ANC.
Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp | 2002 |